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Abstract
Extrapolating survival data is an important task in health technology assessment (HTA). Current
approaches can lack flexibility and there is a tension between using all the data and restricting
analyses to the more recent observations. Dynamic survival models (DSMs) exploit the tempo-
ral structure of survival data, are very flexible, have interpretable extrapolations, and use all
the data whilst providing more weight to more recent observations when generating extrapola-
tions. DSMs have not previously been used in HTA; this thesis evaluated the performance and
usefulness of dynamic models in this context.
Extensive simulation studies compared DSMs with both current practice and other flexible
(emerging practice) models. Results indicated that, compared with current practice, DSMs
can more accurately model the data, providing improved extrapolations. However, with small
sample sizes or short follow-up there was a danger of providing worse extrapolations. Of emerging
practice models, spline-based models often had similar performance to DSMs whilst fractional
polynomials provided very poor extrapolations. Two novel extensions to DSMs were developed
to incorporate external data in the form of relative survival and cure models. Both extensions
helped to reduce the variation in extrapolations. Dynamic cure models were assessed in a
simulation study and provided good extrapolations that were robust to model misspecification.
A case-study demonstrated that extrapolations from an interim analysis can be poor for all
the methods considered when the observed data is not representative of the future. A case-
study demonstrated the feasibility of using DSMs in HTA, and an extension to incorporate
time-varying treatment effects.
DSMs should be considered as a potential method when analysing and extrapolating survival
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data. These flexible models and their extensions show promise but have the danger of providing
poor extrapolations in data-poor scenarios. More research is needed into identifying situations
when use of these should be the default approach in HTA.
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Chapter 1
Introduction
The focus of this thesis is on using time series methods to predict future survival outcomes within
health technology assessment (HTA). These predictions of the future are commonly referred to as
extrapolations within the HTA literature, or forecasts within the statistical literature. Predicting
the future is difficult as by definition there is no available evidence at the time of the prediction
to assess the accuracy of these estimates. Predicting the future is also often a key task within
HTA as these extrapolations can influence whether or not potentially life-saving treatments are
made available to patients. Hence it is important that the best possible statistical methods are
used to generate extrapolations. Time series methods are routinely used for forecasting in many
areas but they have not currently been used for the extrapolation of survival data in HTA. The
main novel contribution of this thesis is to develop and assess the use of time series methods
for predicting future survival to inform HTAs. This contribution includes the identification and
development of suitable methods, along with a comprehensive assessment of their performance.
This chapter provides key introductory material for the thesis. It begins with a background
to HTA and why extrapolations of survival outcomes are an important part of this process.
The motivation for considering time series methods is then described. This chapter concludes
by outlining the aims of this thesis, and how these are achieved by the subsequent chapters.
In general, the writing style uses a passive voice. The exception is where I wish to emphasise
my value added (novel) contributions to this thesis. In particular, this thesis forms part of a
wider doctoral fellowship. As such, some of the work that I have undertaken on extrapolation
1
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for the fellowship is beyond the scope of this thesis. This includes two published first-author
papers. One paper was designed to highlight the methods used in this thesis to a general
medical audience [1]. The analyses performed for this publication have since been superseded
by more complex work which is discussed in this thesis. This publication includes important
methodological details, and so the whole publication is reproduced as Appendix 3. The second
paper examined the impact on uncertainty during the extrapolated phase when using survival
models [2]. A full treatment of uncertainty in both survival extrapolation and HTA is beyond
the scope of this thesis but it is briefly explored in Section 6.4.2. These papers, and other
examples, are discussed at appropriate parts of this thesis.
1.1 Health technology assessment
A health technology is any technology that can be used to improve population health. Ideally,
any health technology that has been proven to work (i.e. is clinically effective) would be made
available via a healthcare system such as the National Health Service (NHS) in England. How-
ever, healthcare resources are limited. This includes limited funds, staff and facilities. Because of
this scarcity of resources, not all clinically effective health technologies can be funded. Instead,
a framework is required to decide which health technologies should be funded or prioritised,
given the resource constraints. HTA is concerned with the scientific evaluation of health tech-
nologies. It has two main components: clinical effectiveness, which evaluates the impact of a
technology on health compared to existing alternatives; and cost-effectiveness, which considers
the trade-off between the impact on individuals’ health and the costs to the healthcare system:
does the technology represent value for money [3]? HTA follows the principles of evidence-based
medicine; decisions are informed by evidence that is identified via a systematic, transparent and
explicit process [4].
Two key outcomes in HTA are the costs to the healthcare system and benefits to patients.
Costs include both the cost of delivering the health technology and any long-term costs such as
those for disease management, re-interventions, or treating side effects. A common measure of
patient benefit is quality adjusted life years (QALYs) [5]. These weight remaining life expectancy
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(survival) by the quality of that life. These weights are known as utilities and are typically
scaled such that a utility of one is equivalent to being in perfect health, whilst a utility of zero
is equivalent to being dead. There are two primary advantages of using QALY. The first is that
they incorporate both quantity and quality of life into a single summary statistic. The second
is that they provide a common outcome by which different technologies may be compared. As
such, the principles of HTA may be applied to any health technology. Examples of HTA include
drugs for cancer [6], screening programmes [7], service (pathway) redesign [8] and alternative
clinical practices [9].
If evidence were available on the costs and QALYs for every intervention, then the choice of which
interventions to fund would reduce to a constrained optimization problem, where the constraint
is the available healthcare budget (costs) and optimisation is performed on the QALYs gained.
However, in practice this evidence is not available due to the multitude of interventions and
the scarcity of data. Instead the comparison is often between a new technology x and current
clinical practice c. The key questions for cost-effectiveness are then:
1. How much more does x cost (∆Cx)?
2. How many more QALYs does x provide (∆Qx)?
Decision-making is then informed by the cost per QALY gained, which is often termed as the
incremental cost-effectiveness ratio (ICER):
ICER =
Incremental costs of x





In England, the National Institute for Health and Care Excellence (NICE) runs a (health) tech-
nology appraisal (TA) process as part of its HTA programme. For this, most health technologies
with an ICER less than £20,000 are likely to be approved, whilst those with an ICER greater
than £30,000 are unlikely to be approved. Between these amounts, decisions are influenced
by other factors, such as innovation, that may not be quantified by the use of an ICER for
decision-making. For technologies which meet certain end-of-life criteria, a higher threshold (or
‘willingness to pay’) of £50,000 is used, such that technologies with an ICER less than £50,000
are likely to be approved [10]. Treatments for very rare conditions are classified by NICE as
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highly specialised technologies. For these technologies, a default threshold of £100,000 is as-
sumed, with higher thresholds applicable for technologies that provide significant QALY gains
[11]. The English NHS is legally obliged to fund and resource health technologies that have
been recommended by the NICE TA process within a certain time frame, if both the clinician
and the patient think the intervention is appropriate [12]. The use of time series models for
predicting future survival in a HTA is presented in Chapter 6, which uses an existing NICE TA
as a case-study.
Decisions on if a health technology should be approved, and so made available to patients,
depend on estimates of the costs and QALYs accrued for the technology. These in turn are
influenced by estimates of survival. As detailed in the following section, the available evidence
on survival is typically shorter than the required survival evidence, necessitating extrapolation.
1.2 Extrapolation of survival data
The impact of health technologies on survival, or mortality, can vary markedly over time. For
example, endovascular repair of abdominal aortic aneurysms was associated with a reduced
mortality rate after 30 days (compared with open repair) but an increased mortality rate after
15 years [13]. Conversely, screening for ovarian cancer had no impact on disease-specific mortality
for the first seven years but reduced disease-specific mortality (compared to no screening) for
the subsequent seven years [14]. These two examples demonstrate that evidence on effectiveness
will depend on the time horizon used. Hence to enable a fair comparison across different health
technologies, the time horizon used in HTA needs to be long-enough to include all important
differences in treatment outcomes and costs [12]. If the health technology impacts on survival,
then by definition a lifetime horizon is required.
However, there is typically discordance between the required evidence and the available evidence,
which requires the use of extrapolation. For example, a review of oncology submissions to the
NICE TA process found that the average time horizon used was 25.2 years whilst the available
evidence covered an average of 2.9 years, with extrapolation required in 28 of the 29 appraisals
[15]. A more recent review of oncology submissions to the NICE TA programme in 2017 found
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that extrapolation was required in all 28 appraisals, with the required time horizon being on
average ten times longer than the maximum available follow-up (31.4 years vs 3.1 years) [16].
1.2.1 Limitations with current extrapolation methods in HTA
Survival models have been developed to describe observed survival data [17]. Current practice
in HTA is to fit survival models to the observed data and use these to generate extrapolations.
More details on current practice are provided in the review contained in Chapter 2 whilst more
details on the technical aspects of survival data are provided in Appendix 1.
There is neither a ‘gold standard’ method for producing extrapolations in HTA, nor is there
agreement on which models or methods should be used [18, 19]. In 2013 the NICE Decision
Support Unit (DSU), which provides support to the NICE TA programme, published a Technical
Support Document (TSD) covering extrapolation of survival data [20]. This document included
a review of English oncology TAs completed by December 2009. The author concluded that
inconsistent, and sometimes arbitrary, approaches were taken to model fitting, with flexible
modelling methods rarely considered and the chosen approach never fully justified. The TSD
provided practical guidance to aid in the choice of methods for analysing and extrapolating
survival data. Six years later, an updated review of NICE TAs found that there was little
improvement in analyses [21]. This updated review also noted that some appraisals included
more complex survival models than those covered by the TSD, suggesting the need for updated
guidance.
To compound the issue of inconsistent approaches to extrapolation in HTA, a number of studies
have noted that competing statistical models can provide very similar fits to the observed data
but markedly different extrapolations. Guyot and colleagues compared fifteen different methods
to estimate the survival benefit of a cancer treatment [22]. Two methods provided almost
identical fits to the observed data but very different extrapolations, with estimated survival
benefits of 13.9 and 80.4 months. Estimates for the other methods ranged from 4.7 months (the
preferred approach) to 195.5 months, demonstrating that goodness of fit to the observed data
cannot on its own be used to choose between competing models when extrapolations are required.
Similarly, estimates of cost-effectiveness, and hence funding decisions, have been observed to be
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sensitive to the extrapolation method used in a number of studies [6, 7, 23, 24].
The current practice of using survival models for extrapolation has also resulted in problems
with how the observed data are used to inform extrapolations. Survival models (and hence their
extrapolations) give more weight to times with larger sample sizes, which occurs at the start
of follow-up. However, recent outcomes (at the end of follow-up) may be more informative of
the future than outcomes at the start [25, 19]. The survival models used as current practice
cannot accommodate this, which has motivated the use of ‘piecewise’ models [26]. These apply
different models at different time-points. Models may be ‘hybrid’, using non-parametric methods
initially, with a parametric model for the subsequent years [19]. Future predictions are based
on estimates from the model fitted to the most recent observations (the extrapolating model).
This approach has two key limitations [27, 28]:
1. The choice of which data to include within the extrapolating model is essentially arbitrary
and extrapolations can be sensitive to this choice
2. Compared with using all of the data, the extrapolating model will be fitted to a reduced
sample size. Often the reduction in sample size will be dramatic, which can lead to poor
extrapolations with increased uncertainty.
Survival models were developed to describe the observed survival data but they were not explic-
itly designed to predict the future. Their use to generate extrapolations has led to the limitations
described above. In contrast, generating forecasts is a main task of time series models, which
avoid the aforementioned limitations. These are described next.
1.2.2 Time series models for extrapolation
The task of predicting the future is not unique to HTA. It occurs in a number of alternative
disciplines including demography [29, 30], epidemiology [31], finance [32, 33], healthcare [34]
information and communications technology [35] and ecology [36]. A prominent approach for
generating extrapolations in these other areas is with time series models [37]. Time series
models account for the fact that outcomes are correlated across time. Because they can exploit
the temporal dependence amongst outcomes and are often used to predict the future in many
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areas outside of HTA, the motivating hypothesis of this thesis is that time series models will be
of value for extrapolating survival data in HTA.
A large appeal of time series models is that they can exploit the temporal structure of the data;
resulting models are known as ‘local’ models. For a local model, the model parameters can vary
continuously over time. In contrast, survival models currently used in HTA are ‘global’ models.
Global models have the property that the model parameters are fixed, so that they are the same
at all time-points. A third type of model is a piecewise model; for this the full-time span is split
into mutually exclusive (and exhaustive) subsets. Model parameters are fixed within a subset
but can vary across subsets. An example of a piecewise model would be if the observed data
were split into two halves, with a different model fit to each half. Global models may be viewed
as a special case of both piecewise models (where there is only one subset) and local models
(where model parameters do not vary). Further, for a piecewise model the full-time span may
be split so that each subset contains a single event time. This piecewise model would then use
the same intervals as a local model but it is not the same as a local model in general. This
special case of the piecewise model is referred to as a local piecewise model. For this model, an
independent model is fit to each time interval meaning that model parameters are independent
across time and the temporal structure of the data is ignored. In contrast, a local (non-piecewise)
model introduces correlations in the parameter estimates across time intervals. These temporal
correlations (also known as autocorrelations) mean that the evolution of parameter estimates
over time follows a time series. The use of different time series will lead to different local models.
To avoid a loss of information, in this thesis the number of time intervals shall equal the number
of unique event times, as recommended in the literature [38]. Previous research has suggested
that results are generally robust to the choice of time intervals, provided that there is at least
one event per interval (as occurs in the approach used here) [39, 40].
To highlight the differences between global and non-global models, a simple example shall be
used. This uses a subset of the survival data from the case-study of Chapter 6 (restricted to
less than 10 months follow-up). This data is provided in Table 1.1 and is summarised by hazard
values over time (denoted by λti). The hazard may be viewed as the probability that a person
will die during a period (interval) of time, given that they were alive at the start of that interval.
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The data displayed in Table 1.1 were obtained by digitising a published Kaplan-Meier graph
so there are multiple events (deaths) per unique event time. The analyses of Chapters 4 and
5 demonstrate analyses with individual patient-level data so have one event per unique event
time.
A review of survival models used for extrapolation in HTA identified the Weibull as the most
frequently used model [18]. This is a linear model of the log-hazard (see my fellowship publication
[1], which is reproduced in Appendix 3, for further details). As such, it has two parameters:
an intercept (β1) and a slope, or trend (β2). In contrast, a piecewise local model divides the
observed data into mutually exclusive time intervals and fits a different linear model to each
interval, so the number of parameters will increase as the number of observed events increase.
For local models, including a correlation between the parameters means that they are no longer
independent. As such, there is no straightforward interpretation of the number of parameters
in a local model.
The data of Table 1.1 relate to 22 unique death times. One approach is to fit a local piecewise
model, assuming a linear change between observations. For this local piecewise linear model
there is a single intercept and 22 trends (β2,ti). Estimates from this model are provided in the
left-hand pane of Figure 1.1, whilst estimates from the Weibull model are displayed in the right-
hand pane. The estimates from the two models are very different: the piecewise model exactly
matches the data. Hence it provides a very good fit to the observations but there is a strong
possibility that it is over-fitting the data, as some of the variation will be due to random noise. In
contrast, there is little danger of the Weibull model over-fitting any noise in the data. It captures
the general trend of the hazard to increase over time. However, there is a possibility that the
Weibull model is under-fitting the data, so potentially failing to capture any important local
variations about the increasing in the trend. Use of the global Weibull model also assumes that
the observed trend is the same at all time-points. Use of local time series models are designed
to overcome the limitations with both piecewise and global models and so identify the optimal
middle-ground between over-fitting (as may occur with a piecewise model) and under-fitting (as
may occur with a global model). The analysis of Table 1.1 with a local model is presented in
Chapter 6, the results of which suggest that there is important local variation in the hazard




















Table 1.1: Data used in Figure 1.1
Time Alive At risk Events Hazard
0.45 137 62.23 3 0.05
0.60 134 19.22 2 0.10
1.31 132 94.30 10 0.11
1.46 121 17.36 1 0.06
2.13 120 79.98 6 0.08
2.51 113 43.22 6 0.14
2.84 107 35.80 4 0.11
3.13 103 29.55 1 0.03
3.85 102 73.14 4 0.05
4.04 98 18.74 1 0.05
4.61 97 55.65 8 0.14
4.90 89 25.53 5 0.20
5.28 84 32.13 6 0.19
5.57 78 22.37 4 0.18
6.00 74 31.84 6 0.19
6.62 68 42.26 8 0.19
6.76 60 8.60 1 0.12
7.53 59 45.14 5 0.11
7.72 54 10.32 1 0.10
8.53 53 42.67 6 0.14
8.63 46 4.40 1 0.23
9.44 45 36.57 5 0.14




















































Global linear (Weibull) model
CHAPTER 1. INTRODUCTION 10
As mentioned, the global model and the local piecewise model provide very different estimates
in Figure 1.1. These differences are driven by the use of different structural assumptions. These
structural assumptions highlight both the strengths and limitations of the two modelling ap-
proaches:
Global linear model (Weibull): This assumes that the evolution of the log-hazard function
over time may be described by a single linear model with two parameters. The two main
strengths of this assumption are:
• It provides a parsimonious description of the data, so is unlikely to over-fit the data.
• Estimates of the two parameters are based on all of the observed data, so will be
more precise than estimates based on subsets of the data.
The main limitations with the assumption of a global linear model are:
• The assumption of global linearity is a strong one; the model will not give a good fit
for non-linear hazard patterns.
• When estimating the model parameters, the most weight is given to data at the
start of follow-up and the least weight is given to data at the end of follow-up (as
these have the largest and smallest sample sizes, respectively). This is problematic
when generating extrapolations as data at the end of follow-up are likely to be more
representative of the future than data at the start of follow-up.
Local piecewise linear model: This assumes that the log-hazard function may be adequately
modelled by the observed hazard rates, with a linear change in-between observations. It
is able to remove the limitations of the Weibull model:
• The assumption of piecewise linearity allows this model to fit closely any type of
complex hazard pattern.
• To generate extrapolations the last estimate of trend may be used. This ensures that
extrapolations are based on the most recent (and hence potentially most relevant)
data.
However, the piecewise linear model loses the strengths of the Weibull model:
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• The observed data is likely to include some random variation; by using the obser-
vations directly the piecewise model will be over-fitting the data. This may also be
noted as the model has more parameters than there are unique event times.
• Estimates of the trend at any given time are based on two observations, so will be
highly variable. This can include ‘jumps’ in the model estimates. It will also induce
additional uncertainty in extrapolations when compared to using the whole data to
inform extrapolations, whilst the reduced sample size means that extrapolations may
be less accurate.
• Use of different time intervals can lead to markedly different extrapolations [27] and
there is no guidance on what time intervals should be used in a piecewise model.
Of note, the local piecewise linear model is a parametric model (having d+ 1 parameters, where
d is the number of unique death times). It is also the same as the Kaplan-Meier estimate of
the hazard, which is referred to as a non-parametric method [17]. Hence for this thesis the
distinction between parametric and non-parametric methods (or models) is not important. The
key distinction is the assumptions made by the differing models along with how realistic they
are [41].
Piecewise models are local models but they do not exploit the temporal dependence amongst
outcomes. Time series models exploit this temporal structure; doing so allows them to retain the
advantages of piecewise models, whilst ameliorating their limitations. The time series models
used in this thesis are an extension of exponential smoothing models [42]. They may be viewed as
piecewise models for which parameter estimates at time ti are correlated with previous parameter
estimates (for times < ti). For a local piecewise linear model the estimate of β2,ti = λti − λti−1
(or the equivalent on the log-scale), for an exponential smoothing model it is a weighted average
of the previous model estimate and the observed data: β2,ti = αβ2,ti−1 + (1 − α)(λti − λti−1).
The advantages of using a time series local model are:
• It makes a very weak structural assumption: that data which are close together in time
are similar (correlated). This allows it to fit many complex hazard patterns.
• Unlike a global model, more weight is given to more recent data when generating extrap-
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olations. Unlike a piecewise model, all of the observed data are used when generating
extrapolations (the amount of weight given to older observations decays exponentially).
• The degree of correlation between observations is estimated during model fitting and can
be constrained to reduce the danger of over-fitting.
• The global and local piecewise local models are included as special cases (with correlations
of one and zero, respectively).
As such, the use of time series models for generating extrapolations in HTA has strong theoretical
support. In particular, their use would immediately resolve an on-going area of disagreement in
the HTA community. This has seen rise to two schools of thought about the best approach to
extrapolation when using common practice survival models. One is that all of the data should
be used to avoid a loss of information, the other that models should be fit to a subset of the more
recent data to give additional weight to the more recent observations [18, 19, 28]. There are to-
date no practical applications or evaluations of the use of time series methods for extrapolation
with HTA. This thesis aims to fill this evidence gap.
1.3 Aims and thesis layout
The main research question to be answered by this fellowship is: “What is the value and role
of time series methods for generating predictions of future survival in HTAs?” To answer this
question it is important to identify alternative methods that may also be used to predict future
survival. This fellowship has the following aims:
1. Identify methods that may be used in addition to time series methods for predicting the
future within the context of HTA.
2. Compare the extrapolation performance of time series and comparator methods.
3. Establish the suitability of using time series methods for extrapolation in a HTA context.
4. Develop good practice for using time series methods to generate predictions.
5. Identify areas for future research.
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To achieve these aims, the following work was undertaken:
1. Establish current practice for extrapolation of survival data via a review of the methods
used in English HTAs.
2. Conduct a literature review to identify alternative methods (to time series models and
current practice) for the extrapolation of survival data.
3. Perform a literature review to describe the current state of the art for applying time series
models to survival data. If required, develop extensions to these models in response to the
challenges of extrapolation in HTA.
4. Implement simulation studies and a case-study to evaluate the extrapolation performance
of the identified methods.
5. Replicate an existing HTA to demonstrate the feasibility of incorporating the output of
time series models in cost-effectiveness models.
6. Use the results of the above analyses to produce good-practice guidelines.
The consideration of uncertainty in extrapolations is also very important. This uncertainty may
be quantified within an economic evaluation via probabilistic sensitivity analyses and value-of-
information analyses [43, 44, 45]. A full treatment of these topics is beyond the scope of this
thesis so is not pursued in detail here, although it is illustrated in Section 6.4.2. Further, I have
provided some exploratory work into this as part of my fellowship. This work highlighted that
the choice of survival model for extrapolation can significantly impact on both the extrapolated
hazard function and estimates of cost-effectiveness. These differences were observed even when
the fits of different models to the observed data were similar and in general this structural
uncertainty was not reflected by estimates of uncertainty from any given survival model. This
work has been published as a peer-reviewed manuscript [2].
The remainder of this these is arranged as follows. Alternative extrapolation approaches to
time series methods are identified in Chapter 2. This chapter includes both a review of the
methodological literature and a review of NICE TAs (Sections 2.1.1 and 2.1.2 respectively).
Together, these reviews help to delineate comparator methods, including both current practice
approaches and emerging approaches. A framework that allows for the use of time series methods
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to extrapolate survival data is described in Chapter 3. This chapter also provides a focused
review of relevant time series literature in Section 3.2 to identify state of the art methods. The
results of this review motivated novel work that was developed as part of this thesis. This work
includes extensions to the framework to make it more useful in a HTA context (Section 3.3) and
a simulation study which was performed to inform model specification (Section 3.4).
Extrapolation performance was assessed using a real patient-level dataset in Section 4.1. For
this case-study both time series methods and the identified competing approaches were fit to an
interim analysis of trial data and extrapolations were compared against the available longer-term
data. Simulation studies were also used to compare the extrapolation performance and technical
properties of the available methods. These simulation studies used complex hazard patterns.
In both situations the overall hazard arises as a mixture of two sub-group hazard functions.
In Chapter 4 these two sub-groups represent different levels of frailty (likelihood of death over
time). The situation where one group may be viewed as cured is covered by Chapter 5, which
considers extrapolating models with and without a cure fraction.
As many of the statistical models considered are more complex than those routinely used in
HTA, it is important to consider the feasibility of incorporating them within appraisals. This is
provided in Chapter 6, which recreates an existing NICE appraisal where differing approaches to
extrapolation had a substantial impact on cost-effectiveness. These approaches to extrapolation
were identified as a key source of decision-making uncertainty. This chapter also illustrates the
incorporation of external evidence to avoid implausible extrapolations, because this issue was
highlighted in the original appraisal.
An overview of the work performed, the contribution to the knowledge base, suggested good
practice guidance, and a discussion of potential avenues for future research are provided in the
concluding Chapter 7.
1.4 Conclusions
Finite health care resources have led to the development of HTA as a framework for helping to
inform decisions about which technologies to fund. To make fair comparisons across different
technologies it is important that a common metric is used and that all differences in outcomes
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are incorporated within the assessment. To achieve this typically requires evidence on outcomes
for a longer time-period than is available. Hence statistical methods are required to predict
future outcomes based on the available evidence. The use of different statistical methods can
lead to substantively different extrapolations, which in turn can lead to different funding de-
cisions. Recent reviews have highlighted that current approaches to extrapolation in HTA are
often arbitrary, with little justification and little consideration of more flexible approaches. In
addition, time series methods are routinely used for making predictions in subject areas outside
of HTA but to this author’s knowledge have not been used in HTA. This suggests that further
research is required into establishing the role and value of more flexible methods for producing
extrapolations in HTA. This thesis seeks to contribute to the knowledge base and help to close
this evidence gap. One of the key contributions is the introduction and evaluation of the role
of time series methods when extrapolating survival data in HTA. This includes novel develop-
ments both to incorporate external evidence and also to facilitate extrapolations. A further key
contribution is the rigorous and comprehensive identification and evaluation of methods for the
analysis and extrapolation of survival data in a number of different situations, including curative
treatments. The choice of methods to evaluate, in addition to time series methods, was informed
by comprehensive reviews of both the methodological literature and the methods used in NICE
TAs. These reviews and their results are detailed in the next chapter.
Chapter 2
Literature review of survival analysis
methods
The primary aim of this thesis is to identify the value and role of using time series methods to
analyse and extrapolate survival data as opposed to alternative methods. To achieve this aim it
is important to identify the alternative methods that are available, and what should be included
as comparator methods in this thesis. Two types of comparator are of interest:
Current practice. This represents statistical models that are routinely used for extrapolating
survival data in HTA. As the field of HTA is broad, this review focuses on submissions
to the NICE TA programme, which has long-been viewed as an internationally influential
example of HTA [46].
Non-standard models. These models are defined as those that may be used to extrapolate
survival data but are neither time series models nor current practice. This literature review
identified more non-standard models than could be evaluated within the timescales of this
fellowship. As such, a clear justification is provided for which non-standard models were
retained. This justification includes a consideration of ease of use and how extrapolations
are generated (for example, if the models are global or local).
The identification of these two types of comparator required two types of literature review.
A review of the methodological literature was conducted to identify the available statistical
16
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methods. A review of NICE TA submissions was then performed to identify which of the available
methods represented current practice. This chapter describes the process of performing these
reviews, the identified models, and details on the models that shall be considered in subsequent
chapters. The methods used are described in Sections 2.1.1 and 2.1.2 for the methodological
review and review of NICE appraisals, respectively. The primary aim of the reviews is to identify
comparator methods to time series methods, but the reviews are broad enough to also identify
relevant studies that used time series methods. Results of both reviews are presented in Section
2.2. A broad overview of the resulting long-list of methods is described in Section 2.2.1. This
overview provides, for each of the identified methods: the applications that it has been developed
for; the strengths and limitations of this method; its use within NICE TAs; and the implications
for this thesis if the method is pursued (including risks and evidence gaps). The results from
this broad overview were then used to justify the short-list of methods to take forwards for
further research, as discussed in Section 2.2.2. For this short-list of methods, a more detailed
technical discussion including their assumptions, strengths and weaknesses is provided in the
published manuscript “Generalized Linear Models (GLMs) for Flexible Parametric Modeling of
the Hazard Function” (hereafter “the GLM manuscript”). This manuscript is an output from
this fellowship and is reproduced as Appendix 3.
2.1 Methods
2.1.1 Methodological review
The aim of the methodological review was to identify the breadth of statistical methods avail-
able for the analysis and extrapolation of survival data. There are a wide variety of different
approaches to performing literature reviews; with at least 14 main types [47]. A mapping re-
view was chosen in consultation with a systematic reviewer at ScHARR, as it was felt that this
would be the most appropriate approach. Mapping reviews attempt to categorise the available
evidence and current knowledge pertaining to a broad topic of interest [48, 49]. Studies are
synthesised by categorising into similar themes (or knowledge clusters), without formal quality
assessment [48, 50]. The mapping review had the following two steps:
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1. Conduct a mapping review of the methodological literature.
2. Use the results of the mapping review to characterise the strengths and weaknesses of the
identified methods.
The mapping review took the form of comprehensive literature searches in two databases, sup-
plemented by pearl-growing techniques [51], hand searching of both key journals and the grey
literature, and a keyword search.
As the review was of the methodological literature, traditional reviewing methods required
modification [52]. In particular, it was important to distinguish between two types of literature
[52, 53]:
1. The methods literature, which presents a method and describes the theory underlying it,
and
2. the ‘case-studies’ (operationalisation) literature, which provides empirical evidence about
how a method may be applied in practice
The focus of the mapping review was on the methods literature. In contrast to traditional re-
views, there is no need to identify every study that describes a given method as there is unlikely
to be any added value from repeatedly reviewing the same methodological approach. As an ex-
ample, the semi-parametric Cox proportional hazards model is a method for analysing survival
data. The paper that introduced this model has been cited almost 35,000 times [54]. Hence, any
search strategy which did not make a distinction between methods literature and case-studies
literature, and which also sought to identify all of the articles which used statistical methods to
analyse survival data is likely to identify an impractical number of articles for reviewing.
Another feature of methodological reviews is that searches should cover a broad range of evidence
sources, including non-journal articles [52, 53]. If key journals are identified, hand-searching
these may be a viable search strategy [53, 55]. The reviews may also be iterative, as the
understanding of the available research methods (and what should be included in search terms)
evolves [56, 57, 58]. More details on the search strategy, including the search terms used, are
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provided in Appendix 2.
The following sources were used:
• Bibliographic databases: PubMed and Web of Science (WoS). Search terms were created
in consultation with an information specialist. Two separate searches were conducted.
The first was to identify studies describing methods specifically for the extrapolation of
survival data. The second was to identify review articles on the analysis of survival data.
• Hand-searching journal articles: Journal of the Royal Statistical Society, Series B (JRSS
B): all articles. Statistics in Medicine: tutorials in biostatistics, Medical Decision Making:
special issue on “Methods for Extrapolating Survival in Cost-Effectiveness Analyses”. The
choice of journals and articles to hand-search was a pragmatic one aimed at identifying
with high specificity (precision) relevant articles, whilst also keeping the number of articles
to sift at a feasible amount.
• Citation searching of key studies identified via the above methods.
• Grey literature: Academic textbooks, and the methods available in the statistical software
packages STATA (user packages) and R (as listed in the CRAN Task View for survival
analysis [59]).
• Key-word searching: The term “Expectation of life” was identified during the searching
process (and was not part of the search terms developed for the bibliographic databases),
so a keyword search for this was performed in PubMed.
For a mapping review results are categorised into themes. The definitions of these themes
evolved as the understanding of both the methods and the implications of the categorisations
evolved. As such, categorisation was an iterative process relying on subjective interpretation.
This approach is also referred to as the concept of literary warrant [47, 60]. The subsequent
classification of themes into five broad groupings likewise evolved over time. It is noted that
these types of classification are by their nature subjective, and that the important aspect is that
the process is explicit and transparent [61, 62]; use of a mapping review ensures that the search
process is systematic.
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Inclusion and exclusion criteria
As the mapping review sought to answer a broad question, the inclusion criteria were intention-
ally kept broad. The literature reviews included grey literature in addition to journal articles;
these are collectively referred to as ‘sources’. The inclusion criteria were:
1. Source contains one or more descriptions of a modelling method for the analysis of survival
data.
2. English language publication.
3. (Books only): Not superseded by a more recent publication.
Further to the first inclusion criteria, sources that only included a general discussion (either of
survival modeling or of extrapolation) were excluded. There were also some pragmatic exclusion
criteria, as it was decided that certain methods would be outside the scope of the fellowship.
The exclusion criteria for the comprehensive review were:
1. Source only describes methods for treatment switching.
2. Source only describes methods for network meta-analysis.
3. Source only describes methods for high-dimensional (or multivariate) outcomes, defined
for this search as more than two outcomes.
The grey literature searches and hand searching of journals had date-based exclusions, as de-
scribed in Appendix 2. All searches were performed on 31st July 2017.
2.1.2 Review of NICE appraisals
The aim of this review was to identify the type and frequency of methods employed to analyse
and extrapolate survival data in practice, using the NICE TA programme. A benefit of using the
NICE TAs programme as the sampling frame for identifying current practice is that it provides
a very focused search, as all of the studies are in the context of HTA, and it is anticipated that
the majority of the studies will include an analysis of survival data.
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A subset of all NICE appraisals that had been published or updated since the start of September
2013 and the end of June 2017 was reviewed. The start date was chosen as being six months
after the last update of the NICE DSU TSD on extrapolating survival data [20]. This guidance
is expected to influence the approach taken to extrapolation in NICE appraisals, which were
assumed to take about six months to complete. In total, there were 140 appraisals in this period.
The number of appraisals to review was not pre-defined; instead reviewing occurred until it was
felt that data saturation had occurred; that is further reviews would not substantially alter the
results of this review. There is an element of subjectivity in identifying the saturation point,
as the possibility cannot be disregarded that important methods were covered in the excluded
appraisals. However, this approach maximises the number of appraisals that can be included
within a time-constrained review. The appraisals were reviewed in a randomly determined order.
Whilst conducting this review, an independent review of NICE cancer appraisals was started in
ScHARR (commissioned by Bristol-Myers Squibb, hereafter referred to as the ‘BMS review’).
This reviewed all cancer appraisals between the start of July 2011 (the initial publication of the
DSU TSD on extrapolation), and the end of June 2017. For my review I included 62 appraisals,
of which 32 were cancer appraisals. The BMS review included a further 30 appraisals that I did
not review. As the results from the BMS reviews are relevant to this work, they are discussed
jointly here. Hence, 92 appraisals are included in this review, of which 62 were reviewed by
myself (67%). These reviews cover all cancer appraisals that commenced since the publication
of the DSU TSD on survival modelling [20], along with a simple random sample of non-cancer
appraisals. Detailed results for the BMS review are available in an open-access publication [21]
(there is a minor difference in the included cancer appraisals, as I included multiple technology
appraisals, whilst the BMS review excluded these).
For each appraisal, details were extracted on the approach described within the company (or
analysis group) submission for analysing and extrapolating survival data (when applicable). If
there were multiple survival outcomes, evidence was extracted for the outcome which had the
most detailed description of the modelling approach. Two previous reviews of NICE TAs have
focused exclusively on cancer submissions ([18, 63]), so results were stratified by whether or not
the TA was cancer-related.
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2.2 Results
For the methodological mapping review, the number of results by evidence source is provided
in Table 2.1. Figures 2.1, 2.2 and provide modified PRISMA diagrams for the mapping review,
providing details on the search process by evidence source.
Table 2.1: Results by evidence source
Source Identified Retained
Web of Science: extrapolation studies 526 11
PubMed: extrapolation studies 807 17
Hand-searching Medical Decision Making 8 8
“Expectation of life” keyword search 320 0
PubMed: statistical reviews 334 10
PubMed: HTA reviews 1106 7
Citation searching 113 5
Hand-searching Statistics in Medicine 79 8
Hand-searching JRSS B 287 10
Academic textbooks 21 10
Software packages 260 32
Total 3861 118
The review of extrapolation studies returned 1,333 articles (807 from PubMed and 526 from
WoS). After removing duplicates, 1,311 articles remained. Of these, 18 relevant articles were
identified (10 were identified by both sources: [18, 19, 26, 64, 65, 66, 67, 68, 69, 70], seven by
PubMed alone: [23, 71, 72, 73, 74, 75, 76] and one by WoS alone: [77]). The Medical Decision
Making special issue provided an additional eight articles [22, 78, 79, 80, 81, 82, 83, 84]. The
targeted keyword search for “Expectation of life” did not result in any additional studies.
The review of statistical reviews identified 10 relevant articles [18, 85, 86, 87, 88, 89, 90, 91,
92, 93]. The review of HTA reviews identified 6 articles [18, 19, 55, 94, 95, 96], in addition
to one article from the grey literature that was already known [15]. Five of the articles only
considered standard survival models with at most two parameters. No review sought to identify
all of the available methods for the analysis and extrapolation of survival data, nor were time
series methods considered.
Citation searching led to a total of 113 studies, of which eight were highlighted as being relevant.
Two of these were existing pearls [18, 19], and one provided an overview of an existing pearl
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[55], hence there were five additional studies [97, 98, 99, 100, 101]. All of these cited the pearl
by Latimer [18], which also had the highest number of citations (42). One study also cited the
pearl by Guyot [94].
Hand-searching journals resulted in the identification of eight tutorials from Statistics in Medicine
[76, 102, 103, 104, 105, 106, 107, 108] and 10 articles from JRSS Series B [109, 110, 111, 112,
113, 114, 115, 116, 117, 118]. The grey literature identified 10 academic textbooks that were of



























































Figure 2.2: PRISMA flow diagram: hand-searches and grey literature
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Figure 2.3: PRISMA flow diagram: extrapolation specific reviews
Across all of the evidence sources, there were a total of 118 retained results, of which 76 were
journal articles. Some of the retained journal articles were duplicated across evidence sources,
removing these led to 62 unique retained articles. The identified approaches for analysing and
extrapolating survival data described in all the retained results were classified into 19 methods,
as detailed in Table 2.2 (along with an additional method, as described below). These were
in turn grouped into five broad categories: models for which time to event is the outcome,
models for which the hazard (or equivalently, the survival) function is the outcome, models that
account for patient heterogeneity, models for patient histories, and an ‘other’ category for all
other approaches. This grouping was based primarily on the type of research question that the
methods aimed to answer.
The 92 NICE appraisals reported the results of 95 analyses (65 cancer). Of these, 81 analysed
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and extrapolated survival data (65 cancer). Table 2.2 also includes details on the percentage of
NICE appraisals that included each method. All but one of the NICE appraisals that included
extrapolation considered standard 1 or 2 parameter models. For the one appraisal that did not
(TA414), the company applied a mixture-cure model, arguing that standard parametric models
would not be appropriate. Of note, five appraisals (one cancer) did not fit an explicit para-
metric model, but instead applied a constant hazard over time, which is equivalent to using an
exponential model (so was classified as such). The only three-parameter model encountered was
the generalised gamma, which was used more frequently in cancer appraisals than non-cancer
appraisals (42% vs 19%). Other notable differences were the use of hybrid models, which were
used in 22% of cancer appraisals but not considered in the non-cancer appraisals. In contrast,
age-time models (which included the impact of ageing on the outcome when extrapolating with-
out using the framework of cure models, as described in more detail in Section 2.2.1) were used
more commonly in non-cancer appraisals. Use of the remaining 15 methods was very low in all
TAs, with 12 methods not considered in any appraisal. One method was not identified by the
methodological mapping review but was used in a NICE appraisal. This was the two-parameter
Extreme value model, which was used in four appraisals (three cancer). Of note, this model al-
ways provided a worse within-sample goodness of fit than all of the other two-parameter models
considered (as a minimum, the Weibull, log-logistic and lognormal were always also considered).
Hence this model is not considered further.
The methodological review identified one approach that used time series methods: Lee-Carter
models [73]. These are categorised as ‘age-time (non-cure) models’ and are described in more
detail in Appendix 2 (“Literature review: incorporating external data”). There were no time
series methods used to extrapolate survival data in NICE TAs. An additional time series method
is the use of dynamic models [128]. These are introduced and described in the next chapter,
along with justification for why they are the primary focus of this thesis. The use of dynamic
time series models for the analysis and extrapolation of survival data was not identified in any
of the reviews, but is included in Table 2.2 for completeness. An overview of the strengths and
limitations of both dynamic models and the identified methods is provided in the next section.
For each identified method this includes a discussion of the potential implications for this thesis
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if it were retained as a comparator. As analyses in this thesis use R, this overview also includes
a discussion of the available R packages known to the author.
Table 2.2: Long-list of identified modelling approaches from the methodological review, and
their use in NICE appraisals
Method Cancer TAs (n = 65) Other TAs (n = 16)
Time as the outcome models
Standard 1 and 2 parameter models 64 (98.5%) 16 (100%)
Three parameter models 27 (41.5%) 3 (18.8%)
Generalised F 0 (0%) 0 (0%)
Hybrid (Kaplan-Meier and parametric) models 14 (21.5%) 0 (0%)
Non or semi-parametric models 0 (0%) 0 (0%)
Hazard as the outcome models
Royston-Parmar (R-P) spline models 2 (3.1%) 0 (0%)
Fractional polynomials (FPs) 0 (0%) 0 (0%)
Generalised additive models (GAMs) 0 (0%) 0 (0%)
Modelling patient heterogeneity
Mixture (non-cure) models 0 (0%) 0 (0%)
Cure models 1 (1.5%) 0 (0%)
Polyhazard models 0 (0%) 0 (0%)
Frailty (multilevel) models 0 (0%) 0 (0%)
Modelling patient histories
Multistate models 0 (0%) 0 (0%)
Competing risks models 0 (0%) 1 (6.3%)
Recurrent events models 0 (0%) 0 (0%)
Other modelling approaches
Age-time (non-cure) models 3 (4.6%) 5 (31.3%)
Relative survival models 0 (0%) 0 (0%)
Joint models (survival and longitudinal) 0 (0%) 0 (0%)
Dynamic models for survival data* 0 (0%) 0 (0%)
*Not identified in any reviews but included as the primary focus of this thesis.
2.2.1 Overview of the identified methods
Time as the outcome models
Overview and research questions developed for: Time as the outcome models were de-
veloped specifically to analyse survival data. These are suitable when only one outcome can be
observed for each individual, and it may only be observed once. A prominent example is overall
survival. The use of parametric models to analyse survival data has a long history, with an early
CHAPTER 2. SURVIVAL ANALYSIS REVIEW 29
example provided in 1952 [129]. Over time a wide variety of such models have been proposed:
some key models are described in Appendix 1. Many of the models can be viewed as special
cases of the four-parameter generalised F [130]. In general, models with more parameters are
more flexible. Standard one and two parameter models (e.g. the exponential and Weibull) have
been used in a number of appraisals [20, 95], as have piecewise models [20, 26].
Strengths: A strength of these parametric models is that a wide variety of different model
specifications are available, with more complex models allowing more flexibility. For example,
there are at least 14 members of the generalised F family ([130]), and models with three or more
parameters are generally flexible enough to model complex hazard functions [102, 131]. Further
flexibility is afforded by the use of hybrid (or piecewise) models, which fit different models to
subsets of the data, with extrapolations based on the most recent (and hence most relevant)
section of the data. Semi-parametric models make fewer assumptions than fully parametric
models, so are more robust to errors due to model misspecification.
Limitations: The variety of models is also a drawback as it is often not clear how model
selection should be performed; hypothesis testing cannot generally be used to choose between
candidate models and within-sample goodness of fit may not predict extrapolation performance.
Models with few parameters may impose unrealistic assumptions, such as no turning points in
the hazard function. Models with more parameters are more flexible, but require larger datasets
to avoid model instability, and may lead to over-fitting. Limitations with the use of hybrid
models for extrapolation include a loss of information and sensitivity to the arbitrary choice
of which data to include in the extrapolating model. Both limitations will lead to additional
uncertainty in extrapolations, compared with using a single model at all time-points. The use of
piecewise models also leads to ‘step’ changes in the estimated hazard, which may not be clinically
plausible [98]. To extrapolate from semi-parametric models, Bayesian methods are required with
a parametric prior; the sensitivity of extrapolations to the choice of prior distribution was not
assessed in the identified literature, so is unclear.
Implications for this thesis: Implementation for many of these methods in R is not an issue,
as eight standard models are available within the package flexsurv [100]. This includes the
generalised F; additional models could in theory be derived as special cases of this.
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For this thesis, the main drawback of considering these models is that it is unlikely to add any
value to the existing literature. The models are well described in both the HTA [19, 20, 94, 95]
and the extrapolation literature [23, 26, 69, 83]. Further, except for the generalised F, many of
the models have been used in a number of NICE appraisals (see Table 2.3).
Hazard as the outcome models
Overview and research questions developed for: Models in this category were not origi-
nally developed for the analysis of survival data. Instead, they were designed to provide flexible
descriptions of non-censored outcomes, replacing potentially restrictive structural assumptions
(such as linearity) with a less strong assumption of smoothness. They can be used to model
the hazard, as described in the GLM manuscript (Appendix 3). Fractional polynomials (FPs)
represent the effect of time on the hazard by a combination of polynomials (typically one or
two), where the powers for the polynomials are estimated from the data and taken from the set
(−2,−1,−12 , 0,
1
2 , 1, 2, 3), or the logarithm of the variable is selected [132, 133].
There are different approaches to the specification of spline models. One is to split the observed
follow-up time into a series of intervals and fit a separate model to each interval. If cubic poly-
nomials are used with certain restrictions (such as not having discontinuities across intervals)
this leads to restricted cubic splines (RCSs) [22, 71, 134]. An alternative uses a mixture of
global splines with penalisation for complexity; for this thesis this approach is referred to as a
generalised additive model (GAM) [97, 135]. The application of RCS models to survival data
was first described by Royston and Parmar [136], such models are referred to as Royston-Parmar
models (RPMs) in this thesis and have been used to extrapolate survival data [22, 71, 80]. Con-
trastingly, there were no identified examples of applying FPs or GAMs to extrapolate survival
data in HTA.
Strengths: A strength of both spline-based models and fractional polynomials is their flexibil-
ity for modelling complex hazard functions. Unlike standard survival models, multiple turning
points in the hazard can be captured, and the models can be made arbitrarily flexible by incor-
porating more parameters. These models can also be combined with some of the other identified
methods (such as being used in a cure model). As such, they can be applied to most research
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questions.
Limitations: All of the methods can require a large number of parameters, so require large
sample sizes for stable estimation and to avoid overfitting (or in the case of FPs, to detect non-
linear functions), with more flexible models requiring more data. There may also be uncertainty
over the best model to use. A further limitation of these methods is that as they were not
developed for the analysis of survival data, difficulties may arise when applying them in this
context, such as estimating negative hazards (if modelling the cumulative hazard, and it is
estimated to decrease [136]).
Implications for this thesis: The lack of examples that apply FPs or GAMs to survival data
represents both a risk and an opportunity for this work. It is a risk as it is unclear how feasible
such an application would be (as there do not appear to be R packages available that explicitly
apply FPs or GAMs to survival data). It is an opportunity, as such work would represent a
useful addition to both the theoretical and applied literature for HTA extrapolation. Whilst
the use of RPMs is well described in the literature, there are few examples of their use in NICE
appraisals.
Modelling patient heterogeneity
Overview and research questions developed for: This category of models is useful in
situations when outcomes are believed to vary because of latent (unobserved) characteristics.
Mixture ([137]) and polyhazard ([67, 64]) models both assume that the unobserved variables
may be represented by multiple sub-models which vary with regards to how these sub-models
are derived and estimated. Sometimes it may be assumed that a sub-group will become ‘cured’
([17]); methods to model this are known as cure models, which typically take the form of mixture
models ([71, 75]). An alternative approach is frailty (multi-level) models ([17, 107]) which model
additional variation in the outcome due to unmeasured variables, with the result that some sub-
groups are more prone to the outcome (more frail) than others. This is achieved by the inclusion
of random-effects. Frailty models may also be used when data are collected on multiple levels;
for example clustering of individuals by centre within a multicentre trial [91].
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Strengths: Mixture (including mixture cure) models may often be motivated on clinical grounds;
for example if it is believed a priori that a certain sub-group may become cured. In addition,
the explicit modelling of heterogeneity can lead to more accurate estimates of uncertainty for
covariate effects. These models are generally very flexible, and so may be used for survival
analysis and extrapolation, even if they are not clinically motivated [138].
Limitations: As the heterogeneity is unobserved, model specification and justification (such as
the number of sub-models or frailty terms) can be difficult [107], which can lead to difficulties in
model fitting [17, 99, 127]. In particular, if there are no covariates in the model, frailty models
are not uniquely identifiable [139], meaning that different assumptions can lead to different
results.
Implications for this thesis: There is a general awareness of models for patient heterogeneity
within the HTA extrapolation literature [19, 64, 67, 75], but only one of the NICE appraisals
used any of these models (a cure model). At the time of conducting this review, R packages
do not appear to be available for either polyhazard or parametric mixture models. A package
for mixture cure models is however available (‘cuRe’ [140]), and it is possible to incorporate
random effect terms within the GLM survival framework (as described in the GLM manuscript
of Appendix 3). As such it would be feasible to include mixture cure models or random effects
within this PhD. For the other models there is a risk that a large proportion of the PhD would
be devoted to correctly implementing these models, which would detract from illustrating their
applied use in HTA.
Modelling patient histories (multiple outcomes)
Overview and research questions developed for: These models are appropriate for the
analysis of survival data when multiple outcomes may occur, and there is interest in modelling
the event histories of individuals. There are two main situations: first if a patient may experience
recurring events such as repeated hospital admissions; secondly if interest is in competing,
mutually exclusive, events such as cancer and non-cancer causes of death. Models are available
for the analysis of recurrent events [99, 124] or competing events [127, 141] in isolation. A broader
class of models, known as multistate models (MSMs), is able to model both types of patient
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history [17, 100]: competing risks (events) are represented by different ‘states’, and transitions
between these are defined, which allows for recurrent events. Standard survival models may
be viewed as a special case of MSMs, with two health states of ‘alive’ and ‘dead’ [100] and no
recurrent events.
Strengths: Advantages of MSMs are their applicability to a broad range of different research
questions, as well as their potential for flexibly modelling more than one outcome [17]. They
may also be used directly in HTA; serving as both the statistical and health economic model
[84].
Limitations: The main drawbacks with MSMs are that model specification can be difficult
[83], and a high amount of both data and data manipulation are required for use [123].
Implications for this thesis: The use of MSMs for extrapolation in HTA has been described
in a tutorial paper [84], and it has also been compared with the use of other health economic
models [83]. However, this only covered the use of MSMs for competing risks. Another study
described the use of competing risks models for extrapolation in a non-HTA context [81]. These
three papers were the only identified papers that covered this category in either a HTA or an
extrapolation context. Only one example of these models was identified in the NICE appraisal
review (of a competing risks model). As such, there is a possibility for further work into the
role of MSMs for recurrent events in HTA. An R package exists for MSMs [142].
Other modelling approaches
Overview and research questions developed for: These are models that do not fit within
the previous categories. Joint models were designed for the analysis of both survival and lon-
gitudinal data [55, 110]. Age-time (non-cure) models were developed for extrapolation (albeit
not always of survival data) and take advantage of the known future ageing of a cohort. These
may be applied either assuming that age and time effects are independent [23, 76], or that
they interact, using Lee-Carter models [72, 73]. Relative survival models were designed to
estimate disease-specific mortality from all-cause mortality where cause of death is unknown
[66, 71, 79, 124]. Dynamic time series models exploit the temporal structure of survival data,
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as outcomes are observed over time. The evolution of model parameters is assumed to follow a
time series, therefore models are very flexible [128, 143].
Strengths: With the exception of dynamic models, the identified approaches all incorporate
additional evidence (on all cause mortality or the effects of age or a longitudinal covariate),
which is likely to improve accuracy, and may facilitate the use of external evidence for informing
extrapolations. This may be particularly advantageous if the external evidence covers a longer
time horizon than the survival data. Dynamic models only impose the weak structural assump-
tion that estimates of the hazard function which are close together in time will be similar, with
the magnitude of similarity estimated during model fitting.
Limitations: The required additional evidence may not always be available. When it is, there
are often multiple approaches, with uncertainty about which should be used. This means that
generating extrapolations within the context of HTA may not be straightforward. For dynamic
models, their flexibility can sometimes provide difficulties in parameter estimation.
Implications for this thesis: Dynamic models are the primary focus of this thesis. Neither
Lee-Carter nor relative survival models have been described in the identified HTA literature.
Hence future work could explore their use in this setting. In addition, the only method that
was used in the NICE appraisals was age-time models, for which all implementations assumed
independent effects. This suggests that further research into implementing any of these other
methods may be beneficial. R packages exist for all of the approaches, although it is unclear if
these may be used to generate extrapolations for survival data (due to a lack of case-studies),
so there is a risk that additional development time may be required.
2.2.2 Identifying comparators
The most commonly used models were the one, two, and three parameter ‘time as the outcome’
models. More details on the specific model types is provided in Table 2.3. This lists the survival
models that were considered in the appraisals that included extrapolation. On average four
different models were considered in each appraisal. Overall, the two most popular models were
the exponential and Weibull, being considered in 91% and 80% of appraisals that included
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extrapolation, respectively. These two models were followed by the log-logistic and lognormal
models, which were both used in three-quarters of all appraisals. The generalised gamma was
the only three-parameter model used, it was often unclear if this model was used or if the two-
parameter gamma model was used; results are provided for these two models combined. Table
2.3 lists seven methods that may collectively be referred to as current practice.
Table 2.3: Models commonly used in NICE appraisals (gamma is both two and three-parameter
versions)
Model Cancer Tas (n = 65) Other TAs (n = 16) Total (n = 81)
Exponential 59 (91%) 15 (94%) 74 (91%)
Weibull 54 (83%) 11 (69%) 65 (80%)
Log-logistic 51 (78%) 10 (63%) 61 (75%)
Lognormal 51 (78%) 9 (56%) 60 (74%)
Gompertz 38 (58%) 8 (50%) 46 (57%)
Gamma 27 (42%) 3 (19%) 30 (37%)
In addition to current practice, a choice is required about the models that shall be used to
represent non-standard comparator models. Of the 18 potential comparator methods identified
in Table 2.2, two methods are categorised as representing current practice (standard one and
two parameter models, and three parameter models). It would not be feasible to include the
remaining 16 methods (some of which cover multiple models or model specifications) as com-
parators. Instead, a pragmatic approach was to restrict comparisons to those approaches that
may also be implemented within the GLM survival framework described in the GLM manuscript
(Appendix 3). Dynamic time series models are also implemented in (an extension of) the GLM
survival framework, hence restricting non-standard comparators to GLM-based approaches in-
creases their comparability with dynamic models. These models were further restricted to those
that could be fit in R. The resulting models are:
• First-order fractional polynomials.
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To summarise, in addition to current practice models there are five types of comparator model.
These represent more complex ‘emerging practice’ models. The GLM manuscript provides an
example of fitting four of these emerging practice models (cure models are not considered, as the
case-study was not for a curative treatment). The GLM manuscript (Appendix 3) also includes
extensions of the models to incorporate random effects. This extension was not considered
further in this thesis for two reasons. First, at a practical level, in the GLM manuscript case-
study this extension did not improve the extrapolations. Secondly, at a theoretical level it is not
anticipated that including random effects would have a noticeable impact on extrapolations. This
is because the random effect terms do not make any explicit assumptions about the evolution
of the model parameters over time (such as global or local changes), which is in contrast to the
five models chosen as emerging practice comparators. The evolution of model parameters over
time for the models considered in this thesis is provided in Table 2.4. It is noted that of the
emerging practice models included as comparators there were some examples of use in NICE
appraisals, with two considering RPMs and one including a cure model.
Table 2.4: Evolution of model parameters over time
Method Modelling of the hazard function over time
Dynamic survival models Local (correlated changes over time)
Current practice Global (does not change over time)
Fractional polynomials (1st
and 2nd order)
Global (does not change over time)
Royston-Parmar Piecewise (changes across intervals but not within intervals)
Generalised additive models Global (does not change over time)
Mixture cure Local (Weighted average of two global models, where the weights
change over time)
2.3 Conclusions
The mapping review of the methodological literature identified 19 models (or classes of model)
for the analysis and extrapolation of survival data, in addition to the use of dynamic models.
These were in turn broadly categorised into five categories. The most prominent approaches
to extrapolation in NICE appraisals were the use of standard one, two or three parameter
survival models, either on their own or as part of a hybrid approach where they are combined
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with Kaplan-Meier estimates of the hazard for earlier time-points. Of these standard models,
the most frequently considered were the exponential and Weibull. These results demonstrate
little change in the approach taken to extrapolation in NICE TAs up to the end of June 2017.
A review of NICE TAs between September 2004 and June 2008 found that the exponential
and Weibull were the most popular options [94]; the same finding was obtained in a review of
NICE cancer TAs completed by December 2009 [18]. Whilst there has been no change to the
most common extrapolation approaches between the earliest review and this review, there is an
emerging interest in more complex survival models such as cure models and spline-based models,
as neither of these were identified in the two previous reviews.
A strength of this review is the variety of different evidence sources considered, which in-
cluded relevant grey literature. There are currently, to this author’s knowledge, no published
methodological-focused reviews of the analysis and extrapolation of survival data. As such, the
results of this review help to fill an important evidence gap by systematically and transparently
identifying methods for the analysis and extrapolation of survival data. In addition, the ex-
plicit comparison of the available statistical models with those that have been operationalised
in NICE appraisals helps to identify implementation gaps. Several models, such as FPs, GAMs,
polyhazard models and joint models were identified that may be used for extrapolation, but to
the date of this review have not been used. This suggests that there are a number of useful
survival modelling approaches that could be considered in the context of extrapolation; some
but not all of these approaches are considered in this thesis.
There are limitations to this review. There is currently no gold-standard method for identifying
methodological articles. A comprehensive search strategy was developed. This was designed
to identify the majority of available methods, but it is not guaranteed to be exhaustive. It is
unclear if an exhaustive and feasible search strategy for methodological studies is possible; fur-
ther research into this aspect of evidence generation would be beneficial. There are at least two
examples of models that were not identified by the methodological review. The first is extreme
value models, which were used in four NICE appraisals (but always gave a worse fit than the
other models considered). The second example is dynamic time series models, which were not
identified by either the methodological review or the review of NICE appraisals. This highlights
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the low awareness and use of this method in medical statistics, reinforcing the importance of
work on this potentially useful survival model. Of the methods that were identified via the
methodological review, it is anticipated that all the main comparators to dynamic models have
been identified. A further limitation is that the extraction of evidence from NICE TAs was
limited. This is because not all the required evidence was made publicly available; in particular
appendices (which may contain further statistical analyses) were usually not available. In addi-
tion, it is important to distinguish between what may be used for the analysis and extrapolation
of time-to-event data, and what should be used. The lack of implementation of certain models
may be for a variety of reasons. For example, there may be a lack of awareness of the model,
software for implementing the model may not be available, or the model may not be suitable
(either for the extrapolation of data, or for use within the context of HTA). However, many of
the models (such as GAMs and FPs) are general methods that are likely to be applicable in any
setting. As such, it is likely that the lack of use of methods in HTA is due to a lack of uptake.
This review has identified methods where further research into the barriers and facilitators of
uptake would be useful.
The analysis and extrapolation of survival data is an important topic and an active area of
research. It is expected that the methods used within NICE appraisals may evolve over-time,
with increased use of more complex methods. For example, with an increasing prevalence of
curative treatments, the use of cure models or other flexible models to capture complex hazard
patterns may become more widespread. The methods identified as ‘current practice’ in this
chapter serve as a useful benchmark. These current practice models have a strong history of use
in appraisals and are straightforward to use in analysis. The inclusion of additional comparators
in this thesis means that the results shall remain relevant even if the types of survival model
commonly used in appraisals changes in the future.
In addition to dynamic time series models, seven models were identified as representing cur-
rent practice (exponential, Weibull, Gompertz, log-logistic, lognormal, gamma, and generalised
gamma) and five model classes were identified as representing emerging practice (first-order FPs,
second-order FPs, RPMs, GAMs, and cure models). Collectively these represent the compara-
tor methods to the use of time series methods. The next chapter provides a detailed overview
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of how time series methods and survival analysis methods may be combined, along with novel
extensions which make this combination more useful within the context of HTA.
Chapter 3
Combining time series and survival
models
When time series models are combined with survival models the resulting model is known as
a dynamic survival model (DSM). These models were introduced in the mid 1980’s but do not
appear to be often used within medical studies [144]. The reviews within Chapter 2, did not
identify any examples of DSMs in HTA. As DSMs represent the primary focus of this thesis, this
chapter provides an overview of DSMs, including their technical specification. An alternative
approach to DSMs (which amalgamate time series and survival models) would be to directly
apply time series models to survival data. This chapter begins with a discussion of why time
series models are not directly used, which motivates the synthesis of time series and survival
models. This synthesis can be achieved using the framework of dynamic GLMs. Dynamic GLMs
extend GLMs to allow model parameters to vary over time and hence represent a very flexible
family of models, including DSMs.
To inform the current state of the art for DSM specification and implementation, a literature
review was performed. The results of this are presented in Section 3.2. Novel extensions to the
DSM were developed for the analyses presented in this thesis. The technical details of these
extensions are provided in Section 3.3. In addition, a key difference between global (standard)
and local (dynamic) survival models is the inclusion of a parameter known as the innovation
variance. It is important that this parameter is appropriately included within a DSM, but there
40
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has been little research into the best methods for doing so. This is explored within a short
simulation study.
3.1 Dynamic survival models
Survival data may be characterised by the number of deaths per time interval, which forms a
time series. There are a number of theoretical advantages to using time series models for the
extrapolation of survival data, as outlined in Chapter 1. Given these, a natural question is why
are time series models not currently used in HTAs? A potential explanation is that there are
three key characteristics of survival data that standard time series models cannot accommodate:
Censoring: Observed survival times are censored if the outcome event has not occurred. This
may be because the person has dropped-out of the study (so is no longer followed-up),
or due to incomplete follow-up of an at-risk person. As censoring is a feature specific to
survival data, methods to handle censored outcomes are not routinely incorporated in time
series models.
Varying sample size: In survival studies it is important to account for the set of people who
are at-risk of experiencing the outcome event (such as death). By definition, after ex-
periencing the event these people will no longer be at-risk, neither will people who are
censored. Hence, due to the occurrence of both events and censoring, the available sample
size will decrease over time. Typical time series problems (such as estimating the future
temperature or rainfall in a region) are for tasks for which there is no well-defined sample
size.
Unequally spaced observations: Time series data are usually aggregated across equal time
intervals (for example, the average daily temperature or annual rainfall). It is possible
to represent survival data using equally spaced intervals, but this leads to a loss of in-
formation, so unequally spaced intervals (with one event per interval) are used in this
thesis.
Because of these three reasons, time series models cannot be directly combined with the standard
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specification of survival models (as provided in Appendix 1 where, for example, the likelihood
function includes information on censoring). This includes the use of Lee-Carter models, a type
of time series method identified in the comprehensive review of Chapter 2. Lee-Carter models
may be used to extrapolate summary mortality data, assuming that observations are equally
spaced over time, with no censoring and no differences in the underlying sample size. For the
approach used in this thesis, the combination of survival models and time series models occurs
within the framework of GLMs and their extension to dynamic GLMs. I provide a detailed
overview of GLMs, dynamic GLMs, and how to represent survival models as GLMs in the
published GLM manuscript, which is reproduced as Appendix 3. Below, a brief overview of the
key concepts is provided.
The theory of GLMs provides a unified approach for the analysis of a number of different data
structures [145, 146], of which the Poisson and Binomial distributions are of particular interest
to this thesis. It has long been noted that survival data may be modelled using either the
Poisson or Binomial distribution [38, 129, 147, 148, 149], hence survival data may be analysed
using generalised linear models. As an example, the GLM manuscript shows that the Weibull,
Gompertz, log-logistic and lognormal survival models may all be written as linear GLMs. The
framework of GLMs was introduced in 1972 [145], thirteen years later, this GLM framework was
extended to also include time series models, with the resulting framework known as dynamic
GLMs [150]. The general specification for dynamic GLMs is as follows:
Observation model: yti ∼ distribution(τti , µti ]) E[yti ] = µtiτti (3.1a)
Response function: µti = η(x
T
tiβti) (3.1b)
Transition model: βti = Fβti−1 + ζti , ζti ∼MVN(0,Zti) (3.1c)
Initial conditions: β0 ∼MVN(b0,Z0) (3.1d)
With the following components:
• yti is the outcome of interest (number of deaths in the interval starting at time ti and end-
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ing at time ti+1). It is assumed that there are T observations at times ti, i ∈ {1, . . . , T}.
Extrapolations are required for H time units (e.g. if ti is measured in years and extrapo-
lations are required for 5 years, then H = 5) and are denoted as ŷT+hi , hi, i ∈ {1, . . . ,H}
• The distribution of yti is assumed to be a member of the exponential family. For survival
data either the Poisson (when modelling the hazard rate) or Binomial (when modelling
the probability of death) distributions are the most relevant.
• τti contains information on the ‘at risk’ sample size in the interval [ti, ti+1). Let nti be the
number of people alive at time ti and cti be the number of censored events in the interval
[ti, ti+1). The calculation of τti depends on assumptions about when events and censorings
occur; this thesis uses the standard assumption that censorings occur half-way through
the interval, whilst events occur at the end (see for example Chapter 2 of Tutz and Schmid
[127]). Then: τti = (ti+1 − ti)(nti − cti/2). Hence τti contains information on the at-risk
sample size, the spacing between observations, and censoring (the three characteristics
of survival data that cannot be accommodated by standard time series models). For a
Poisson model, τti is included as an offset term. for a Binomial model it is included as the
sample size. Use of a Binomial model requires that τti be an integer. For this requirement
to be met, it must be assumed that censoring occurs at the end of the interval and intervals
are either of the same length (so this interval length may be defined as = 1), or the interval
lengths must all be integer multiples of the shortest length. Intervals with an unequal,
non-integer, length are used in this thesis to avoid a loss of information, so the Binomial
distribution is not considered further.
• β is a vector of parameter coefficients to be estimated from the data. In the context of a
DSM, the β are not directly observed, so are also referred to as latent variables.
• xt is a covariate vector, assumed known (with transpose xTt ). In general, covariates shall
not be considered in this thesis as the primary focus is on modelling the evolution of the
hazard function, not the impact of covariates on this function. Chapter 6 demonstrates
the inclusion of a covariate to describe a time-varying treatment effect.
• η() is a one-to-one response function which maps the linear predictor (xTt βt) to f(ti). Its
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inverse is known as the link function.
• F is a function (or transition matrix) describing how the coefficients evolve over time.
• MVN denotes a multivariate Normal distribution.
• The error term ζti is assumed to be an independent and identically distributed series and
Zti is a variance-covariance matrix. In the time series literature this is also referred to
as the innovation term; this term shall also be used in this thesis to emphasise the link
between survival and time series methods.
• The initial conditions specify starting values for the latent variables (at time ti = 0).
Of the terms in Equation (3.1), the observation model and response function define a standard
GLM. The transition model represents a time series model; its effect is to allow the parameters
of the GLM to vary over time, giving a dynamic GLM. The initial conditions define the initial
values (at time zero) of the parameters.
When applying a dynamic GLM to model the hazard or survival function, resulting models are
known as DSMs. For this thesis the following DSM specification is used:
Yti ∼ Poisson(exp(β1,ti)τti)
β1,ti = β1,ti−1 + β2,ti−1φωti
β2,ti = β2,ti−1φ+ ζti
ζti ∼ N(0, Z).
(3.2)
Where ωti = ti+1 − ti is the interval width. Global models occur when the innovations are all
= 0. To contrast with dynamic models, global models are also referred to as static models. For
global models, parameter estimates do not vary over time, the only variation is in the Yti , as
described by its distribution (here Poisson). In Equation (3.2) the first line includes both the
observation model and response function, the subsequent two lines are the transition model, and
the last line represents the initial conditions.
For the model of Equation (3.2) β1,ti may be interpreted as the log-hazard (or average value) at
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time ti. The change in the log-hazard for a unit time during the interval starting at time ti is
given by β2,ti . For extrapolations β2,T may be interpreted as the trend of a linear model. The
variable 0 ≤ φ ≤ 1 is a dampening parameter; the lower the value of φ the more the impact of
the extrapolated trend is reduced (dampened). Damped trend models are used in the time series
literature [151], but have not been considered for DSMs before, so their use here represents a
novel contribution. A particular problem arises when using damped trend models to extrapolate
data with unequal time intervals as it is unclear how to define the time intervals for extrapolated
periods; the approach developed for this thesis is described in Section 3.3.3. If φ = 1 there is no
dampening, resulting models are referred to as local trend models in this thesis.
In theory both β1,ti and β2,ti may vary over time. In Equation (3.2) only the β2,ti vary. This is
for the following three reasons:
1. Do to their flexibility, within-sample estimates of the hazard function are in general very
similar for DSMs with and without variation in the β1,ti .
2. Based on experience with DSMs (obtained during this thesis), allowing both the level and
trend to vary led to increased variability of hazard estimates. This increased variation was
particularly pronounced at the end of follow-up due to the small sample remaining at-risk.
3. When extrapolating survival data, it is typically expected that there will be a trend in the
extrapolations (for example, due to the effects of ageing or frailty). Hence, it was decided
that it was important to base extrapolations on the most recent estimates of trend. As
such, if only one of (β1,ti , β2,ti) is allowed to vary, it was deemed important to let the β2,ti
vary.
The modelling of both level and trend as time series is considered in the simulation study of
Chapter 4.
Three models of particular interest arise from Equation (3.2):
Local level model: The product β2,ti−1φ is set to zero so there is only one latent variable:
β1,ti . This is modelled as a time series following a random-walk, so the transition equation
becomes β1,ti = β1,ti−1 + ζti . Extrapolations are a constant value ŷT+hi = exp(β1,T )
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Local trend model: This sets φ = 1. The trend is modelled as a random-walk. Extrapolations
follow a linear trend in the log-hazard: ŷT+hi = exp(β1,T + hiβ2,T ).
Damped trend model: This estimates all of the parameters in Equation (3.2). The trend
follows a first-order autoregressive process. Extrapolations follow a linear trend in the
short term but are gradually damped so that in the long-term extrapolations are constant:




2)β2,T ). This model may also be viewed as a weighted average
of a local level and a local trend model, with the weighting given by φ [151].
For a derivation of the extrapolations from each model, see Appendix 1 (“Model specification for
dynamic survival models”). As detailed above, the use of DSMs leads to explicit analytical for-
mula for generating extrapolations that have intuitive interpretations relating to the anticipated
future behaviour of the hazard function. This is in contrast to the majority of the alternative sur-
vival models for which no such intuitive interpretation is possible. This represents an important
advantage of DSMs when used for extrapolation as it may be possible to obtain clinical input
into the likely qualitative long-term behaviour of the hazard function and encode this knowledge
via the appropriate choice of DSM, with alternative assumptions about the long-term hazard
behaviour tested in sensitivity analyses which use other DSMs.
The local trend model is a special case of the damped trend model. When modelling a trend, one
approach is to work with only the damped trend model, as the local trend will be recovered if it
is appropriate. This approach is not pursued, as a key theme in this thesis is the importance of
clinical input in model choice: the damped and local trend models make different assumptions
about the long-term behaviour of the hazard function; it is argued that the choice between
these may be based on subject-matter considerations. For implementation, when φ = 0 it is not
possible to identify a unique value for β2,ti (any value may be used, as it is multiplied by zero).
This makes estimation of the damped trend model problematic; in practice it is recommended
that 0.8 ≤ φ ≤ 1 (see Chapter 7 of Hyndman and Athanasopoulos [152]). For this thesis the
less restrictive range 0.7 ≤ φ ≤ 1 is used as use of this lower range allowed for more flexibility
whilst not affecting model convergence.
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3.2 Current state of the art: a pearl-growing review
The aim of this review was to identify papers that described methodological aspects of DSMs in
order to identify the latest methodological developments. A broad and comprehensive review of
the methodological literature was conducted in the previous Chapter to identify methods for the
extrapolation of survival data. This comprehensive review did not identify any studies that used
DSMs, which emphasises the importance of conducting an additional review specific to DSMs.
The review of this chapter was developed as a focused search of the methodological literature.
To ensure that the review was focused on DSMs, a pearl-growing strategy was adopted [51].
Pearl-growing methods use an initial search to identify a set of ‘pearl’ articles. These pearls
are then used to expand the initial results by both checking the reference lists of the pearls and
searching for articles that have cited the pearls. Pearls may also include authors; results are then
expanded by searching for additional publications by the authors. Searches may be iterative if
the expanded results include new pearls. The application of pearl-growing methods in this review
is described in the following section. The decision as to which articles were deemed to be pearls
was based on an informal assessment of the quality of the article (such as if sufficient details were
provided on the methods employed, and if it provided advances beyond previously published
literature), and how relevant the subject of the article was to this thesis. For example, it was
decided that for this thesis parameter estimation would be based on Hamiltonian Monte Carlo
(see Section 3.3.2 for details and justification). As such, studies which focused on alternative
methods for parameter estimation were retained but not marked as pearls.
3.2.1 Methods
The pearl-growing review had the following components:
1. Key-word searches. The phrase “Dynamic survival model” was searched for in both WoS
and Google Scholar.
2. From (1), identify an initial set of pearl articles and pearl authors.
3. Perform citation searches of pearl articles in WoS.
4. Identify publications for pearl authors in WoS.
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5. Search the reference lists of pearls for additional articles.
6. From (3) to (5), identify any additional pearls (articles or authors).
7. Repeat steps (3) to (6) until no new pearls are identified.
The first component (initial search) included searching two databases. The intention of this was
to broaden the identified articles. Subsequent searching (components 3 and 4) were intended to
be more focused, so only one database was considered. All searches were performed on the 28th
of February 2018.
This search had the following inclusion and exclusion criteria:
• Papers that described a methodological aspect of a DSM were included.
• Papers that only described an application of DSM were excluded.
• There was no date restriction.
• Papers not in English were excluded.
• Grey literature was included if it provided sufficient methodological details.
3.2.2 Results
The two databases (WoS and Google Scholar) were searched separately. Fifteen articles were
returned by the WoS search, of which six were retained as relevant studies [40, 144, 153, 154, 155,
156]. The search of Google Scholar returned 83 unique studies, of which seven were retained.
These seven included the six identified by WoS, along with one additional study [39]. Of these
seven articles, three were judged to be pearl articles, and the first authors of these articles were
identified as pearl authors [40, 144, 153]. Four articles were not deemed to be pearl articles, as
they focused on enhancements to DSMs that were not of direct relevance to this study. These
enhancements were:
• Incorporating spatial effects [154].
• Use of auxiliary mixture sampling for parameter estimation [155].
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• Incorporating the mechanics of kinematics within parameter estimation [156].
• Using a random time grid to measure the interval width [39].
Round one of pearl-growing led to the identification of a further five relevant articles: one via
citation searching [157], and four from checking reference lists [128, 143, 158, 159]. Of these five
articles, three were judged to be pearls, with their first authors identified as pearl authors (two
studies had the same first author, so there were two pearl authors). One article was deemed to
not be a pearl as it focused on methods for parameter estimation [157], whilst the other article
did not describe any enhancements to the DSM beyond those described in the studies initially
identified [159]. Of note, for one pearl author identified during the initial review (Jianghua He
[144]), searching for author publications provided 2,745 results. After sifting the first 100 results,
the majority appeared to be from different authors (with the same name). Instead, the author’s
personal website was used to identify publications: https://goo.gl/DW2P6S.
During round two of pearl-growing, citation searching led to seven relevant articles [160, 161,
162, 163, 164, 165, 166]. A further five articles were identified via author publications [167, 168,
169, 170, 171], and one additional article was found via reference list searching [172]. In total 13
relevant articles were identified. None of these 13 were deemed to be pearls. For eight articles,
there were no enhancements to the DSM beyond those described by articles previously identified
[160, 161, 164, 165, 168, 169, 170, 172].
Three studies described enhancements that were beyond the scope of this thesis. They were:
• To replace the transition model with a hidden Markov chain [162].
• The analysis of multivariate outcomes [163].
• The use of distributions other than the Normal in the transition model of Equation (3.1c)
[167].
In addition, two studies described the use of DSMs when a proportion of the sample was as-
sumed to be ‘cured‘ and so could not experience the outcome of interest [166, 171]. However,
these studies both assumed that cured individuals never died, so their usefulness to this thesis
was limited.
CHAPTER 3. DYNAMIC SURVIVAL MODELS 50
As no further pearls were identified, the pearl-growing review ceased after three rounds of
searching (the initial search, and two rounds of pearl-growing). In summary, the initial searches
identified seven relevant articles, whilst pearl-growing led to identifying an additional 18 rel-
evant articles. The sifting process is illustrated in Figure 3.1 (initial search and round 1 of
pearl-growing) and Figure 3.2 (round 2 of pearl-growing). Where the reason for exclusion is ‘ap-
plication’, the corresponding article may or may not have used a DSM (this was not checked).


























































Figure 3.2: PRISMA flow diagram for the DSM: round 2 of pearl growing
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Methodological details
Estimation methods
All 25 of the identified articles used a Bayesian framework for parameter estimation. The meth-
ods described for estimating the parameters of DSMs have evolved over-time. Initial approaches
used linear Bayes [128] and posterior mode estimation [143]. The use of Markov chain Monte
Carlo (MCMC) algorithms is now the most popular approach, being used in 71% of the identified
articles that were published since 2000 (MCMC methods for DSMs were first described in 1997
[168]). Of note, the two authors who introduced linear Bayes and posterior mode estimation
both used MCMC for later publications [154, 168, 170, 171]. These three estimation methods
are briefly described below; further details are provided in Appendix 1 (“Parameter estimation
for dynamic models”).
Linear Bayes: Estimation with linear Bayes makes no distributional assumptions about the
model parameters. Instead, two statistical moments of the distribution are estimated: the
mean and variance [144]. It is further assumed that the innovation variances (ζti) follow
an inverse gamma distribution, which facilitates calculations via conjugate analyses. This
allows for analytical expressions to sequentially update estimates of the mean and variance
over time. Full details are described by a number of authors [39, 128, 144]. The linear
Bayes approach was the first described method for estimating a DSM [128]. Compared to
the other methods it is relatively easy to implement and quick to run [144].
There are two main limitations with the linear Bayes approach. First, it requires that
the innovation variances are known but provides no formal method for estimating these
[143, 144]. Secondly, the mean and variance may not provide an adequate description
of the full distribution of model parameters if they are non-linear [173, 174]. Linear
Bayes estimation was the first method to be described for DSMs in 1987 [175]. Due
to its limitations, as other methods for parameter estimation became available (notably
MCMC in 1997 [168]), it declined in popularity: five publications were in the years 1991
to 1997, with the next publication in 2010. This 2010 publication compared linear Bayes
with MCMC and concluded that use of MCMC provided results that were similar to
the use of linear Bayes with optimal (known) innovation variances [144]. In practice the
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error variances will be unknown, so linear Bayes estimates will provide worse results than
MCMC.
Posterior mode estimation: This approach obtains an approximate analytical expression for
the likelihood, along with an algorithm for estimating the parameters that maximise this
approximate likelihood [143]. As suggested by the name, posterior mode estimation is
based on estimating the mode of the posterior distribution of the model parameters: the
mode is the most probable value and can by approximated by a Normal distribution.
Neither starting values nor innovation variances can be estimated using this algorithm;
estimates of these are obtained via a separate expectation-maximisation algorithm. A
benefit of posterior mode estimation is that it may be seen as a natural extension of model
estimation methods for a DSM which used a Normal distribution in place of the Poisson
[143] (the Kalman filter; see Appendix 1 for more details). It has also been noted that this
approach may be motivated via a non-Bayesian framework. Estimation is then based on
maximising a penalised likelihood, typically using the extended Kalman filter [158].
As with the linear Bayes method, use of posterior mode estimation provides analytical
expressions for sequentially updating estimates of the mean and variance of the states. An
advantage over linear Bayes is that there is no need to specify the innovation variances, as
these may be estimated.
Posterior mode estimation shares the same limitation as linear Bayes in that only the mean
and variance of a distribution is specified. Further, the mode may be a limited summary
measure for non-linear distributions [176], particularly if there are regions of sparse data
(such as at the end of follow-up) [168]. Posterior mode estimation also underestimates
uncertainty [168]. Another limitation is that estimation will typically be slower than
for linear Bayes [143]. After the introduction of MCMC methods for DSM parameter
estimation in 1997, only one further methodological paper using posterior mode estimation
was identified: a publication in 2000 which described an extension to incorporate random
effects [153].
Markov chain Monte Carlo: Monte Carlo simulation techniques are a broad range of meth-
ods that may be used to estimate parameters of interest and their distributions via simu-
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lation. A Markov chain is a sequence of random variables with the property that at any
iteration, the current distribution of the random variable will only depend on its previous
value [177]. During each iteration, the random variable is updated according to an algo-
rithm so that eventually the Markov chain will converge to the target distribution, which
for a DSM is the distribution of parameter estimates. As such, simulations from the target
distribution may be used to describe the posterior distribution of the DSM parameters.
The majority of applications of MCMC for a DSM used a combination of Gibbs sampling
and Metropolis-Hastings (M-H), which are both MCMC algorithms [40, 144, 154, 166, 168].
Within the Gibbs sampler it is possible to use conjugate analyses to aid implementation by
assuming that the innovation variances follow an inverse gamma distribution [178]. An al-
ternative approach is to assume that they follow an inverse Wishart distribution [168, 179]
All three methods considered so far will only provide approximate solutions. However, an
advantage of MCMC over both linear Bayes and posterior mode estimation is that the
number of simulations may be made arbitrary large to improve accuracy. As previously
noted, a simulation study suggested that MCMC methods provide results that are as good
as linear Bayes with known innovation error variances [144]. Using MCMC, a number of
extensions to the standard DSM have been described. These include incorporating random
effects (frailty terms) [40], spatial terms [154, 170], cure models [166, 171], and multivariate
outcomes [157].
Disadvantages of MCMC methods include being more computationally intensive than the
previous two approaches [156], and potential issues in converging [40, 168].
Modelling prior distributions
The key difference between dynamic and global (or static) models is the inclusion of innovation
terms for the evolution of the parameters over time. Hence it is anticipated that appropriate
modelling of the innovation terms will be of particular importance for DSMs. In particular,
the specification of prior distribution for the innovation variance(s) may be important. Two
classes of prior distribution are of interest for this thesis. Uninformative (vague) priors do not
contain any information about likely values for the parameter of interest. As such, posterior
distributions should not be influenced by the choice of uninformative prior distribution. Weakly
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informative priors convey some information about the anticipated distribution of the parameter
of interest, without being overly restrictive about the range of possible values. The primary
motivation behind weakly informative priors is that their additional information (compared with
uninformative priors) helps model fitting algorithms to converge, whilst results should remain
robust (insensitive) to the choice of weakly informative prior. A full discussion of uninformative
and weakly informative prior distributions may be found in Chapter 2 of Gelman et al. [177].
In general, the reporting of these priors was incomplete and inconsistent in the identified liter-
ature. Only seven applications specified a prior distribution for the innovation variances. All of
them used an uninformative prior, which was either an inverse gamma (I.G.) distribution for the
variance (four studies [144, 155, 168, 170]) or a gamma distribution for the reciprocal of the vari-
ance, which is also known as the precision (three studies [157, 161, 165]). The following values
were used: I.G.(0.001, 0.001) in two studies, I.G.(0.01, 0.01), I.G.(1, 0.005), Gamma(1, 0.01),
Gamma(0.01, 0.01), Gamma(0.001, 0.001). These seven priors are all designed to be uninforma-
tive: the I.G. distributions do not have a defined variance, whilst for the gamma distributions
the variances ranged from 100 (mean = 1) to 10,000 (mean = 100). Of note, whilst the gamma
distribution has a defined mean and variance, it allows for zero values. As such, when used to
model the precision, the implied prior for the variance does not have a mean or variance. The
identified papers were published between 1997 and 2011. It is likely that the choice of prior was
based on it being a conjugate prior distribution (which improves the efficiency of MCMC [180]);
the I.G. is a conjugate for the variance and the gamma is a conjugate for the precision.
For the latent states the most common approach was to use an uninformative prior represented
by a Normal distribution with a zero mean and large variance, such as 100 [39, 40, 155, 162] or
1000 [128, 165].
Extensions to the standard DSM
The following extensions or enhancements to a standard DSM were identified:
• Incorporating random effect (frailty) terms to model unobserved heterogeneity [40, 153].
• Incorporating spatial terms [154, 170].
• Extending to model a cured fraction (although it was assumed that the cured fraction
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would never experience the outcome event) [166, 171].
• Modelling multivariate outcomes [163, 157].
• Incorporating multiple (competing) outcomes [158, 168], including correlated outcomes
[181]
• Using random time grids to define the time intervals (instead of defining them in advance)
[39, 40].
• Incorporating probability kinematics to improve estimation with linear Bayes [156].
Comparisons of static and dynamic models
A formal comparison of static and dynamic models was performed in four studies. Two of these
assessed performance using case-studies, comparing DSMs with their equivalent static model.
They both found that the use of dynamic models led to improved predictions [172, 182]. Another
study used both a case-study and a simulation study to compare a DSM against a spline-based
model and concluded that the spline-based model was superior [170]. The final study used a
simulation study to compare a DSM against a Cox model which incorporated splines [144], and
the DSM was found to out-perform the Cox-spline model. None of these comparisons used
survival data. As such, there is a very limited and inconclusive body of evidence about the
performance of dynamic models compared to alternative models, and it is unclear how relevant
the conclusions are to the setting of HTA.
3.3 Novel methodological work on DSM for this thesis
These novel contributions fall into four sections: incorporating external data, parameter estima-
tion with Hamiltonian Monte Carlo, use of a damped trend model for extrapolating unevenly
spaced data, and assessing the sensitivity of results to the choice of prior distribution for the
innovation variance. These are discussed in turn.
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3.3.1 Incorporating external data
The case-study of Chapter 6 and the simulation study of Chapter 5 both incorporate external
data in the form of general population life tables. The motivation for the case-study was to
restrict extrapolations of the hazard so that they never fell below the age-matched general pop-
ulation estimate of the hazard. Incorporating this constraint provides dynamic relative survival
models (DRSMs), as it combines DSMs with relative survival models (which were identified via
the comprehensive review of Chapter 2). The methodological details of these DRSMs have not
previously been described in the articles identified in the pearl-growing review of Section 3.2.
The simulation study of Chapter 5 was designed to reflect treatments where a proportion of
the treated population can be viewed as ‘cured’ from their disease and so experience future
survival that is the same as the general population. These dynamic cure-fraction survival mod-
els (DCFMs) have been previously described in the DSM literature [166, 171]. However, both
previous examples assumed that cured individuals would never experience the event of interest.
This is implausible in the context of modelling all-cause mortality, as it implies that cured indi-
viduals would never die. Hence the extension to model a non-zero hazard for the cured fraction
represents a novel extension of the DSM. These two extensions are discussed in turn and use
the following terminology: λPti , λ
E
ti denote the general population hazard and the disease-specific
(excess) hazard respectively (both at time ti).
Dynamic relative survival models







β1,ti = β1,ti−1 + β2,ti−1φωti
β2,ti = β2,ti−1φ+ ζti
ζti ∼ N(0, Z).
(3.3)
When compared with the specification of a DSM in Equation (3.2) the only change is to the
observation model, which now includes the term λPti . Hence exp(β1,ti) = λ
E
ti and so β1,ti may now
be interpreted as modelling the log-excess hazard. The dynamic part of the model now relates to
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the evolution of the disease-specific hazard over-time. This is of particular use, as it is expected
that the natural history of a disease will be driven by changes in the disease-specific hazard,
which in turn will be affected by the treatment received. Choice of the specific DRSM to use
may then be driven by clinical input into the likely long-term behaviour of the disease-specific
hazard beyond the end of the available data. The impact of alternative assumptions may be
tested by assessing alternative DRSMs in scenario analyses. There are three options considered
in this thesis:
The excess hazard decreases to zero. This is modelled with a local trend model. It as-
sumes that individuals who are still alive after a certain time-point may be viewed as
‘cured’ from their disease, as their subsequent survival matches that of the general popu-
lation. The time until this ‘cure’ occurs is determined by the observed data.
There is a constant excess hazard. A constant hazard is represented by a local level model.
This model is appropriate if it is assumed that individuals will always be at an increased
risk of death compared to the general population, and that this risk is unlikely to vary
over time.
The excess hazard decreases in the short-term, to a constant value. A damped trend
model is suitable in this instance. This model assumes that individuals will never be cured
from their disease but that the impact of the disease on their chances of dying decrease
over time.
Note that the interpretation of the local trend and damped trend models above assumes that
the extrapolated trend is decreasing. If it is increasing then these two models assume that the
observed increase in the excess hazard will either persist indefinitely or increase over time to a
constant value, respectively.
The DRSM of Equation (3.3) assumes that the overall observed hazard is an additive composition
of the general population and disease-specific hazards. Alternative assumptions are possible
[183], in particular assuming a multiplicative composition as is implemented in packages such
as flexsurv [100]. If a multiplicative relative survival model were used (i.e. exp(β1,ti)λ
P
ti ),
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then for values of λEti < 1, the overall hazard would be less than the general population hazard.
The DRSMs used in this thesis are designed to constrain the overall hazard to never fall below
the general population hazard, so only the additive specification is considered. It is also noted
that multiplicative relative survival models are considered to be less biologically plausible than
additive models, and also generally provide worse fits to data [184].
Dynamic cure-fraction survival models
Survival models with a cure-fraction assume that the cure occurs at the start of study follow-
up. Hence the overall observed survivor and hazard functions will be weighted averages of the
survivor and hazard functions for the cured and uncured sub-groups. Let SPti , S
U
ti be the survival
for the cured and uncured populations, and let λUti be the hazard for the uncured population
(this is not the same as the excess hazard, in contrast the hazard for the cured population is
λPti ), all at time ti. If the fraction of cured patients is ρ, then the observed survival and hazard
functions over time are given by:
Sti = ρS
P













For the specification of the DCFM, Yti ∼ Poisson(λtiτti), with the response function and transi-
tion model the same as the DSM of Equation (3.2). Hence exp(β1,ti) = λ
U
ti , which dynamically
changes over time according to the transition model. As with both the DSM and DRSM, model
choice for a DCFM may be guided by clinical input, this time into the likely long-term behaviour
of the hazard function for uncured patients.
For this thesis two novel extensions to DSMs to incorporate external evidence are provided.
These build upon the methodology of relative survival models and cure models. Approaches
for incorporating external evidence which do not use dynamic models were identified by the
comprehensive reviews of Chapter 2, falling under the ‘other modelling approaches’ category.
These additional approaches are beyond the scope of this thesis, but their technical details are
provided in Appendix 1 for completeness as this may be a useful area for further research.
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3.3.2 Estimation using Hamiltonian Monte Carlo
The current approach to parameter estimation in DSMs is via MCMC, as described in Section
3.2 and Appendix 1 (technical appendix). The construction of Markov chains typically uses
a type of M-H algorithm [185]. A limitation with many M-H algorithms is their relative lack
of efficiency; they do not incorporate any information about the parameter space that they are
exploring. It is possible to enhance standard M-H algorithms by incorporating information about
the gradient of the target density to produce more efficient algorithms known as Hamiltonian
Monte Carlo (HMC) [186], which also includes the Langevin method as a special case [187].
HMC supplements the stochastic MCMC algorithm with a deterministic algorithm based on
Hamiltonian dynamics. This additional process uses differential equations and may be thought
of as representing the ‘total energy’ of the Markov chain (and may be compared to the total
energy of a physical system, which is the sum of kinetic and potential energy). More detailed
descriptions of these algorithms can be found else [186, 187].
The HMC algorithm is more efficient than M-H MCMC. However, it still requires ‘tuning’
to ensure that it provides useful results. Automated tuning is an area of ongoing research.
Suggested approaches include incorporating information about the geometry of the state-space
[188] and restricting the Markov chain not to visit previously explored areas of the target density
[189]. This latter approach, known as the No U-turns sampler (NUTS) has been demonstrated
to perform at least as well as HMC with manual tuning [189].
An implementation of HMC is provided in the Stan software; an open-source program that may
be used to specify statistical models and perform Bayesian inference [190, 191]. It is a C++
program, but it can be run via other programs such as R and Matlab. It provides automatic
calculation of the required differential equations (and so gradients of the target space) for a
given model specification. This implementation is both more robust and more efficient than
alternative (standard) MCMC methods [186, 189, 191]. Stan is also typically faster to run than
alternative programs and can fit a wider variety of models [190]. The R interface to Stan is used
in this thesis [192]. Hence, to my knowledge, this thesis represents the first use of both Stan
and HMC for estimating the parameters of a DSM.
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3.3.3 Generating extrapolations from a damped trend model
None of the identified DSM studies used a damped trend model. This model is used in the time
series literature (for example [152] Chapter 7) but assumes equally spaced intervals. Dampening
occurs at discrete time-points (once per interval), and there is no guidance on how to generate
extrapolations for which future intervals are not defined. As such, the approach developed for
this thesis was to apply a time series model to the observed interval widths and use this to
generate extrapolated interval widths for use when generating extrapolations from a damped
trend model. Formally:
1. Use a dynamic linear model (local level) to generate future values of ωi (the interval width).
This is applied to the logarithm of the ωi (to map them onto the real line), whilst noting
that the ωi may be viewed as equally spaced. The model is then:
log(ωti) ∼ Normal(δ1,ti , σ2)
δ1,ti = δ1,ti−1 + ζti
ζti ∼ N(0, Z).
(3.5)
Where the value of σ is estimated from the data.
2. Use the dynamic linear model to generate future values of log(ωti); log(ωT+1, ωT+2, . . . ).
3. Recursively estimate the times at which future dampening occurs as: tT+i = tT+i−1 +
ωT+i, i > 0.
4. Repeat the previous step until tT+i > H
3.3.4 Choice of prior for the innovation variance
The implementation of DSMs in this thesis is Bayesian. As such, prior distributions need to
be specified for each of the model parameters. When compared with standard survival models,
the main added value of DSMs is that they allow parameters to vary over time. The level
of this variation is controlled by the value of the innovation variance. It is hypothesised that
model estimates of the hazard function may be sensitive to the correct specification of the
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prior distribution for the innovation variance. This hypothesis was tested in a simulation study,
described in the next section.
3.4 The impact of different prior distributions for the innovation
variance
Where existing studies have described the prior used, this was always either the inverse gamma,
or equivalently the gamma for the inverse of the innovation variance (see the DSM literature
review, Section 3.2, for more details). These priors were potentially chosen as they have a
conjugacy property, which can ease computations in MCMC [180]. This thesis uses HMC in
preference to MCMC, so does not need to worry about choosing conjugate prior distributions.
In addition, DSMs may be viewed as hierarchical models, for which a case-study showed that
use of an inverse gamma prior led to poor posterior estimates [193]. Potential alternatives that
were suggested include the half-Normal and half-Cauchy distributions, as well as uniform priors
with range equal to the parameter space of the prior. However, as this range is [0,∞], the non-
finite upper limit means that the posterior will over-estimate the variance [193]. Two studies
evaluated the impact of prior choice in a DSM. One used a simulation study to compare five
different prior distributions for the standard deviation: four were inverse gamma, with parameter
pairs (0.01, 0.01), (10−4, 10−4), (10−5, 10−5), (10−8, 10−8), along with a uniform prior on [0,∞]
[170]. The authors found that results were robust to the choice of prior. In contrast, in a
separate case the authors noted that use of a Gamma(1, 0.01) for the precision provided better
results than a Gamma(0.01, 0.01) [161].
There is no consensus on what prior distribution should be used for the innovation variance in
a DSM, so a simulation study was performed with the following aims:
1. Identify rates of convergence for key model parameters.
2. Compare model estimates of the innovation variance against the true value.
3. Assess agreement between model-estimates of the log-hazard and the true values.
In addition, the impact of choice of prior distribution was also assessed using the case-studies
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of Section 4.1 and Chapter 6. Details on the methods for these and results are provided in
Appendix 2.
3.4.1 Methods
The presentation of the methods follows published guidance [194], with separate sections for
each of the key components of the simulation study.
Data-generating mechanism and estimand
Data were simulated from a local-level dynamic survival model. The starting value of the log-
hazard βt0 = log(0.05) and data were simulated for 25 evenly spaced time periods. The initial
at-risk sample size was τt1 = 300. For a pre-specified value of the innovation variance Z, data
were simulated as follows:
1. Generate 25 innovations from Normal(0, Z); ζti , ti ∈ (1, . . . , 25).
2. Generate 25 log-hazard values: βti = βti−1 + ζti .
3. Sample the number of deaths in the first time interval yt1 ∼ Poisson(300 exp(β1,t1)).
4. Update the at-risk sample size: τti = τti−i − yti−1
5. Sample the number of deaths per subsequent interval as yti ∼ Poisson(exp(β1,ti)τti)
6. Discard any time-intervals for which the at-risk sample = 0.
Three different values of Z were used: 0.001, 0.01, and 0.1. The focus of this study was on small
values for Z, as a variance of 0 is equal to a static mode, and it was felt to be important that
DSMs can identify this special case. For each value of Z, 200 datasets (nsim) were simulated.
The primary estimand was Z. The secondary estimand was the time-varying log-hazard βti .
Prior distributions
Six uninformative and six informative prior distributions were considered. The informative pri-
ors were designed to be weakly informative, but the interpretation of what constitutes weak prior
information is subjective, hence these priors are referred to as ‘informative’. The parameterisa-
tion of all the priors is provided in Table 3.1. Uninformative priors were defined as those with
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an undefined variance. All of the priors are for the variance, except the first two priors which
are for the standard deviation. The choice of distributions was based on those considered in the
literature (either for DSMs, or for hierarchical models in general), as well as distributions which
have support on the positive line, so are appropriate for modelling variances. Initial values were
not specified for any of the parameters, instead the Stan defaults were used.
Table 3.1: Prior distributions used for the variance (apart from prior IDs 1 and 2).
ID Uninformative prior distributions Mean (variance)
1 Uniform(0,∞) for standard deviation Undefined (undefined)
2 Uniform(−∞,∞) for log(standard deviation) Undefined (undefined)
3 Uniform(0,∞) Undefined (undefined)
4 Inv.Gamma(0.01, 0.01) Undefined (undefined)
5 Inv.Gamma(1, 0.005) Undefined (undefined)
6 Half-Cauchy(0, 0.3) Undefined (undefined)
Informative prior distributions
7 Half-normal(0, 0.3) 0.44 (0.11)
8 Half-normal(0, 5) 1.78 (1.82)
9 Gamma(0.01, 0.01) 1 (100)
10 Gamma(0.02, 0.1) 0.2 (2)
11 Gamma(2, 1) 2 (2)
12 Lognormal(0, 1) 1.65 (1.72)
Performance measures












(θ̂ti − θ) (3.7)
where θ̂ti is the model-based estimate of the estimand θ̂i. For both performance measures, lower
values indicate better model performance.
The performance of model estimates of the log-hazard were compared visually using Bland-
Altman plots [195]. This plots the average of the model estimates and the truth on the x-axis,
against the difference on the y-axis. For perfect fit, the difference should be zero. There should
also be no pattern in the differences by average measurement.
A final performance measure for each model was whether it converged during parameter esti-
mation. Four chains were used during model estimation. Convergence was assessed using the
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R̂ statistic (also referred to as the potential scale reduction, see Chapter 11 of Gelman et al.
[177]). This is the ratio of the between-chain variance to the within-chain variance. A value of
R̂ ≈ 1 implies that the fitting algorithm may have converged, whilst larger values suggest that
more iterations may be required. There are no specific rules to identify when R̂ is too large,
although an upper bound of 1.01 has been recently suggested [196]. As such, two upper bounds
are considered for this study: 1.01 and 1.20 (as an arbitrary less strict upper bound). In addi-
tion, trace plots were used to visualise assess convergence and identify if a lack of convergence
was associated with particular parameter values [180]
3.4.2 Results and discussion
Summary values of the distribution of R̂ values for each prior distribution are provided in Table
3.2. A clear lack of convergence may be seen for the second prior distribution (uniform for the
log of the standard deviation), with a mean R̂ value much larger than for the other distribu-
tions. In addition, over 70% of simulations had an R̂ value greater than the cut-off of 1.01, and
almost half had values greater than 1.2. Hence, the second prior distribution was not considered
further. Use of an I.G. prior resulted in models with good convergence; for the two prior distri-
butions considered, mean and max R̂ values were 1.00 and 1.05 for both. These were the lowest
observed max R̂ values for all of the distributions, along with the Gamma(2, 1) prior, but this
prior had more values > 1.01. As such, the two I.G. priors resulted in the smallest distribution
of R̂ values. The first prior distribution (uniform for standard deviation) had one very large R̂
for Z = 0.001. Apart from this it has similar performance to the other priors.
To summarise, with the exception of the second prior, all of the prior distributions showed
acceptable mean R̂ values, which ranged from 1.00 to 1.01. There was no notable difference be-
tween uninformative and informative priors and only some minor differences in the tail behaviour
of the R̂ statistic between the different priors.
A comparison of model estimates of the innovation variances against the known true value is
provided in Figure 3.3. The corresponding MSEs for these estimates are provided in Figure
3.4 and Table 3.3. Results for the bias were very similar and are not reported. The first prior
has large MSE and bias for Z = 0.001, due to the previously noted lack of fit, so is not shown
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Table 3.2: Convergence diagnostics (R̂) for the prior distributions.
ID Uninformative prior distributions Mean R̂ Max R̂ R̂ > 1.2 R̂ > 1.01
1 Uniform(0,∞) for standard deviation 1.01 3.11 0.20% 12%
2 Uniform(−∞,∞) for log(standard deviation) 1.43 11.71 48% 71%
3 Uniform(0,∞) 1.00 1.08 0% 14%
4 Inv.Gamma(0.01, 0.01) 1.00 1.05 0% 9%
5 Inv.Gamma(1, 0.005) 1.00 1.05 0% 8%
6 Half-Cauchy(0, 0.3) 1.00 1.07 0% 11%
ID Informative prior distributions Mean R̂ Max R̂ R̂ > 1.2 R̂ > 1.01
7 Half-normal(0, 0.3) 1.00 1.06 0% 9%
8 Half-normal(0, 5) 1.00 1.07 0% 13%
9 Gamma(0.01, 0.01) 1.01 1.24 0.20% 15%
10 Gamma(0.02, 0.1) 1.01 1.13 0% 16%
11 Gamma(2, 1) 1.00 1.05 0% 14%
12 Lognormal(0, 1) 1.00 1.07 0% 8%
in Figure 3.4. Overall, the inverse gamma (1, 0.005) had the best performance as it had the
lowest MSE values for two of the prior values considered (Z = 0.01, 0.1) and the third lowest
MSE for the other prior (Z = 0.001). Two of the gamma priors (with parameters (0.02, 0.1)
and (0.01, 0.01)) also had very good results, as their MSE was always amongst the three lowest
values (along with the previously mentioned inverse gamma). Of the uninformative priors, use
of either an inverse gamma or half-Cauchy resulted in better performance than use of a uniform
distribution. The largest errors (and biases) were observed for the gamma (2, 1) and lognormal
(0, 1) priors.
A visual comparison of model estimates of the log-hazard against the true values is provided via
Bland-Altman plots in Figure 3.5. These all showed close agreement, except for the first prior
for variance = 0.001, as previously noted. There was also, for all the prior distributions, a slight
increase in the spread of differences for the largest values of the average log-hazard. This is to
be expected, as larger hazard values imply that almost all the at-risk sample will die, which
reduces the sample size and so will make hazard estimates less precise.
Based on MSE and bias, results from the simulation studies supported the use of either an inverse
gamma prior distribution or a gamma distribution with a large variance relative to its mean.
However, with regards to impact on predicted hazard values, any of the prior distributions that
were considered performed well, with the exception of the second prior; Uniform(−∞,∞) for
the logarithm of the standard deviation. This robustness of log-hazard estimates to the choice
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of prior was also observed in the two case-studies (see Appendix 2). Together, the results of
the simulation study and case-studies suggest that the specific choice of prior is primarily of
importance if the resulting model estimation fails to converge. Hence, as it had the lowest MSE
and bias in the simulation studies, the inverse gamma (1, 0.005) is adopted as the default prior
distribution for the innovation variance in this thesis. Other prior choices would have been
considered if model estimation failed to converge, although this never occurred for the analyses
presented in this thesis.
Table 3.3: Mean squared error (x1,000) with 95% confidence intervals: estimates of innovation
variance.
ID Uninformative priors Z = 0.001 Z = 0.01 Z = 0.1
1 Uniform(0,∞) std. dev. 9.54 (7.64 to 11.44) 18.45 (15.72 to 21.18) 55.4 (52.22 to 58.58)
3 Uniform(0,∞) 1.21 (0.95 to 1.47) 2.43 (1.76 to 3.11) 1.71 (1.3 to 2.12)
4 Inv.Gamma(0.01, 0.01) 0.54 (0.46 to 0.62) 0.73 (0.52 to 0.94) 1.12 (0.86 to 1.39)
5 Inv.Gamma(1, 0.005) 0.05 (0.04 to 0.05) 0.06 (0.03 to 0.09) 0.82 (0.64 to 0.99)
6 Half-Cauchy(0, 0.3) 0.94 (0.77 to 1.1) 1.65 (1.24 to 2.05) 1.32 (1.02 to 1.62)
ID Informative priors Z = 0.001 Z = 0.01 Z = 0.1
7 Half-normal(0, 0.3) 1.01 (0.82 to 1.2) 1.74 (1.31 to 2.18) 1.4 (1.09 to 1.7)
8 Half-normal(0, 5) 1.17 (0.92 to 1.42) 2.34 (1.69 to 2.99) 1.66 (1.27 to 2.05)
9 Gamma(0.01, 0.01) 0 (0 to 0) 0.22 (0.12 to 0.32) 1.11 (0.82 to 1.39)
10 Gamma(0.02, 0.1) 0.01 (0 to 0.01) 0.23 (0.14 to 0.32) 1.1 (0.84 to 1.35)
11 Gamma(2, 1) 6.26 (5.45 to 7.07) 8.49 (7.05 to 9.93) 2.67 (2.08 to 3.26)
12 Lognormal(0, 1) 10.8 (9.99 to 11.6) 12.07 (10.87 to 13.27) 2.5 (2.01 to 2.99)
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Figure 3.3: Comparison of model estimates of the innovation variance and the true values. Black
line represents truth.
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Figure 3.5: Bland-Altman plot of the log-hazard: model estimates vs truth (rows = value of Z).
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3.5 Conclusions
The union of time series and survival models is known as DSMs, which are in turn a special
case of dynamic GLMs. This chapter has introduced the specification of DSMs, which has two
main components. The first is a model for the observed data (observation model), which is a
GLM for survival data. The second is the transition model, which defines a time series model
for the temporal evolution of the parameters of the observation model. It is important to ensure
that the application of DSMs in this thesis builds upon the current state of the art for DSMs,
which was identified via a pearl-growing literature review. This review identified that MCMC
methods were the most advanced method for parameter estimation in current implementations.
The review also highlighted some key evidence gaps, as there was a paucity of comparative
studies, both comparing DSMs to alternative survival models and comparing the impact of
different prior distributions for the innovation variance (which defines how ‘dynamic’ a DSM
is). Further, there were no identified articles that considered incorporating external evidence
with a DSM. These evidence gaps are addressed within this thesis. Two novel extensions to
incorporate external evidence in the form of general population life tables were described; one
for which this external evidence was used to constrain the extrapolations (so future hazards
never fell below the general population hazards) and one where the life tables were used to
represent the future survival of a cured fraction of individuals. The impact of prior choice for
the innovation variance was evaluated in a simulation study which compared 12 different prior
distributions and found that estimates of the hazard function were generally insensitive to the
choice of prior distribution, of which an inverse gamma prior gave the smallest bias and MSE.
This chapter has provided an overview of DSMs, including useful extensions to incorporate
external evidence and a simulation study to inform model specification. This novel work was
motivated by the results of a focused literature review to identify the current state of the art
for DSMs. The previous chapter identified a set of comparator methods that may be used as
alternatives to DSMs for the analysis and extrapolation of survival data. The subsequent two
chapters evaluate the performance of DSMs and the comparator methods, in both a case-study
and simulation studies.
Chapter 4
Comparing dynamic survival models
with current and emerging practice
To be useful in a technology appraisal, survival models should combine good within-sample
fit with accurate extrapolation performance. Extrapolation performance relates to the ability
of a statistical model to accurately predict future observations (outcomes), given the available
observations. Evaluations of both within-sample fit and extrapolation performance require that
future observations (which were not used for model fitting) are available. Ideally this evidence
would be obtained from real datasets, such as trials with long-term follow-up. For this thesis
one such dataset was identified, and it is analysed in this chapter. There are two particular
strengths of this case study. First, it enabled access to patient-level data with long-term follow-
up. Secondly, there is a published interim analysis which serves as a natural choice of data to
use to generate extrapolations (which are compared against the full dataset). This case study
is a trial of abiraterone acetate (henceforth referred to as abiraterone) in prostate cancer.
To avoid estimates of overall goodness of fit (within-sample and extrapolations) being driven
by the quirks of a single dataset, evaluations should be conducted for multiple datasets. As
there was a lack of additional suitable real datasets for this thesis, the required evidence was
obtained via simulation. The advantage of simulation studies is that the ‘truth’ (here the true
hazard function) is known, so can be used to evaluate performance. Two simulation studies
were performed for this thesis. Both had the aim of assessing the overall goodness of fit - of
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DSMs, current practice, and emerging practice - for realistic hazard patterns. The next chapter
considers a hazard function indicative of a sample with a cured fraction. This chapter considers
a multi-modal hazard function (one with two turning points), arising from a mixture Weibull
model. This could represent a population of ‘low-risk’ and ‘high-risk’ individuals. An overview
of the methods used to conduct the simulation study is provided, along with the study results
and a discussion of their implications for this thesis. The two analyses within this chapter (the
case study and the simulation study) are discussed fully in turn, followed by an overarching
conclusion.
4.1 Abiraterone case-study
The objective of this case study is to evaluate the extrapolation performance of DSMs and
alternative approaches when applied to real data. The data used for this case study come from
the clinical trial COU-AA-301, which compared abiraterone to placebo treatment in people
with castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy
(NCT00638690). The individual patient-level data were accessed via the Yale University Open
Data Access Project [197]. The full dataset had almost complete follow-up and an early cut of
the data has been published in the form of an interim analysis [198]. The approach taken here
is to apply the statistical models to the early cut of the data, using the more complete data to
evaluate the performance of the extrapolations.
The following subsection describes the available data, how the interim data were recreated from
this, and provides an initial exploratory analysis. Subsequent subsections provide details on how
the candidate extrapolation models were identified. The extrapolations from these models are
then compared against the longer-term data. The final subsection for this case-study provides
a discussion of the findings.
4.1.1 Data used and exploratory analysis
The pivotal trial COU-AA-301 was an international trial evaluating the clinical effectiveness
of abiraterone. Patients were randomised 2:1 to receive either abiraterone or placebo, both
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study groups also received prednisone. Treatment was until disease progression and the primary
outcome was overall survival. Between May 2008 and July 2009 1,195 patients were enrolled
(abiraterone = 797, placebo = 398). A pre-specified interim analysis was published in 2011,
based on 552 deaths (planned deaths = 534), with a median follow-up of 12.8 months [198]. A
further analysis was published after 775 deaths occurred [199]. Following this analysis, patients
who remained on treatment (125 [16%] and 18 [5%] for abiraterone and placebo respectively)
were un-blinded and the placebo group crossed-over to receive abiraterone. An adjustment for
treatment switching to abiraterone is not considered here due to the small numbers involved.
The data available for this study were made available by Janssen Research and Development,
L.L.C. via the Yale University Open Data Access Project and represent more complete follow-up
than either of the previous analyses, with 984 deaths (82.3% of the original study population).
Data are for individual patients and were accessed via a secure online platform. For these data
survival times (deaths or censorings) are measured as times from randomisation. As calendar
times (for study entry) are not available, the interim dataset was replicated based on the following
steps:
1. Find the follow-up time of the 552nd death in the dataset. Let this time = T ∗.
2. Censor all follow-up times greater than T ∗.
3. For newly censored times, set the follow-up time = time of last study visit.
One further difference from the original interim analysis is that 12 people did not have any event
or censoring times, so were excluded from all analyses (hence N = 1, 195–12 = 1, 185).
A comparison of the available data and the published interim analysis is provided in Table 4.1.
The replicated interim data is generally very similar to the published analysis, albeit with a
slight under-estimate of median survival for the abiraterone group. Median follow-up in the full
dataset is almost three times that of the interim analysis, with almost twice as many deaths. Of
those who had not died in the full dataset, 155 (13.1% of the total sample) were still alive (and
so censored at the last study visit day), with a further 38 patients withdrawn from the study
and 6 lost to follow-up (and so censored at the recorded timings of the study-events).
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Table 4.1: Comparison of cost-effectiveness results: original submission and replication.
Published Data used in this case study





797, 398 791, 392 791, 392
Median follow-up 12.8 13.1 36.2
Median survival:
Abiraterone 14.8 13.9 15.9
Placebo 10.9 11.1 11.2
Deaths: Total 552 (46.2%) 552 (46.7%) 984 (83.2%)
(Abiraterone, Placebo) (333, 219) (329, 223) (651, 333)
The subsequent exploratory data analysis and model fitting uses the replicated interim analysis.
An overview of the number of participants remaining in the study over time is provided in Table
4.2. For up to one year of follow-up the absolute number of patients remaining in the study is
large, suggesting that hazard estimates should be sufficiently precise. There is a notable drop-off
in numbers after 1 year which is mainly due to censoring, but even at 14 months participant
numbers remain acceptable for both the abiraterone (n = 199) and placebo (n = 47) groups.
Table 4.2: Participants in the study (replicated interim dataset). Data are counts (percentage
of starting cohort).
Time Abiraterone Placebo
(months) (n = 791) (n = 392)
2 768 (97%) 379 (97%)
4 714 (90%) 340 (87%)
6 660 (83%) 303 (77%)
8 591 (75%) 263 (67%)
10 529 (67%) 214 (55%)
12 434 (55%) 164 (42%)
14 199 (25%) 47 (12%)
Graphs of the empirical hazard, along with a smooth non-parametric estimate, are provided in
Figure 4.1 for both treatment groups. Some things to note.
• As the hazard is a rate, its value will depend on the time-intervals that are used. For this
exploratory graph, fortnightly estimates of the hazard are used, to reduce the variation in
the plotted hazards. For all model estimation, continuous time estimates of the hazard are
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used. For models using the GLM and DGLM frameworks, this uses one death per time
interval, as discussed in Chapter 3.
• A loess smoother is used to obtain the smooth non-parametric estimate. This is intended
to provide an informal visual aid, without making any structural assumptions. A limitation
with this approach is that it does not account for the decreasing sample size over time.
The loess smoother also cannot be used for extrapolation.
• Figure 4.1 plots the log-hazard against log-time. This mirrors the specification used for
the majority of the models considered here. In addition, using the logarithm of time gives
more visual emphasis to estimates at the start of follow-up (where there is more data).
The x-axis begins slightly earlier for abiraterone than placebo as the first event occurs
earlier.
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For both groups, the log-hazard follows a near-linear increase over time. This is most pro-
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nounced for the abiraterone group; for the placebo group some of the additional variation may
be attributable to the smaller sample size. This suggests that, of the standard survival models,
the exponential is unlikely to provide a good fit, whilst the Weibull (which is a linear model
of the log-hazard against log-time) may provide a good fit. All of the other standard survival
models are able to capture an increasing hazard. However, of note, neither the log-logistic nor
the lognormal can model a hazard pattern that increases indefinitely. Instead, they assume that
after a certain time-point the hazard function will decrease.
There are at least two potential drivers for the observed increase in the hazard of mortality
over time. The first is the impact of ageing, as in general, older participants are more likely to
die than younger participants. The second is disease-specific (deaths due to prostate cancer).
Some insight into the impact of ageing on temporal changes in the hazard may be obtained by
plotting the hazard rate against baseline age. This is not the same as estimating the temporal
association between age and the hazard of death (as baseline age provides a cross-sectional
measure) but it may be a useful proxy measure. In addition, differences by baseline age have
been used to generate extrapolations in previous studies [23, 76] (See ‘Modelling on both the age
and timescales’ of Appendix 2 for further details on this approach). An approximate estimate
of the disease-specific (excess) hazard is also obtained by removing the age-matched general
population hazard. This is obtained for the USA for the year 2008 (enrolment was May 2008 to
July 2009) from the Human Mortality Database [200]. Resulting plots are in Figure 4.1.
The relationship between baseline age and hazard is very similar for both treatments. On the
log-scale, there appears to be a piecewise linear relationship between age and the overall log-
hazard, with a large increase for those under 60 and a smaller increase for those over 60. Before
the age of 60 the excess hazard is approximately zero (hence cannot be plotted on the log-scale)
and follows a linear increase after the age of 60. This suggests that ageing will lead to increases
in both the overall hazard and the disease-specific hazard over time, with larger increases at the
start of follow-up, due to ageing amongst those under 60. The observed changes in the overall
hazard over time will depend on both the impact of ageing and disease-specific impacts.
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4.1.2 Candidate extrapolation models; within-sample fit
Five classes of survival model were considered:
1. Current practice models: Eight survival models were considered: exponential, Weibull,
Gompertz, gamma, log-logistic, lognormal, generalised gamma, and generalised F. Two
models were chosen to be taken forwards as candidate extrapolation models.
2. RPMs: between zero and five internal knots were considered, with outcomes of both
the log cumulative hazard and log cumulative odds considered, resulting in 12 potential
models (when using no internal knots the two models correspond to Weibull and log-logistic
models, respectively). One model was chosen for extrapolations.
3. GAMs: As model complexity is automatically penalised during model estimation, only
one model was considered, which used the log of time.
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4. Fractional polynomials: Both first and second-order polynomials were considered, with
the use of log-time. One model was chosen for extrapolations.
5. DSMs: local trend and damped trend models were used. These have the same specification
(including prior distributions) as for the simulation study of this chapter, which provides
more details. Both models used a global level.
For classes one, two, and four, multiple models may be fit. The choice of model(s) to use for
extrapolations was based on a combination of goodness of fit to the observed data and the
plausibility of extrapolations. Goodness of fit included both visual fit and two quantitative
measures: Akaike and Bayesian information criteria (AIC and BIC, respectively).
Within-sample goodness of fit values for the standard and RPMs are provided in Table 4.3. Both
information criteria provide very similar values. Whilst models with lower AIC are preferred, it
can be hard to evaluate meaningful differences in AIC values, as there are no guidelines for non-
nested models. To alleviate this, the inverse evidence ratio (IER) is used. This is a measure of
how plausible a model is, relative to the ‘best’ model (the model with the minimum information
criteria). Let ICm be the information criteria value (such as AIC) for model m, and IC
∗ be the
minimum of ICm. Then the IER for model m is defined as: exp(−0.5 ∗ [ICm − IC∗]). The best
fitting model will always have an ICm = 100%, whilst values for poorly fitting models will be
close to zero [201]. IER values are calculated within each class of model. An advantage of using
IERs is the relative ease of comparing models, although other methods such as linking BIC to
Bayes factors may also be used [202].
Visual goodness of fit (within and out of sample) was considered for all but is only presented
for the models taken forwards for extrapolation. These visualisations are provided in Figures
4.3 and 4.4 for the abiraterone and placebo groups, respectively.
The Weibull and gamma models had very similar AIC and BIC values and for both groups
are the two best standard models, with IERs of at least 85% (no other standard models had
values greater than 39%). Within-sample the Weibull and gamma models provide very similar
estimates for both treatment arms, whilst extrapolated values are lower for the gamma. Both
Weibull and gamma models were considered for extrapolation.
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Table 4.3: Goodness of fit measures.
Abiraterone Placebo
Current practice models AIC IER BIC IER AIC IER BIC IER
Weibull 1,086.3 100% 1,093.9 100% 536.3 87% 543.1 87%
Gamma 1,086.6 85% 1,094.2 85% 536.0 100% 542.8 100%
Log-logistic 1,088.2 39% 1,095.8 39% 539.6 16% 546.4 16%
Generalised gamma 1,088.3 37% 1,099.6 6% 538.0 37% 548.2 7%
Generalised F 1,090.3 14% 1,105.4 0% 540.0 14% 553.6 0%
Gompertz 1,096.0 1% 1,103.5 1% 545.1 1% 551.9 1%
Lognormal 1,102.6 0% 1,110.2 0% 542.5 4% 549.3 4%
Exponential 1,135.6 0% 1,139.4 0% 580.8 0% 584.2 0%
Royston-Parmar models AIC IER BIC IER AIC IER BIC IER
Hazard scale; 0 knots 1,086.3 100% 1,093.9 100% 536.3 5% 543.1 100%
Hazard scale; 1 knots 1,088.2 39% 1,099.6 6% 537.9 2% 548.2 8%
Hazard scale; 2 knots 1,090.2 14% 1,105.4 0% 537.4 3% 551.0 2%
Hazard scale; 3 knots 1,091.9 6% 1,110.9 0% 533.0 28% 550.0 3%
Hazard scale; 4 knots 1,092.8 4% 1,115.6 0% 535.1 10% 555.6 0%
Hazard scale; 5 knots 1,093.7 3% 1,120.2 0% 530.4 100% 554.3 0%
Odds scale; 0 knots 1,088.2 39% 1,095.8 39% 539.6 1% 546.4 19%
Odds scale; 1 knots 1,089.2 23% 1,100.6 3% 540.7 1% 550.9 2%
Odds scale; 2 knots 1,090.8 10% 1,106.0 0% 537.1 4% 550.8 2%
Odds scale; 3 knots 1,092.4 5% 1,111.4 0% 533.5 21% 550.6 2%
Odds scale; 4 knots 1,092.8 4% 1,115.6 0% 536.2 6% 556.6 0%
Odds scale; 5 knots 1,093.8 2% 1,120.3 0% 530.9 80% 554.7 0%
AIC: Akaike’s information criteria. IER: Inverse evidence ratio.
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For the abiraterone group, the RPM corresponding to the Weibull (hazard scale, no internal
knots) had the lowest AIC and BIC; no other model had an IER greater than 40%, with IER
values decreasing with increasing model complexity. For the placebo group use of AIC and
BIC led to contrary findings. The BIC supported the use of a Weibull (next largest IER was
19%, corresponding to log-logistic model), whilst more complex models had lower AIC values.
Visually the more complex models appeared to be over-fitting the data, suggesting that in this
instance AIC may not be sufficiently penalising model complexity. Since the best-fitting (and
plausible) RPM was the Weibull for both groups and this was already chosen as a standard
model, no RPMs were used for extrapolation.
The fitted GAM provided visual estimates that were very similar to the RPM with the lowest
AIC, suggesting a Weibull for abiraterone and a function with six turning points in the hazard
for the placebo group. These are used for extrapolation even though it is noted that the placebo
GAM may be over-fitting the data (resulting in very large extrapolated hazards).
For both groups, the FP1 with the lowest AIC was the same model as a Weibull. This model
provided very similar visual estimates (within-sample and extrapolations) to the best-fitting
FP2 (based on AIC). For both groups the AIC for the FP1 (Weibull model) was slightly lower
than that for the FP2; (placebo: 682.1 vs 683.8, abiraterone: 533.4 vs 534.5). As such, the FP1
model corresponding to the Weibull was chosen for both groups. Hence, as with the RPM, no
FP models were used for extrapolation. More information on the relationship between FP(1)
models and current practice models is provided in Appendix 3.
For the abiraterone group, both DSMs provide similar estimates to the Weibull model up to
about 9 months. After this time, the local trend model estimates higher hazards than the Weibull
and the damped trend model estimates lower hazards. Similar extrapolations were observed for
the placebo group, with the damped trend providing the lowest extrapolated hazards of all
models considered and the local trend the second highest (below the GAM, which appeared to
be over-fitting). The higher extrapolations from the local trend model (compared with standard
models) may be due to the potential increase in the hazards at the end of follow-up noted in
Figure 4.1. Of all the models considered, the damped trend model is the only one which assumes
that the extrapolated trend will decrease over time. The impact of this assumption is evident
CHAPTER 4. COMPARATIVE STUDIES 83
Figure 4.3: Within-sample estimates and extrapolations for selected models: abiraterone.
in Figures 4.3 and 4.4, which leads to notably different extrapolations compared with the other
models. Extensions to relative survival models were explored, but provided virtually identical
results, so are not reported here.
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Figure 4.4: Within-sample estimates and extrapolations for selected models: placebo.
4.1.3 Goodness of fit of extrapolations
A visual comparison of the model-estimates to the longer-term data is provided in Figure 4.5,
which also include a smooth non-parametric estimate (black-dashed line). For both treatment
groups, the trend observed in the interim dataset does not persist in the long-term. For the
placebo group, the short-term increase in the hazard during the period of the interim data is
followed by an almost immediate decrease. As such, none of the models provide good extrapo-
lations. For the abiraterone group, the hazard continues increasing to about 2.5 years albeit at
a lower rate than was observed in the interim dataset. The damped trend model provides ade-
quate extrapolations up to about 2.5 years. After this time the observed hazards decrease, and
no models provide a good description. Extrapolations beyond three years were not considered
due to the small sample sizes (at three years the number of patients remaining in the study was
62 and 23 for the abiraterone and placebo arms, respectively, whilst at 3.5 years the numbers
were 24 and 3, respectively). Extrapolation goodness of fit measures (mean-squared error and
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bias, as defined in the simulation study chapters), were also calculated but are not displayed
given the clear lack of fit for the extrapolations from each of the models considered.
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4.1.4 Discussion
A variety of different models were considered for extrapolating the hazard function from the
interim dataset. For both treatment groups the observed hazard was increasing and the use of
standard survival models favoured either the Weibull or gamma. These models both provided
monotonically increasing extrapolated hazards. Similar extrapolations were obtained from the
more flexible FPs, RPMs and GAMs, along with the local trend model. In contrast, the damped
trend model provided extrapolations that increased at a much lower rate for both groups. All
of the models predicted that hazards would continue to increase in the future. However, for
both treatment groups the long-term hazards eventually decreased; this decrease occurred after
approximately one and 2.5 years for the placebo and abiraterone groups, respectively. As none of
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the considered models were able to model a turning point in the hazard function (from increasing
to decreasing) during the extrapolated period, the extrapolations were generally all poor. The
damped trend model assumes that the hazard function will eventually change from increasing
to constant; this is closest to what occurred in the full dataset, hence the extrapolations from
the damped trend DSM were closest to the longer-term data. However, as this is a single case-
study, the generalisability of this finding to other scenarios is unclear. The main finding from
this case-study is that any model used for extrapolation is only as good as the dataset that it
uses. If the unobserved future contains turning points, then any extrapolation model would do
poorly unless it incorporates external data to identify the turning points.
4.2 Simulation study: methods
The reporting of the simulation study follows published guidance [194]. Components of the
simulation study are reported based on their aims (provided in the previous section), data
generating mechanisms, methods (models), estimands, and performance measures.
4.2.1 Data generating mechanism
A two-component mixture-Weibull model was used as the data generating mechanism (each
component is an individual Weibull model). This model was chosen because it is capable of
producing complex (multi-modal) hazard functions and may be interpreted as representing latent
frailties (two sub-populations), representing patients with either a high hazard (short survival)
or a low hazard (long survival) [203]. The survival and hazard functions are given by:
Sti = ρ exp(−Λ1t
γ1








i ) + Λ2γ2t
γ−12
i (1− ρ) exp(−Λ2tγ2)
Sti
(4.2)
respectively, where γ and Λ are the respective shape and scale parameters (indexed by com-
ponent), and ρ is the mixing proportion. The values used for this study are: γ1 = 1.8,Λ1 =
0.02, γ2 = 1.4,Λ2 = 2.3, and ρ = 0.5. A plot of λti is provided in Figure 4.6. The data generat-
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ing mechanism was designed to reflect a ‘true’ hazard with two turning points, and a long-term
increasing hazard (to reflect the impact of ageing on the hazard of death). As this is a simulation
study, the time units to use are arbitrary; they were chosen to represent years. There are two
turning points, at approximately 0.5 and 1.75 years. After the second turning point hazards
increase monotonically.
Nine scenarios were simulated, with 200 datasets simulated for each scenario. These scenarios
corresponded to three different sample sizes (small = 100, medium = 300, large = 600), and
three different lengths of follow-up (short = two years, medium = three years, long = four
years). The key differences between lengths of follow-up were where follow-up ended relative to
the second turning point, ranging from very soon after (short follow-up) to a longer time after
(long follow-up). Follow-up times less than the second turning point were not considered, as
without evidence on the long-term increasing trend the competing models would not be able
to provide plausible extrapolations. The sample sizes were chosen to be representative of those
typically seen in clinical practice. Details on these scenarios are provided in Table 4.4. Figure
4.6 shows the simulated hazards (in grey) for each scenario along with the true hazard (in black,
which is the same for each scenario). Hence, for each scenario Figure 4.6 displays 200 grey lines
(hazards), where the number of observations for each hazard is equal to the sample size for that
scenario.
Table 4.4: Details of the nine scenarios simulated.
Scenario Follow-up (survival %) Sample size
Short follow-up, small sample size
Two years (46.8 %)
100
Short follow-up, medium sample size 300
Short follow-up, large sample size 600
Medium follow-up, small sample size
Three years (43.3%)
100
Medium follow-up, medium sample size 300
Medium follow-up, large sample size 600
Long follow-up, small sample size
Four years (39.2%)
100
Long follow-up, medium sample size 300
Long follow-up, large sample size 600
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Figure 4.6: Simulated hazards (grey-lines) for the nine scenarios, along with the truth (black-
line)
4.2.2 Estimand and performance measures
The estimand was the mean natural logarithm of the time-varying hazard function λti . The
natural logarithm was used as this maps λti to be in the range (−∞,∞), and it may be assumed
to be approximately Normally distributed. As such, both positive and negative deviations would
be equally likely.
When the estimand is the mean, and positive and negative deviations from the mean are pe-
nalised equally, then the squared error is a consistent loss function (performance measure) [204].
Here consistency means that the performance measure is minimised when model estimates equal
the estimand. The primary performance measure used was the mean (of the) squared error
(MSE), with bias as a secondary performance measure. In addition to being a consistent loss
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function, the MSE has the benefit that it may be interpreted as penalising for both bias (how
close are the model estimates to the truth) and variance (how much do estimates vary across
simulations). Use of bias as a secondary measure provides insight into how the two components












(θ̂j,i − θi) (4.4)
where nsim is the number of simulations, θi is the estimand, and θ̂j,i the corresponding model-
based estimate (the subscripts i, j are for time and simulation), respectively. For MSE lower
values indicate better model performance, for bias values closer to zero indicate better model
performance. As the hazard function is a time-varying estimand the performance measures are
also time-varying. Summary (mean) values of the MSE and bias were calculated separately for
the out-of-sample (extrapolations) and within-sample time periods. These summary measures
use a novel method to calculate; details are provided in Appendix 1. The time-horizon was 20
years (after which survival was essentially 0%), with time-steps of 0.05 years.
4.2.3 Models
Four different classes of survival model were used: current practice, DSMs, spline-based models,
and FPs. Together, the last two classes represent ‘emerging practice’ for this simulation study.
All fitting was performed in R (v 3.5.3). For each model class, multiple model specifications
were considered:
Dynamic survival models. Models with a time-varying trend were used as models without
a trend would extrapolate a constant value, which was deemed to be unlikely. Both
local trend and damped trend models were used; for both the level could be either global
(constant) or local - this results in four models. Parameter estimation was performed using
the RStan package [192].
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Current practice. Seven models were initially evaluated: exponential, Weibull, Gompertz,
lognormal, log-logistic, gamma, and generalised gamma. The main results do not include
the Gompertz model, for reasons described later. Current practice models were fit using
the flexsurv package citeRN191.
Spline-based models. Two implementations were used. One used the generalised additive
models (GAMs) implemented in the mgcv package [135]. The default of a thin-plate spline
was used, with a maximum dimension of seven and a Poisson family. The second was
the Royston-Parmar model (RPM) within the flexsurv package. Between zero and five
internal knots, on the hazard scale were considered.
Fractional polynomials. First-order and second-order models (FP(1) and FP(2) respectively)
were considered. Higher-order models are possible, but rarely required due to the flexibility
of FP(2) models [205]. It is possible to choose between FP(1) and FP(2) models using a
closed-test procedure [205], but for this study FP(1) and FP(2) models were kept separate.
This is because FP(2) models are more complex than FP(1) models, and there was interest
in seeing if extrapolation performance varied by model complexity. Fitting was performed
with the stats package.
For current practice models and the RPMs, individual patient data were used. For the DSMs,
GAMs, and FP models fitting was in the GLM framework, as described in the GLM manuscript
of Appendix 3, with one observed death per time interval (to avoid a loss of information). For
FPs, GAMs, and DSMs it is possible to use either ‘time’ or log(time), with corresponding linear
models being the Gompertz and Weibull. Initially both approaches were considered. Time is
explicitly included as a covariate in FPs and GAMs and use of the full set of powers for FPs is
only possible if the covariate is positive. To ensure this when using log(time), the actual covariate
values used were log(time +1). This approach is standard for Poisson regression models where
zero values are problematic and has the benefit that zero values of time are mapped to zero
values of log(time) [206]. For consistency this approach was also used for GAMs. Results were
worse when time was used instead of log(time) for each model class. In addition, use of the
Gompertz model produced very good within-sample fits but very poor extrapolations which
lacked face validity as they very quickly tended towards zero. Clinically, this is implausible since
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it implies that people will not die after a certain time period. As such, the results presented
in this chapter use log(time). The impact of using time as the covariate is shown in Appendix
2 and the impact of including the Gompertz model in the pool of current practice models is
considered in Section 4.3.1.
Multiple model specifications were considered for most of the model classes. In practice, the
choice between these specifications would be based on a combination of clinical considerations
(such as: are the extrapolations plausible? Does the specification reflect our understanding of
the disease process?) and empirical goodness of fit (such as information criteria). As this is a
simulation study, the choice between model specifications was based purely on AIC for current
practice, RPM, FP(1) and FP(2) models. The AIC was chosen in preference to other information
criteria as it has both theoretical support (as identifying, from a given set of models, the model
that best approximates reality; see Chapter 2 of Burnham and Anderson [201]) and empirical
support as a “reasonable choice” (Chapter 7 o Hyndman et al. [42]). Model choice was not
required for the GAMs or either of the two DSMs. Of the models considered, only the DSMs
are Bayesian in implementation. For these, default (uninformative) priors were used with the
exception of the innovations, which were modelled by a zero-mean Normal prior for which the
variance had an inverse gamma (1, 0.005) prior. The choice of prior for the innovation variances
was informed by the results of the de novo analysis in Section 3.4.
In total, nine models are presented for each scenario:
1. Local trend, global level dynamic model.
2. Local trend, local level dynamic model.
3. Damped trend, global level dynamic model.
4. Damped trend, local level dynamic model.
5. Current practice: best within-sample fit (of the six models considered).
6. Generalised additive model.
7. Royston-Parmar model: best within-sample fit (of the six models considered).
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8. First-order fractional polynomial model: best within-sample fit (of the eight models con-
sidered).
9. Second-order fractional polynomial model: best within-sample fit (of the 36 models con-
sidered).
Results for each of the individual current practice models are provided in Section 4.3.1.
4.3 Simulation study: results
For each model, the visual patterns of within-sample fit and extrapolations were broadly similar
across the nine scenarios considered. Increasing the sample size led to a reduction in the variation
of extrapolations as expected but had little other effect. Results were more sensitive to changes
in length of follow-up. Figure 4.7 provides results for a sample size of 300 for the three lengths
of follow-up considered and all nine models. Plots for the remaining sample sizes are provided in
Appendix 2. Time-varying estimates of the MSE and bias in the model estimates are provided
for the three scenarios with a sample size of 300 in Figure 5.4. Figures for the remaining six
scenarios are provided in Appendix 2.
For the within-sample period, the current practice models provided a poor fit to the observed
data for all the scenarios: the hazard was under-estimated for the first year and then over-
estimated for the subsequent years, with the turning-point in the hazard not captured. The
remaining models all provided visually improved within-sample fit, although they also typically
had more variability in their estimates. With the shortest follow-up (two years) none of the
models identified the long-term increasing trend in the hazard function. With the longest follow-
up (four years) two dynamic models (local trend and damped trend models; both with a global
level) along with the GAM identified the long-term increasing hazard; the remaining models
did not. For the three models that identified the long-term increasing hazard, the bias in the
extrapolations decreased with increasing sample-size as they were able to identify the true trend
with more accuracy. For the largest sample size the local trend (global level), damped trend
(global level), and GAM all provided approximately unbiased estimates. The extrapolation
performance of the two DSMs with a local level also improved with increasing sample size, but
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they consistently under-estimated the true hazard even with the longest follow-up. In contrast,
for the current practice models and RPMs, the bias was not affected by increasing the sample
size. Results for a follow-up of three years were similar to those for four years, but with more
uncertainty in the extrapolations. This uncertainty led to some extreme departures from the
true hazard values for the GAMs and DSMs. In contrast, use of standard models or RPMs led
to extrapolations that were always biased, but there were never any extreme departures from
the truth.
In general, GAMs required less data (sample size or follow-up) than DSMs to identify the
turning-point in the hazard, but GAMs also produced more variable extrapolation estimates
than the DSMs. This large variation is a particular concern as in a given appraisal only a single
extrapolation would be observed and there is a danger that it would correspond to one of the
very poor extrapolations. Both of the FP model classes provided extremely poor extrapolations;
in general extrapolated hazards very quickly tended towards zero or very large numbers. In
addition to being very poor, these extrapolations lacked face validity. As such, estimates from
FP models are not considered further, beyond providing and commenting on summary goodness
of fit values in Table 5.2.
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Figure 4.7: Model estimates of the log-hazard (blue lines) and true values (black lines).
(a) Dynamic survival models.
(b) Current and emerging practice (excluding Gompertz).
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Despite generally having the worst within-sample fit (as measured by both MSE and bias), the
current practice models often provided some of the best extrapolations with short-to-medium
follow-up. However, as can be seen in Figure 4.7, the apparent good extrapolation performance
of the current practice models is an artifact of their poor within-sample fit. The current prac-
tice models extrapolated the short-term decreasing trend in the hazard and failed to reflect the
longer-term increasing trend. Due to the poor within-sample fit, the extrapolated (decreasing)
hazards were by chance close to the true (increasing) hazards. This point is further emphasised
when comparing the performance of the current practice models with the RPMs. The latter
model class provided less-biased within-sample estimates for all nine scenarios, demonstrating
that RPMs were better at estimating the short-term decrease in hazards. Both the current
practice and RPMs extrapolated a decreasing hazard for all nine scenarios, but the RPM ex-
trapolations were always more biased with larger MSE than the current practice extrapolations.
When comparing the four dynamic model specifications, the damped trend models produced less
variation in extrapolations than the local trend models. This is to be expected, as the process
of dampening is cumulative over time so that eventually extrapolations reduce to a constant
value. For each of the nine scenarios the damped trend models had lower summary MSE and
bias values than the corresponding local trend specification. Allowing the level to vary over time
resulted in smaller trend estimates when compared to dynamic models with a fixed (global) level.
This is because for global level models all of the variation in the hazard function is attributed to
the trend, whilst for local level models some of the variation is subsumed by fluctuations in the
level. For damped trend models with a local level, extrapolations were almost constant implying
the extrapolated trend was approximately zero. The smaller trend estimates for the local level
models resulted in less bias when the long-term extrapolations were incorrectly estimated to
decrease (as occurred with short follow-up) but more bias when the long-term increase in the
hazard function was identified (as occurred with longer follow-up). The damped trend local
level model also had small variation in extrapolations, with the smallest extrapolation MSE of
all nine models considered for all nine scenarios. This is despite the fact that the damped trend
local level model extrapolated an essentially constant hazard for all nine scenarios.
Overall values of MSE and bias (averaged across the within-sample and out-of-sample time
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periods) are provided in Table 5.2. For each of the nine scenarios considered, the DSM with a
damped trend and a local level provided the lowest MSE values. The next lowest MSE values
were typically observed for the current practice and RPMs, despite these two model types
predicting a long-term decrease in hazards for all nine scenarios. As the scenarios became more
data rich (increasing follow-up and/or sample size), the performance of the DSMs improved
relative to the other models. For example, with a sample size of 600 and four-years follow-
up, the four DSMs had the lowest MSE of all the models considered. The class of FPs give the
worst extrapolations for every scenario, as shown visually in Figure 4.7. This may be due to their
sensitivity to extreme values, combined with extrapolating polynomial trends [207]. Omitting
the FPs, the largest MSE values were observed for the GAM in seven of the nine scenarios. The
poor performance of the GAMs is primarily driven by the large variability in extrapolations, as
it provided the least-biased estimates in four scenarios. For the remaining five scenarios a DSM
provided the least-biased estimates (two each for the two DSMs with a damped trend, one for
the local trend global level DSM).
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Figure 4.8: Mean squared error and bias values over time (within-sample and extrapolations).
(a) Mean squared error (MSE).



























Black reference line is for current practice model
(b) Bias.




















































Table 4.5: Goodness of fit over the entire time horizon.
Overall mean Sample size 100. Follow-up: Sample size 300. Follow-up: Sample size 600. Follow-up:
squared error 2 years 3 years 4 years 2 years 3 years 4 years 2 years 3 years 4 years
Damped trend, local level 0.51 0.34 0.42 0.23 0.38 0.29 0.26 0.41 0.27
Current practice 1.01 1.19 1.26 0.94 1.15 1.19 0.90 1.12 1.15
Royston-Parmar model 1.98 2.38 1.87 2.21 2.38 1.50 2.25 2.36 1.40
Damped trend, global level 3.75 4.98 2.36 7.88 2.29 0.52 8.07 1.41 0.35
Local trend, local level 3.33 4.41 2.96 6.86 4.13 1.26 9.18 3.39 0.71
Local trend, global level 6.03 7.12 4.27 15.61 6.67 1.36 18.04 4.65 0.57
Generalised additive model 32.89 18.16 6.85 18.49 6.59 2.12 20.27 4.09 1.53
Fractional polynomial: order 1 312.40 103.82 22.49 326.43 41.25 8.61 331.78 35.71 9.14
Fractional polynomial: order 2 531.90 258.30 147.35 205.23 55.05 85.21 121.62 24.07 65.57
Overall bias
Damped trend, local level 0.38 -0.03 -0.19 -0.12 -0.35 -0.40 -0.30 -0.30 -0.31
Current practice -0.36 -0.37 -0.35 -0.55 -0.55 -0.54 -0.60 -0.58 -0.56
Royston-Parmar model -0.92 -1.07 -1.10 -1.07 -1.10 -1.11 -0.88 -0.79 -0.77
Damped trend, global level -0.35 -1.83 -1.80 -1.17 -0.78 -0.56 -0.76 -0.18 -0.14
Local trend, local level -0.93 -1.80 -2.14 -1.32 -1.36 -1.23 -1.06 -0.64 -0.48
Local trend, global level -1.36 -2.85 -3.13 -1.73 -1.72 -1.30 -1.31 -0.45 -0.11
Generalised additive model -1.55 -2.18 -1.99 -0.06 -0.09 0.05 0.15 0.31 0.23
Fractional polynomial: order 1 -10.52 -11.87 -12.24 -5.36 -4.10 -3.91 -2.37 -1.75 -1.83
Fractional polynomial: order 2 -5.45 -8.03 -6.72 1.45 -0.79 -1.84 4.05 3.53 3.08
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For both the spline-based models (RPM and GAM), model flexibility is determined by the
complexity of the model: for RPMs this is the number of internal knots (varying between 0
and 5 inclusive), which was based on minimising AIC. For GAM model complexity is based
on the number of parameters; as these are shrunk during parameter estimation, the result is a
non-integer number (between 0 and 10 inclusive). Results for RPMs and GAMs are provided in
Figure 4.9 and Table 4.6, respectively. Of note, the RPMs never chose a model with zero internal
knots (which would be equivalent to a Weibull model). For the shortest available sample size,
there was a preference for simple one-knot models. For the remaining sample sizes, as follow-up
increased there was an increased tendency to select more complex models. For GAMs there
was a strong tendency for more complex models in the scenarios with increasing sample size
or follow-up. Given that the extrapolation performance of GAMs increased in these scenarios,
this suggest that increasing data richness allows for models of increasing complexity. The total
number of parameters in the RPMs is the number of internal knots +2. Hence, the RPMs had a
tendency to select less complex models than the GAMs. For example, with a sample size of 600
and follow-up of 3 years, the majority of RPMs typically had 4 parameters, whilst the GAMs
had on average 6.7 parameters.
Table 4.6: Model complexity: generalised additive models.
Sample size Follow up Mean 95% confidence interval
100 2 years 4.06 2 to 7.92
100 3 years 5.28 2 to 8.78
100 4 years 5.51 2 to 9.08
300 2 years 5.11 3.81 to 7.96
300 3 years 6.35 4.35 to 9.54
300 4 years 6.67 5.36 to 9.47
600 2 years 5.95 4.3 to 9.37
600 3 years 6.99 5.31 to 9.81
600 4 years 7.36 6.04 to 9.77
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Figure 4.9: Number of internal knots chosen for Royston-Parmar models.






































4.3.1 Current practice: the influence of the Gompertz model
As previously noted, results for current practice omit the Gompertz model as it provided very
poor extrapolations, lacking face validity. This was compounded by the Gompertz model pro-
viding very good within-sample estimates, so including it would have resulted in drastically
decreased extrapolation performance for the current practice models. To illustrate this issue,
the goodness of fit for each of the seven models comprising current practice are provided in Fig-
ure 4.10 for the three scenarios with a sample size of 300 (results for the remaining six scenarios
are near-identical and not reported). This demonstrates that none of the models are able to
provide an adequate description of the long-term hazards, with all the models extrapolating a
decreasing trend. Of the seven models considered, the Gompertz is the only model that does
not model time on the logarithm scale (see Table 2 of the GLM manuscript in Appendix 3),
but uses the original time-scale. Use of the logarithm of time compresses the time scale. For
example, the difference between two and ten years follow-up changes from eight years on the
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original scale to 1.6 years on the logarithm scale. As such, models that use the logarithm scale
for time lead to less extreme extrapolations, avoiding the implausible estimates that arise from
the Gompertz model.
Summary MSE values are provided in Table 4.7, separately for the observed and extrapolated
time periods. Based on within-sample fit, the Gompertz had the lowest average MSE in six
of the scenarios, and the second lowest MSE (behind the generalised gamma) in the remaining
scenarios. The Gompertz always had the largest out-of-sample MSE, with values that were
always at least 16 times larger than the next worst extrapolating model (and more than 200
times worse than the best extrapolating current practice model in five of the scenarios). Results
for bias (not shown) were similar: the Gompertz had the best within-sample and worse out-of-
sample values for all nine scenarios. The best extrapolating models based on MSE (bias) were
the Weibull (lognormal), gamma (Weibull), and gamma (gamma) for follow-ups of two, three,
and four years respectively (irrespective of sample size). Of note, the generalised gamma nearly
always provided worse extrapolations on average than its special cases (the gamma, Weibull,
and lognormal). This suggests that the additional flexibility of the generalised gamma led to
over-fitting temporary trends in the data.
Based on the individual simulation results, the Gompertz and generalised gamma models had
the lowest within-sample MSE in 66% and 34% of simulations, respectively (no other model ever
had the lowest within-sample MSE). The Gompertz never gave the best extrapolations, and the
generalised gamma was only the best extrapolating model in 0.2% of simulations (4 / 1,800).
The gamma was most frequently the best extrapolating model (55% of simulations), followed
by the Weibull (30%) and Lognormal (12%). Whilst the Gompertz model always provided poor




















































Table 4.7: Summary within and out-of-sample mean-squared errors across scenarios.
Sample size = 100 Sample size = 300 Sample size = 600
Summary MSE values In-sample Out-of-sample In-sample Out-of-sample In-sample Out-of-sample
Follow-up = 2 years
Exponential 0.90 1.41 0.88 1.39 0.88 1.40
Gompertz 0.16 47.29 0.12 46.27 0.11 45.82
Weibull 0.63 0.66 0.59 0.59 0.59 0.59
Log-logistic 0.53 0.77 0.49 0.75 0.49 0.75
Lognormal 0.46 0.67 0.43 0.66 0.43 0.65
Gamma 0.70 0.86 0.66 0.79 0.66 0.80
Generalised gamma 0.29 1.33 0.29 1.18 0.29 1.12
Follow-up = 3 years
Exponential 1.25 0.73 1.20 0.67 1.21 0.68
Gompertz 0.18 49.02 0.15 46.96 0.14 47.32
Weibull 0.69 0.31 0.65 0.28 0.65 0.27
Log-logistic 0.61 0.78 0.57 0.78 0.57 0.78
Lognormal 0.54 0.71 0.50 0.71 0.50 0.71
Gamma 0.79 0.28 0.74 0.24 0.75 0.23
Generalised gamma 0.29 1.75 0.29 1.66 0.29 1.60
Follow-up = 4 years
Exponential 1.11 0.35 1.09 0.33 1.09 0.33
Gompertz 0.38 36.20 0.32 33.41 0.31 33.57
Weibull 0.53 0.36 0.51 0.33 0.51 0.33
Log-logistic 0.47 0.98 0.45 0.97 0.44 0.97
Lognormal 0.42 0.91 0.40 0.90 0.40 0.90
Gamma 0.61 0.19 0.59 0.16 0.59 0.15
Generalised gamma 0.22 2.24 0.22 2.07 0.22 2.00
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4.4 Simulation study: discussion
The within-sample fit and extrapolation performance of nine statistical model classes was evalu-
ated in nine scenarios covering different lengths of follow up and different sample sizes. A single
data-generating mechanism was used, with two turning points in the hazard function. Only
the global-level DSMs and GAMs were able to correctly extrapolate an increasing hazard func-
tion, but only in the more data-rich scenarios, and extrapolations were highly variable. Current
practice models provided the worst within-sample estimates of all the models considered. The
DSMs and emerging practice models were able to provide improved within-sample fit due to
their increased flexibility. However, this extra flexibility sometimes resulted in overfitting and
extrapolating short term trends in the data that were not present in the longer term. A stark
example of this was observed for the two FP model classes, for which extrapolations tended
sharply towards implausibly small or large values. The danger of the more flexible models over-
fitting was in general reduced with increased sample size or follow-up, which led to improved
extrapolation performance. A corresponding improvement in extrapolation performance for the
more data-rich scenarios was not observed for current practice models.
Despite providing consistently biased extrapolations, current practice models exhibited very low
variation in estimates across simulations. Similar results were observed for RPMs. In contrast
GAMs gave the widest variation across simulations. Estimates from DSMs were less variable
than from GAMs, but they required longer follow up before they could identify the increasing
hazard function. Amongst the DSM specifications considered, damped trend models generally
provided superior extrapolations than local trend models in all scenarios, whilst allowing the
level to vary led to more conservative estimates of the extrapolated trend.
A strength of this simulation study is the large number of survival models considered. For
each scenario DSMs, current practice, spline-based models, and fractional polynomials were all
evaluated. When including different model specifications, collectively 62 different models were
fit for each scenario, with nine models retained for estimating extrapolation performance. In the
sensitivity analysis that used models as a function of time a further 47 models were considered.
The large number of models included in this simulation study provides important insights into
how extrapolation performance varies with model specification. For example, current practice
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models provided poor within-sample estimates, and their extrapolation performance remained
biased with little effect of increasing follow-up. In contrast DSMs and GAMs provided very good
within-sample fits, with increasing extrapolation performance as the follow-up time increased.
Another important finding was that the use of log-time in the specification of models led to
superior extrapolation performance than use of time for all of the models considered.
The use of model selection also showed that within-sample goodness of fit plays a very limited role
in identifying models that provide accurate extrapolations. For example, the current practice
model with the best within-sample fit typically provided the worst extrapolations. A further
strength of the study is the use of time-varying estimands instead of a single summary measure
of accuracy such as the estimate of lifetime mean survival, which is affected by both within and
out-of sample fit (an accurate estimate may occur if short-term over-estimates of hazard and
long-term under-estimates cancel out, or vice-versa).
To this author’s knowledge the extrapolation performance of DSMs, GAMs and FPs has not
been assessed before, in either simulation studies or case-studies. Neither have previous studies
considered the impact of modelling on the time scale versus using the logarithm of time. Hence
the findings of this study provide valuable contributions to the literature. The use of time-
varying estimands, and the methods to combine these into a summary measure, also represent
a novel development.
There are limitations to this work. Only a single data generating mechanism (a mixture Weibull)
was considered, with only one set of parameters. The within-sample fit and extrapolation per-
formance of the candidate models in other settings is currently unknown and would be a fruitful
area for future research. The existing data generating mechanism included two turning points,
so in this sense favoured the more flexible models. However, survival data are inherently com-
plex with a multitude of potential competing effects, such as ageing, frailty, treatment benefits,
and adverse events. Collectively these are likely to cause complex shapes in the hazard function.
As this is a simulation study, the generalisability of the results depends on the simulated data
being realistic. The simulated data had a short-term increase in the hazard function, followed
by a decrease then a longer-term increase. For this thesis three case-studies in extrapolating
overall survival are presented (one each in Section 4.1 and Chapter 6, and one in the GLM
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manuscript of Appendix 3). These all have a short-term increase followed by a decrease in the
hazard function; it may be argued that in the long-term the hazard function is likely to increase
again due to the impact of ageing. As such, this suggests that the data generating mechanism
used in this analysis is not unrealistic, and so the results will be useful to general practice.
In this study a total of (9× 200 =) 1,800 datasets were simulated and for each 62 models were
fit, resulting in 111,600 sets of extrapolations. Because of this, model selection was largely au-
tomated and based on minimising AIC where multiple model specifications were available (such
as for the 6 RPMs). The one exception is for current practice models, where the Gompertz
was omitted on the grounds of its extrapolations lacking clinical plausibility. This does not
fully reflect the extrapolation task; it is likely that further improvements in the extrapolation
performance of the flexible models would have been observed if clinical plausibility were used to
adjust model specification when their extrapolations were clinically implausible. This is likely to
particularly affect results for GAMs and global level DSMs, as extrapolations from these showed
large variability.
Given that several models provided biased extrapolations (such as the current practice and
RPMs for all nine scenarios), it was felt that exploring the accuracy of estimates of uncertainty
would be of very limited value. Accurately quantifying uncertainty is important, but secondary
to the task of providing accurate extrapolations. Estimates of uncertainty that arise from the
use of different model classes is beyond the scope of this thesis, but it is briefly explored in
Section 6.4.1.
In addition to considering the performance of these models under alternative data generating
mechanisms, further simulation studies could seek to identify if there are certain situations when
one or more of the model classes out-performs the other models, and so may be used as the
default approach. The current results suggest that whilst use of a DSM may be beneficial, there
is a danger that it will provide worse extrapolations than current practice models, especially
in data-poor scenarios. This suggests the use of a variety of different model classes in scenario
analysis, with the choice of base-case model made on a case-by-case basis. This choice would
consider the specifics of the extrapolation problem, such as the plausibility of extrapolations, the
richness of the available data, the qualitative differences in extrapolations arising from different
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models, and how extrapolations compare to any external evidence that is available.
The class of spline models considered in this simulation study included both RPMs and GAMs.
These provided similar within-sample estimates but markedly different extrapolations; RPMs
provided stable extrapolations, but failed to identify the long-term increasing hazard function,
and their extrapolation performance did not improve with increasing follow-up or sample size.
In contrast, extrapolations from GAMs were highly variable but were often able to correctly
identify the increasing hazard trend, and extrapolation performance improved in more data-rich
scenarios. Key differences between RPMs and GAMs are that the former use knot placement for
cubic polynomials with post-hoc correction for model complexity, whilst the GAMs used here
employed thin-plate regression splines, did not require the specification of knots, and model
complexity was penalised during parameter estimation. Future research could explore which of
the differences in model specification contribute to differences in extrapolation performance, and
for both GAMs and RPMs if alternative model specifications would further improve performance.
For example, an existing case-study noted that the extrapolation performance of RPMs can be
sensitive to the choice of knot location [208]; default values (placed at quantiles of the observed
death times) were used in this simulation study.
4.5 Conclusions
The results of the abiraterone case study illustrate an important point: without incorporating
external evidence, survival models will only provide accurate extrapolations if the data to which
they are fit is predictive of the future. This point is in some sense obvious, but it is important
to emphasise, as without long-term evidence it is not possible to validate the assumptions used
when extrapolating. For the simulation study, all nine scenarios included the last turning-point
in the hazard function within the observed period of follow-up. If shorter follow-up times had
been used, extrapolation performance would have been worse. The case study has supplemented
the simulation study of this chapter by considering the extrapolation performance of dynamic
models when using a real dataset of observed survival.
The simulation study demonstrated that in situations when survival outcomes may arise from
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distinct patient populations, current practice models are unlikely to provide accurate estimates
of the observed data or realistic extrapolations. Of the alternative models considered, DSMs
and GAMs were the only ones able to capture the long-term behaviour of the hazard function.
However, extrapolations from these more flexible models were more variable than extrapolations
from current practice models and had the potential to be less accurate. Of the flexible models,
GAMs were able to estimate the long-term behaviour with less mature data than DSMs, but
they also provided more variation in estimates.
The data generating mechanism used in the simulation study was a mixture Weibull model. This
reflects two distinct patient populations, with each experiencing a different hazard of mortality.
A related, but conceptually distinct, situation arises when one of the patient populations may be
viewed as cured, and so experiences only general population mortality. This situation allows for
the incorporation of external evidence in the form of life tables to describe general population
mortality. The extrapolation performance of DSMs and comparator methods in this situation
is considered in the next chapter.
Chapter 5
Comparing cure fraction models
Within the HTA literature there has been growing interest in the assessment of health technolo-
gies with a potentially curative effect [134, 208, 209, 210]. A characteristic of these treatments is
that a sub-group of the treated population may be viewed as ‘cured’ from their disease, and so
experience survival that is the same as the corresponding general population. The overall aver-
age hazard function that is observed is then a mixture of two hazard functions; a disease-specific
hazard and a general population hazard. Parametric survival models have been developed to
reflect the presence of a cured fraction (as identified in the methodological mapping review of
Chapter 2), and for this thesis a novel extension of DSMs to incorporate a cured fraction (giving
DCFMs), is described in Chapter 3. These models incorporate external data in the form of
general population life tables. The extrapolation performance of these ‘cure models’ was as-
sessed in a simulation study, reported in this chapter. Extensions of current practice models to
incorporate a cure fraction have been used in HTA but estimates of the cure fraction have been
shown to be very sensitive to model specification. For example, in a NICE appraisal estimates
of the cure fraction varied by approximately 35% depending on the cure model used, whilst in
a case-study it varied from 0% to 23%. [208, 211]. To assess the impact of not incorporating
external data, models which do not assume a cure fraction were also considered, as was the
impact of applying cure models to data that were simulated from a data-generating mechanism
without a cure fraction (the mixture-Weibull of Chapter 4).
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5.1 Methods
The reporting of the simulation study methods uses the same guidance and structure as Chapter
4, and so covers aims, data generating mechanisms, estimands and performance measures, and
models [194]. These are discussed in turn.
5.1.1 Aims
This simulation study had two primary aims.
1. To compare the goodness of fit, for both within-sample and extrapolations, of models with
a cure fraction. This includes dynamic models, models representing current practice, and
models representing emerging practice.
2. To assess the impact of not incorporating external data, by comparing extrapolations from
cure models against extrapolations from models which do not assume a cure fraction.
There were three secondary aims.
1. To identify the accuracy with which the true cure fraction was estimated.
2. To evaluate the performance of the cure models when the true data did not include a cure
fraction.
3. To explore the effect of incorrectly including external evidence (in the form of relative
survival models) in the two situations when the truth does and does not include a cure
fraction.
5.1.2 Data-generating mechanisms
The ‘true’ survival and hazard functions were simulated from a Weibull cure data-generating
mechanism. With this mechanism, hazard and survival functions are represented by a Weibull
model for individuals who will die from the disease. For individuals who are cured from the
disease general population life-tables are used to estimate the hazard and survival functions. A
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Weibull model with shape (γ) and scale (Λ) values of 1.6 and 2.6, respectively was used. This
provides a mean disease-specific survival of 2.33 years, with survival less than 0.05% at eight
years. Data on general population (background) hazard and survival were taken from the En-
glish 2016 life-tables [212] assuming a starting age of 63 years (the mean age in the case-study
of Chapter 6). It was assumed that one quarter of the sample would be cured (ρ = 0.25).
The equations for obtaining the observed survivor and hazard functions were provided in Equa-













ti × (1− ρ)
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The time-units are interpreted as years. Details of the individual components are provided in
Figure 5.1. The disease-specific and background hazards are both monotone-increasing, with
larger hazards observed for the disease-specific group, as expected. The observed hazard is a
(time-varying) mixture of the two hazards, where the weights are the corresponding proportions
of people still alive. The observed hazard function has two turning points. There is an initial
increase in the hazard driven primarily by the strong increase in hazard for the uncured group.
Over time, as the proportion of the alive sample who are uncured decreases, the rate of increase
in the hazard slows down. After about 2.5 years the overall hazard changes from increasing to
decreasing, as it approaches the general population hazard function. This is reached after about
seven years (when almost all the uncured individuals are dead); after which the hazard function
again increases.
As with the simulation study of Chapter 4, nine scenarios were considered, with 200 datasets
simulated for each scenario. These scenarios corresponded to three different sample sizes (small
= 100, medium = 300, large = 600), and three different lengths of follow-up (short = two
years, medium = four years, long = eight years). When defining length of follow-up, the longest
follow-up was chosen so that there were almost no uncured individuals still alive. The shortest
follow-up was chosen to be representative of the lengths of follow-up often seen in cancer trials
[63], with medium follow-up falling in-between. Of note, the shortest follow-up scenarios do not
include the initial turning-point in the hazard, whilst both the medium and long follow-scenarios
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include the first but the second turning-point is only included in the long follow-up scenarios.
The sample sizes were chosen to represent typical sample sizes of cancer treatments. Details on
the nine scenarios are provided in Table 5.1. Figure 5.2 shows the simulated hazards for each
scenario (in grey) along with the true hazard (in black, which is the same for each scenario).
Figure 5.1: Hazard and survival values for the cured (general population) and uncured (disease-
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Table 5.1: Details of the nine scenarios simulated.
Scenario Follow-up (survival %) Sample size
Short follow-up, small sample size 2 years (63.9%) 100
Short follow-up, medium sample size Cured = 97.7% 300
Short follow-up, large sample size Uncured = 52.6% 600
Medium follow-up, small sample size 4 years (34.8%) 100
Short follow-up, medium sample size Cured = 95.5% 300
Short follow-up, large sample size Uncured = 14.5% 600
Long follow-up, small sample size 8 years (22.7%) 100
Short follow-up, medium sample size Cured = 90.1% 300
Short follow-up, large sample size Uncured = 0.3% 600
Figure 5.2: Simulated hazards (grey-lines) for the nine scenarios, along with the truth (black-
line)
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5.1.3 Estimand and performance measures
The estimand was the natural logarithm of the time-varying hazard function, with primary and
secondary performance measures of MSE and bias, respectively. The estimand and performance
measures are the same as those used in the simulation study of Chapter 4, which provides further
details on these and justification for their use. A time-horizon of 40 years was used (at which
overall survival was 0.1%), with time-steps of 0.05 years.
5.1.4 Models
A key distinction between the models considered was if external evidence (general population
mortality) was included or not. These situations are discussed in turn.
Models with external information; cure models
The following models were considered. All the models are able to incorporate external evidence
and make the assumption that a proportion of the sample will be cured. For all the models the
correct background mortality was supplied for the cured group. Hence the models estimated the
cure proportion and the hazard function for the uncured group.
Weibull cure model. This model is the same as the data-generating mechanism, so the model
structure is ‘correctly specified’.
Lognormal cure model. In contrast to the previous model, the model structure is now ‘in-
correctly specified’ (misspecified) with regards to the true functional form of the hazard
for the uncured group.
Royston Parmar cure model. Between zero and four internal knots were considered. Models
were fit on the hazard scale, so include as a special case the Weibull cure model (when
there are zero knots). As such, the model is ‘over specified’ - it includes the correctly
specified model as a special case but allows for a wider range of more flexible models. For
each dataset, the model with the lowest AIC was used to generate extrapolations.
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Dynamic cured fraction models. Two models were considered: a local trend model, and a
damped trend model. Both models had a global level. The local trend model is over-
specified (it is the same as the Weibull cure model if the innovation variance = 0), whilst
the damped trend model is incorrectly specified.
Of the current practice models, cure fraction versions are only implemented in existing software
for the exponential, Weibull and lognormal. The exponential was not considered as it was
assumed that there would be sufficient subject-matter knowledge to rule-out a constant hazard
for the uncured fraction. Extensions to model a cure fraction are not currently available for
fractional polynomials or GAMs, hence these models were not considered. Based on the results
of the simulation study in Chapter 4 the extrapolation performance of GAMs was broadly
similar to that of DSMs, whilst the performance of FPs was generally very poor. As such, their
omission is not expected to majorly limit the conclusions drawn. The range of models considered
allows for both a comparison of DCFMs against other cure models, and an exploration of the
impact of model misspecification or over-specification. All model fitting was done in R. DCFMs
were fit using RStan, the remaining models were fit using the cuRe package [192, 140]. The
specification of the DCFMs was the same as the DSMs as described in Chapter 4, except with
an additional cure fraction. The proportion of excess deaths observed during trial follow-up
(based on comparing observed deaths with those expected from general population mortality)
was removed from the upper-bound of the cure fraction as it was assumed that these deaths
occurred amongst uncured individuals. The lower bound for the cure fraction was zero, and it
had a uniform prior distribution amongst these bounds.
Models with external information; relative survival models
Dynamic relative survival models (DRSMs) were considered. These incorporate external evi-
dence on the general population hazard function under the assumption that it provides a lower
bound for the overall hazard function. As with the DCFMs, two specifications were evaluated,
with either a local trend or a damped trend model (both with a global level), with fitting using
the RStan package. Further details on model specification are provided in Section 3.3.
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Models without external information
The models without external information were the same as those used for the simulation study
of Chapter 4, which provides a detailed description. Again, where multiple model specifications
were possible, model choice was based on minimising AIC, to provide an automated method
that reflects current approaches to model choice [20]. Key details are repeated below.
Standard practice. Six models were evaluated: exponential, Weibull, lognormal, log-logistic,
gamma, and generalised gamma. One model was retained. The Gompertz was omitted as
it provided implausible extrapolations for follow-up times of two and four years: extrapo-
lations quickly tended towards infinity, which lacked face validity given the observed range
of hazard values. In a separate analysis (reported in Section 5.2.2) the individual results
for these models are considered, along with the Gompertz.
Fractional polynomials. First-order and second-order models (FP(1) and FP(2) respectively)
were considered. One model was retained for each of the FP(1) and FP(2) models.
Spline-based models. Two implementations were evaluated. One used the generalised ad-
ditive models (GAMs) implemented in the mgcv package. The second was the Royston-
Parmar model (RPM), with up to five internal knots (no internal knots being the same as
the Weibull model), as estimated by the flexsurv package, with one RPM retained.
Dynamic survival models. Two models were used: a local trend DSM and a damped trend
DSM. Both models had a global level.
This provided seven models for which the within-sample and extrapolation performance were
examined.
5.2 Results
For the nine scenarios considered, varying the length of follow-up had a larger impact on results
than varying the sample size. Hence the results presented here are for the three follow-ups (two,
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four, eight years), with a sample size of 300. Results for the remaining six scenarios are provided
in Appendix 2.
5.2.1 Cure models
A visual comparison of the model extrapolations and the true log-hazards is provided in Figure
5.3. With the shortest follow-up, all the considered models provided poor predictions. The
Weibull and RP cure models both resulted in very similar extrapolations, with both exhibiting
the largest variation of the five models considered. Extrapolations from the Weibull and RP cure
models generally fell into one of two categories. For the first a large, persistent over-estimation
of the hazard function arose in models which estimated a cure fraction of approximately zero.
For the second the cure fraction was over-estimated, resulting in an under-estimate of the true
hazards (extrapolations quickly fell to general population hazards), until the true values also
matched the general population hazards. Extrapolations from the DCFMs also under-estimated
the true hazards and were visually very similar to those from the second category of Weibull
and RP cure models extrapolations. The lognormal cure model provided extrapolations that
nearly always over-estimated the truth. These extrapolations were also visually distinct to the
first category of extrapolations from the Weibull and RP cure models due to the different model
structure used. With the shortest follow-up, increasing the sample size led to less variation in
extrapolations from the lognormal cure model (but not improvement in fit) and had a negligible
impact on extrapolations from the remaining four cure models. For all five cure models visual
goodness of fit improved as the length of follow-up increased; with the longest follow-up all the
cure models provided very good fits except for the lognormal cure model, which continued to
systematically over-estimate the truth.
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Figure 5.3: Estimates of the log-hazard compared to the truth: cure models
Estimates of bias and MSE over time are provided in Figure 5.4 whilst summary measures
of MSE and bias averaged over the entire time horizon are provided for all nine scenarios in
Table 5.2. Results for the remaining six scenarios are provided in Appendix 2. Within-sample
estimates were all unbiased (95% confidence intervals all included zero) with point-estimates
very close to zero. Across the nine scenarios, mean within-sample bias ranged from -0.09 to zero
(both DCFMs), -0.01 to 0.04 (RP cure model), -0.03 to 0.04 (Weibull cure model) and -0.06 to
0.10 (lognormal cure model). For a given sample size, the worst within-sample bias estimates
were always for the longest follow-up. This will be because the longest follow-up represents the
most complex observed hazard function. Similar within-sample results were obtained for MSE
values which, when compared to the range of MSE values for the extrapolated period, were very
minor.
In the scenarios with the longest follow-up, all the models apart from the lognormal had overall
(within-sample and extrapolated period) MSE and bias values that were very close to zero.
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Further, except for the lognormal, the goodness of fit of the models generally increased as the
length of follow-up or the sample size increased. The lognormal cure model had similar within-
sample fit to the other models; the poor overall performance of this model was due it providing
poor extrapolations.
As noted for the visual fit, bias across the entire time horizon is largest in the scenarios with
the shortest follow-up, and approximately zero with the longest follow-up. The exception to
this is the lognormal cure model, which remains biased even with eight years follow-up. When
compared against the correctly specified model (Weibull cure model), the lognormal cure model
always had estimates of bias that were both larger and more variable, whilst the RP cure model
provided almost identical point-estimates but larger variation. With short and medium follow-
up, the two DCFMs both had more bias than the Weibull cure model with more variation for
short-term extrapolations, but in the longer-term provided unbiased estimates with less variation
than the Weibull cure model. Results for MSE were generally the same as for bias, except for
the lognormal for the shortest follow-up, as this had generally lower MSE than the Weibull cure
model. This low MSE arises because extrapolations for the lognormal cure model, despite being
more biased than the Weibull cure model, had much lower variance. Varying the sample size had
very little impact on the results. Hence, for the non-dynamic cure models, model misspecification
(using a lognormal cure model instead of a Weibull cure model) led to an increase in the bias
of extrapolations, whilst using an over-specified model (RP cure model) had a negligible impact
on bias. The overall goodness of fit of the DCFMs was similar to that of the correctly specified
Weibull cure model, despite being over-specified (local trend) or misspecified (damped trend).
Based on overall goodness of fit, with shorter follow-up the two DCFMs typically provided the
best MSE values. Overall, the Weibull cure model and damped trend cure models had the lowest
MSE in four scenarios each. The remaining scenario had the least mature data (follow-up two
years and sample size = 100). For this, the lognormal cure model provided the best MSE. The
second lowest MSE was from a DCFM in six scenarios, and the RP cure model in the remaining
three.
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Figure 5.4: Mean squared error and bias values over time (within-sample and extrapolations).
Sample size = 300.
(a) Mean squared error (MSE).





























Black reference line is for Weibull cure model
(b) Bias.
























































Table 5.2: Goodness of fit over the entire time horizon: cure fraction models.
Overall mean Sample size 100. Follow-up: Sample size 300. Follow-up: Sample size 600. Follow-up:
squared error 2 years 3 years 4 years 2 years 3 years 4 years 2 years 3 years 4 years
Weibull cure model 1.73 0.34 0.04 1.35 0.14 0.01 0.84 0.04 0.01
Lognormal cure model 0.85 0.87 0.23 0.87 1.04 0.17 0.92 1.06 0.17
Royston-Parmar cure model 1.77 0.34 0.06 1.36 0.31 0.02 0.91 0.22 0.01
Local trend cure model 0.90 0.13 0.07 0.70 0.08 0.02 0.66 0.06 0.01
Damped trend cure model 0.87 0.13 0.07 0.68 0.08 0.02 0.64 0.06 0.01
Overall bias
Weibull cure model 0.20 0.16 0.08 0.07 0.04 0.01 0.01 0.02 0.02
Lognormal cure model 0.33 0.45 0.48 0.49 0.59 0.60 0.18 0.20 0.21
Royston-Parmar cure model 0.08 0.12 0.08 0.05 0.10 0.07 0.01 0.02 0.02
Local trend cure model -0.42 -0.37 -0.37 -0.10 -0.08 -0.07 -0.04 -0.03 -0.02
Damped trend cure model -0.42 -0.37 -0.36 -0.10 -0.08 -0.06 -0.04 -0.03 -0.02
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Estimate of the cure fraction
Estimates of the cure fraction for each model and each scenario are provided in Figure 5.5.
Estimates are summarised using box and whisker plots. For these, the box spans the 25th and
75th percentiles, with whiskers extending to 1.5 times the inter-quartile range (range between
25th and 75th percentiles). Estimates outside the whiskers are shown as solid circles. Two
summary values are displayed: the mean (cross) and median (line). The true value of 0.25 is
denoted by a dashed line.
For the shortest follow-up none of the models provided accurate estimates of the cure fraction; the
lognormal cure model underestimated the true value, with the remaining models overestimating
the true value (based on their point estimates). As the length of follow-up increased estimates
became more accurate: at the longest follow-up (when virtually all the uncured patients had
died), the Weibull and RP cure models correctly identified the true cure fraction, with a very
slight over-estimate for the two DCFMs (mean = 0.26 for both). In contrast, the lognormal cure
model continued to under-estimate the cure fraction (mean = 0.20). In addition to increasing
the accuracy of estimates, increasing follow-up also led to a decrease in variation. This was most
notable for the Weibull and RP cure models. Increasing sample size also led to a decrease in
variation, albeit to a lesser extent whilst also not affecting the accuracy of estimates.
In general, the Weibull and RP cure models provided slightly more accurate estimates of the
true cure fraction than the two DCFMs. This did not however correspond to improved goodness
of fit. This was most notable for the scenarios with shortest follow-up, for which both DCFMs
had better overall MSE despite substantially over-estimating the cured fraction (range for mean
estimates: DCFMs 44.5% to 45.3%, Weibull and RP cure models 30.3% to 34.7%).
For all nine scenarios the lognormal cure model tended to underestimate the cure fraction,
often markedly. For example, with a sample size of 600 and two to four years follow-up, the
mean cure fraction was 0.22% and 0.58% respectively. These estimates were between 30% to
45% (two years follow-up) and 24% to 27% (four years follow-up) smaller than estimates from
the remaining models. One explanation for this underestimation may be because the non-cure
fraction lognormal is able to adequately model the shape of the observed data. However, the
more flexible DCFMs and RP cure model can also model the types of observed hazard patterns
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but had markedly different estimates of the cure fraction. Instead, this result appears to be
because for short-to-medium follow-up the non-cure lognormal gives a slightly better fit to the
observed data than a lognormal with a cure fraction. This is explored in more detail in Section
5.2.2
Figure 5.5: Estimates of the cure fraction
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Dashed line shows true cure fraction (0.25). For each model, the cross shows the mean, the line shows the median
5.2.2 Non-cure models applied to data with a cure fraction
Visual extrapolations from the models which do not include a cured fraction (hence do not
incorporate external information) are provided in Figure 5.6, along with DRSMs. The two
DRSMs incorporate life tables but are misspecified as they do not allow for the possibility of
a cured fraction. Due to the large number of models considered, this figure is split into two
panes; for comparison current practice is included in both. Without external evidence none
of the models provide accurate extrapolations. DRSMs include external evidence and avoid
implausibly low extrapolations, but in general they also provide extrapolations that are more
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variable (with no notable improvement in accuracy) than their corresponding DSMs. The one
exception is for the scenarios with the longest follow-up (eight years) for which the local trend
DRSM provides accurate extrapolations. Estimates from the damped trend DRSM remain poor
even at the longest follow-up. Neither current practice nor emerging practice models (without
external information) were able to accurately predict the long-term hazard function for any
of the scenarios considered. Estimates of bias and MSE are not quantified here as there is
little merit in identifying the model with the best goodness of fit due to the generally poor
extrapolation performance of the models considered. The poor performance of models without
external evidence is not unexpected, as such models can only provide plausible extrapolations
if the available data includes some of the long-term trend in the hazard. For this simulation
study the long-term trend only becomes apparent towards the end of the longest follow-up when
effectively all the uncured group is dead. In addition to providing less accurate extrapolations,
models without external evidence also generally provided more variable extrapolations than
models with external evidence.
Qualitatively, the performance of models without external evidence was similar to the models
in the previous chapter (which assessed the same models when the truth came from a mixture-
Weibull model). For example, the flexible models provided better within-sample fit than the
current practice models but higher variation in extrapolations. Again, the variation in extrap-
olations was largest for the GAM and FP(2) models, followed by the local trend model. In
contrast to the previous chapter, the extrapolation performance of the FP(2) models was no
worse than the GAMS (visually estimates are very similar), although this is primarily because
in this simulation study extrapolations from both model classes lack face validity, with values
much greater or smaller than the observed range of hazard values. In both simulation studies
the damped trend DSM provided less variable extrapolations than the local trend model, the
degree of dampening was the most pronounced in the six scenarios of this chapter with follow-up
of two to four years.
Figure 5.6 shows three distinct extrapolation patterns from the current practice models. With
the shortest follow-up some extrapolations increased very sharply towards infinity, whilst the
majority of extrapolations demonstrated either a moderate increase or a moderate decrease.
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With the middle follow-up the sharply increasing extrapolations vanished, whilst for the longest
follow-up only the moderate decreasing extrapolations remained. These distinct patterns will
arise from different parametric models; differences amongst the individual current practice mod-
els are explored in more depth in the next section.
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Figure 5.6: Estimates of the log-hazard compared to the truth: models without a cure fraction
(a) Current practice and dynamic models
(b) Current and emerging practice
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Non-cure current practice models
Visual estimates of both within-sample fit and extrapolations for the seven models comprising
current practice are provided in Figure 5.7. For within-sample fit, all the models except for
the exponential provide similar goodness of fit for follow-ups of two to four years (range in
mean MSE values: 0.01 to 0.04), whilst for the longest follow-up none of the models provided
good descriptions of the observed hazard function (range 0.28 for generalised gamma to 0.48 for
gamma). For the scenarios with short-to-medium follow-up, despite all the models (excluding
the exponential) having very similar within-sample fit, extrapolations varied markedly; extrap-
olations from the Gompertz, Weibull and gamma all increased, those from the log-logistic and
lognormal decreased, whilst the generalised gamma provided extrapolations that could increase
or decrease but on average were constant. This further highlights the potential futility in basing
model choice on within-sample goodness of fit, as models with near-identical within-sample fit
could provide qualitatively discrepant extrapolations (with no models providing accurate ex-
trapolations). When comparing the Weibull and lognormal models with the corresponding cure
fraction models, the cure models provided notably improved within-sample fit for the scenarios
with the longest follow-up (range in improvement in MSE: 0.41 to 0.44 for the Weibull cure
model and 0.14 to 0.18 for the lognormal cure model). For the scenarios with shorter follow-up
there was very little difference in MSE values although the non-cure lognormal model typically
provided lower bias values on average than the lognormal cure model. In practice MSE values
are not available (these rely on knowing the truth), so model selection is based on goodness of fit
measures such as AIC. The impact of choosing a cure or non-cure current practice specification



























Figure 5.7: Estimates of the log-hazard compared to the truth: current practice (non-cure) models
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Impact of omitting the cure fraction on model selection
As illustrated in Figure 5.6, incorrectly using a model without a cure fraction results in very
poor visual extrapolations of the hazard function. Within-sample fit however appears generally
acceptable, with the exception of the scenarios with the longest follow-up for the least complex
models: current practice and FP(1). In practice there will be uncertainty about if the assumption
of a cure fraction is tenable, so both models with and without a cure fraction may be considered.
This subsection examines the impact of the choice of cure fraction on model selection. Here the
focus is on AIC, as visual within-sample goodness of fit is often similar between cure and non-cure
models, whilst extrapolations from many of the non-cure models may be deemed to be clinically
plausible in the absence of a cure fraction. Table 5.3 provides the average absolute improvement
in AIC by scenario when using a cure model in preference to its non-cure alternative. Dynamic
models are omitted from Table 5.3 as their hierarchical structure means that there is no unique
definition of the number of parameters (see Chapter 7 of Gelman et al. [177] for further details).
On average, use of a cure model led to an improved within-sample fit for all nine scenarios,
with larger improvements in more data-rich scenarios (longer follow-up and/or increased sample
size). However, in the scenarios with the least data, there was very little difference between cure
fraction models and their corresponding non-cure models, suggesting that it would be difficult
to choose between the models in these situations. Given that extrapolations varied markedly
between cure and non-cure models, this highlights the difficulties with model specification in
data-poor scenarios.
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Table 5.3: Improvement in AIC with cure model. Values are mean (95% confidence interval).
Weibull Lognormal Royston Parmar model
Two years
n = 100 1.88 (0.88 to 5.68) 1.79 (0.74 to 6.57) 1.52 (0.13 to 3.69)
n = 300 8.17 (6.81 to 12.7) 9.01 (6.6 to 20.54) 7.8 (6.47 to 10.38)
n = 600 17.34 (15.89 to 22.35) 19.7 (15.71 to 30.43) 16.89 (15.64 to 19.59)
Four years
n = 100 5.75 (2.91 to 12.37) 4.27 (2.58 to 11.16) 4.54 (2.77 to 7.8)
n = 300 18.35 (12.95 to 28.02) 16.74 (12.67 to 30.59) 15.33 (12.62 to 19.28)
n = 600 38.38 (29.87 to 54.7) 35.34 (28.06 to 52.82) 31.11 (27.75 to 34.65)
Eight years
n = 100 29.08 (15.27 to 48.35) 13.32 (6.17 to 29.63) 10.66 (5.75 to 16.66)
n = 300 88.58 (67.86 to 114.82) 40.17 (27.73 to 60.16) 27.95 (21.74 to 34.17)
n = 600 176.12 (142.79 to 221) 80.28 (61.01 to 108.85) 53.26 (46.33 to 60.14)
5.2.3 Cure and relative survival models applied to data without a cure frac-
tion
Models incorporating a cure fraction have been shown to provide a good fit to data with a
cure fraction, which involve complex multi-model hazard shapes. A similar hazard pattern was
used in Chapter 4, which was generated from a non-cure mixture of Weibull distributions. This
section explores the fit of the cure models to the nine scenarios generated in Chapter 4, to
compare their goodness of fit with the non-cure models. For completeness the two DRSMs are
also considered.
As with the other analyses in this and the previous chapter, varying length of follow-up had
a larger impact than varying sample size. Visual goodness of fit for the within-sample and
extrapolated phase are provided for the three lengths of follow-up with a sample size of 300
in Figure 5.8 for the dynamic models, and in Figure 5.9 for the current practice and Royston
Parmar models. Both figures include models with a cure fraction and their corresponding models
without external evidence (for comparison). The dynamic models also include the extension to
relative survival models (DRSMs). Results for the remaining six scenarios (not displayed) were
very similar to those presented here. Overall goodness of fit values, averaged across the within-
sample and extrapolation periods, are provided in Table 5.4 for all nine scenarios. Within-sample
fit (MSE and bias) was generally worst for the current practice and Weibull cure model, with
the remaining models all providing similar within-sample estimates.
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For the dynamic models, incorporating external evidence led to reduced variation in the extrap-
olations whilst also avoiding implausibly small extrapolations as they were constrained by the
general population hazards. For data-poor scenarios these changes led to improved MSE values
compared to dynamic models without external evidence. However, both DCFMs along with
the local trend DRSM failed to identify the true long-term increase in the hazard function for
any of the scenarios (with all three models providing very similar extrapolations). In the two
scenarios with the richest data (follow-up of four years with a sample size of 300 or 600), the
two dynamic models without external evidence had the lowest MSE values (of the six dynamic
models). For the remaining seven scenarios, the damped trend DRSM had the lowest MSE val-
ues, with the second lowest MSE values for the local trend DRSM in five scenarios and the local
trend DCFM in the remaining two. Results for bias were similar, with the damped trend DRSM
being the least biased dynamic model in eight scenarios (and the second least biased, behind
the damped trend DSM in the remaining scenario). The damped trend DRSM also had lower
MSE and bias values than current practice models without external evidence in eight scenarios.
For the remaining scenario, the difference in MSE (bias) values was 0.01 (0.06). In contrast, the
remaining dynamic models with external evidence always had worse MSE and bias values than
current practice models without external evidence.
None of the remaining three cure models (Weibull, lognormal, Royston-Parmar) were able to
identify the long-term increase in the hazard for any of the nine scenarios. The overall goodness
of fit of these models was similar to that of the DCFMs. The non-cure current practice model
had a lower MSE and bias than the lognormal and Weibull cure models, although as discussed
in the previous chapter this is primarily an artefact of the poor within-sample fit of the current
practice non-cure model, combined with unrealistically low variation during the extrapolated
phase. Differences between the two formulations of the RPM were most pronounced at the
shortest follow-up (favouring the non-cure version), with little overall difference at follow-ups of
three and four years.
With the exception of RPM cure models, estimates of the cure fraction were similar for each of
the cure models, with mean values ranging from 0.48 to 0.33 across the nine scenarios (for RPM
cure models the range was 0.44 to 0.13). For all models increasing follow-up or sample size led
CHAPTER 5. CURE FRACTION MODELS 132

















































































Table 5.4: Goodness of fit over the entire time horizon: cure and non-cure models fit to non-cure scenarios.
Overall mean Sample size 100. Follow-up: Sample size 300. Follow-up: Sample size 600. Follow-up:
squared error 2 years 3 years 4 years 2 years 3 years 4 years 2 years 3 years 4 years
Model 2.44 2.34 2.05 2.41 2.33 1.95 2.45 2.34 1.94
Weibull cure model 3.65 3.34 2.91 3.63 3.32 2.83 3.63 3.33 2.82
Royston-Parmar cure model 3.38 2.51 1.86 3.32 2.18 1.58 3.25 1.99 1.54
Local trend cure model 3.68 3.24 2.62 3.64 2.76 1.79 3.44 2.35 1.57
Damped trend cure model 3.68 3.24 2.61 3.64 2.76 1.78 3.45 2.35 1.54
Non cure models
Current practice 1.01 1.19 1.26 0.94 1.15 1.19 0.90 1.12 1.15
Royston-Parmar model 1.98 2.38 1.87 2.21 2.38 1.50 2.25 2.36 1.40
Local trend, global level 6.03 7.12 4.27 15.61 6.67 1.36 18.04 4.65 0.57
Damped trend, global level 3.75 4.98 2.36 7.88 2.29 0.52 8.07 1.41 0.35
Overall bias
Lognormal cure model -1.15 -1.10 -0.96 -1.15 -1.11 -0.93 -1.17 -1.11 -0.93
Weibull cure model -1.61 -1.44 -1.22 -1.61 -1.43 -1.19 -1.61 -1.44 -1.18
Royston-Parmar cure model -1.51 -1.18 -0.94 -1.50 -1.09 -0.86 -1.48 -1.04 -0.86
Local trend cure model -1.64 -1.47 -1.23 -1.64 -1.30 -0.90 -1.57 -1.16 -0.79
Damped trend cure model -1.65 -1.47 -1.22 -1.64 -1.30 -0.90 -1.57 -1.16 -0.78
Non cure models
Current practice -0.36 -0.37 -0.35 -0.55 -0.55 -0.54 -0.60 -0.58 -0.56
Royston-Parmar model -0.92 -1.07 -1.10 -1.07 -1.10 -1.11 -0.88 -0.79 -0.77
Local trend, global level -1.36 -2.85 -3.13 -1.73 -1.72 -1.30 -1.31 -0.45 -0.11
Damped trend, global level -0.35 -1.83 -1.80 -1.17 -0.78 -0.56 -0.76 -0.18 -0.14
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5.3 Conclusions
The extrapolation performance of cure models, relative survival models (which incorporate ex-
ternal evidence) and non-cure models (which do not) was assessed in a simulation study where
the truth included a cure fraction. The performance of the models incorporating external ev-
idence was also assessed using the mixture Weibull simulation study of the previous chapter
(which did not include a cure fraction).
For the cure fraction simulation study, use of models with a cure fraction led to generally ac-
ceptable extrapolations. In contrast, non-cure models failed to provide plausible extrapolations
for up-to eight years of follow-up, when over three-quarters of the sample had died. Relative
survival models improved on the performance of models without external evidence but did not
perform as well as cure models. However, at the shortest follow-up considered (two years, with
over a third of the sample dead), even the correctly specified Weibull cure model provided poor
extrapolations (Figure 5.3). Of the cure models considered, the Weibull and lognormal models
both make strong structural assumptions about the shape of the disease-specific hazard: that
it is either monotonic or has a single turning point, respectively. The results shown here sug-
gest that when these strong structural assumptions are incorrect, resulting extrapolations can
be poor. In contrast, the cure RPM and DCFMs make very weak structural assumptions and
provided extrapolations that were similar to the correctly specified model across the scenarios
considered. In particular, the misspecified damped trend cure fraction model had the lowest
overall MSE in four of the nine scenarios, and the second lowest in a further two. When applied
to the mixture Weibull data, the models that incorporated external evidence provided extrap-
olations with reduced variability which avoided implausibly low estimates. However, most of
these models failed to identify the true long-term increase in the hazard function. The one ex-
ception was the damped trend dynamic relative survival model, which often had the best overall
goodness of fit of all the models considered.
For the cure fraction simulation study, the correctly specified Weibull cure model led to the most
accurate estimates of the cure fraction for the cure models considered, on average. However,
this did not result in improved goodness of fit (within-sample or extrapolations). Further, with
short follow-up, estimates from the Weibull cure model were also highly variable whilst within-
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sample fit was no better than that from a non-cure Weibull model. Together these highlight
the lack of identifiability for data with a cure fraction; where the cure fraction is unknown the
overall observed hazard function may be described equally well by different combinations of
disease-specific hazard functions and cure fractions.
There is limited assessment of the performance of cure fraction models in the literature. Using
long-term registry data for ovarian cancer, Dickman and colleagues show that estimates of the
cure fraction (their primary outcome of interest) was sensitive to model choice; varying from
0.059 for the lognormal cure model to 0.151 for the Weibull cure model [138]. The authors
further note that, whilst the true cure fraction is unknown, the Weibull cure model provides
more plausible estimates of the cure fraction. This is despite this model having worse within-
sample fit (based on AIC), leading the authors to caution that “The estimate of the cure fraction
can be unstable when there are a small number at risk toward the end of follow-up”. The results
of this chapter indicate that instability in estimates of the cure fraction are strongly influenced
by the length of follow-up, with more variation when fewer deaths were observed. Grant and
colleagues performed a simulation study to assess the performance of Weibull cure models when
applied to data representative of a NICE appraisal [210]. Separate cure fractions were modelled
for patients pre-progression and post-progression, with an overall cure fraction of 40% and the
majority of uncured people dead by 150 months. Models fit to 40 months of follow-up were found
to fit the observed data well but under-estimate the overall cure fraction and provide visually
poor extrapolations. Hence the results of Grant and colleagues support the findings of this
study in demonstrating that extrapolation with short follow-up (relative to lifetime follow-up)
can provide poor extrapolations, even if within-sample fit is good
To this author’s knowledge, this is the first time that the within-sample and extrapolation
performance of different parametric cure models has been assessed. It is the first time that
DCFMs have been considered, as this extension of DSMs is a novel development of this thesis.
Another strength of this study is the assessment of the impact that model misspecification has
on both goodness of fit and model selection in practice. This includes both misspecifying the
model for disease-specific mortality in a cure fraction model, and the misspecification of not
using a cure fraction model for data with a cure fraction. For the former, use of a misspecified
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current practice model did not affect within-sample fit but led to very poor and consistently
biased extrapolations. In contrast, use of a misspecified DCFM had little effect. For all model
classes, use of a model without external evidence provided extremely poor extrapolations.
A potential limitation of this study is that the results realistically only represent an upper-
bound on the performance of the cure models in practice. This is because for this study it has
been assumed that the survival of the cured patients is known with certainty (the same life
tables are used in the data-generating mechanism and the models). In reality, there is likely
to be some misspecification in this; individual patient characteristics and local geographical
factors may lead to survival that is different to national life tables. This would affect absolute
goodness of fit but is unlikely to affect the relative performance of the models assessed. The
hazard function of the uncured population is also relatively simple, arising from a monotonic
Weibull model. In reality the hazard function may not be monotonic which again may hamper
model performance. This is likely to most affect the Weibull and lognormal cure models, as this
study has demonstrated that these extensions to current practice models are sensitive to model
misspecification. This simulation study also only assessed one instance of one data-generating
mechanism. Future research could continue to assess the goodness of fit of cure models with
different data-generating mechanisms, or in situations with real data with long follow-up where a
proportion of the sample are known to be cured. This could include situations where the ‘cured’
fraction have a mortality that is persistently elevated compared to the general population. This
elevated risk could be due to prior treatment effects, or if there are underlying risk factors for
other-cause mortality that are not addressed by the curative treatment. In addition, it would be
beneficial to know if cure versions of RPMs are affected by misspecification (do not include the
true model as a special case). Given the promising performance of GAMs in the mixture-Weibull
(non-cure) simulation study, extensions to this model to incorporate a cure fraction would also
be of interest. In the previous simulation study GAMs provided more variable extrapolations
than dynamic models, so it would be interesting to see how the inclusion of external data affected
this variation. Future studies could also expand the data-generating mechanism to consider the
impact of disease progression on both survival and censoring, as was modelled in the study of
Grant and colleagues [210].
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The presence of a cure fraction creates complex hazard patterns which can pose a challenge
for extrapolation. Extensions of current practice models to incorporate a cure fraction work
well if they match the true data-generating mechanism but can provide poor results otherwise.
Dynamic models with a cure fraction generally performed as well as the correctly specified
model, whilst avoiding the sensitivity to model misspecification. For all the models evaluated,
incorrectly omitting the cure fraction led to very poor extrapolations, whilst the usefulness of
cure models was limited when the true data-generating mechanism did not involve a cure fraction.
When the truth did include a cure fraction, all the cure models provided poor extrapolations at
the shortest follow-up considered, and in the data-poor scenarios there was little difference in
the within-sample fit of cure and non-cure models. Hence incorporating external data, in the
form of general population hazards, can in some situations improve extrapolation performance
but it is not guaranteed to do so, and it is not a substitute for having adequate follow-up. A
limitation of this and the previous chapter is that neither considered the use of dynamic models
in the context of a technology appraisal. This evidence gap is addressed in the next chapter.
Chapter 6
Dynamic survival models in health
technology assessment: a case study
Survival models, including DSMs, are used to generate estimates of transition probabilities for
use in HTA. The previous two chapters have examined the extrapolation performance of DSMs
and compared this to alternative survival models. In contrast, this chapter demonstrates the
use of DSMs in the context of HTA, when extrapolations impact upon estimates of overall
costs and QALYs and hence cost-effectiveness. To demonstrate this, this chapter presents a
re-analysis of an existing NICE appraisal focusing on the extrapolation of overall survival (OS)
data. In the original appraisal current practice models and RPMs were both considered. As
shall be seen, estimates of cost-effectiveness were sensitive to the choice of extrapolating model,
and there was disagreement between the approach favoured by the submitting company and
the approach of the evidence review group (ERG), who provided an independent critique of
the company submission. For this case-study, extrapolations are re-estimated using DSMs; it
is contended that a key strength of the dynamic models in these situations is the ability to
base model choice on the anticipated clinical characteristics of survival (or mortality) during
the extrapolated phase. In addition, a key criticism of the company’s original approach to
extrapolation was that eventually the extrapolated hazards fell below that of the age-matched
general population. This motivates the use of DRSMs, first introduced in Section 3.3, which
incorporate general population hazards as external data and ensure that extrapolations never
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fall below these values.
This chapter begins with an overview of the pivotal trial used for the extrapolation of OS data,
along with the extrapolation approaches employed by the submitting company and the ERG.
Extrapolations arising from DSMs and DRSMs are then presented, followed by a replication
of the original health economic model. The impact of dynamic models on estimates of cost-
effectiveness and the uncertainty in these estimates are then discussed, as well as an extension
to incorporate time-varying treatment effects.
6.1 Case study: squamous non-small-cell lung cancer
The existing HTA was a submission to NICE as part of their TA programme [213]. As part
of these appraisals, a company submits evidence on the clinical- and cost-effectiveness of a
technology. This evidence is subject to a critique by an independent ERG. A NICE committee
considers both the company submission and ERG critique as part of their decision-making
process. The NICE committee provides recommendations on whether or not the technology is
judged to be cost-effective and produces a recommendation of whether the technology should
be recommended for routine use.
For this appraisal, the population of interest was people with previously treated locally advanced
or metastatic (stage IIIB or IV) squamous non-small-cell lung cancer. The intervention was
nivolumab and the sole comparator in the company’s submission was docetaxel. The main
evidence source was the pivotal open-label phase III trial CheckMate-017 (NCT01642004) which
compared nivolumab (n = 135) against docetaxel (n = 137) for the population of interest (whose
previous treatment was with platinum combination chemotherapy) [214]. Patient follow-up was
between 11 and 24 months. At the end of follow-up there had been 86 (63.7%) and 113 (82.5%)
deaths in the nivolumab and docetaxel arms, respectively. Treatment was until either disease
progression or unacceptable levels of toxicity. The primary outcome measure was OS. Evidence
on effectiveness come solely from this trial and there was no treatment switching in the data
used in the original company’s submission.
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6.1.1 Company’s approach to extrapolation
Extrapolations were obtained for both OS and progression-free survival (PFS). For both out-
comes, the company based their approach to extrapolation on the guidance in NICE TSD 14
[20]. First, the assumption of proportional hazards was checked both visually and using sig-
nificance testing. The company considered both current practice survival models and RPMs.
For the former, it is unclear if the company considered all seven models described in TSD 14
(exponential, Weibull, Gompertz, log-logistic, lognormal, gamma, and generalised gamma), as
results were only shown for the log-logistic, lognormal and generalised gamma models. RPMs
with up to two internal knots modelled on the hazard, normal and odds scales (corresponding
to extensions of the Weibull, lognormal and log-logistic models, respectively) were considered.
Both AIC and BIC were considered for goodness of fit. The plausibility of extrapolations was
assessed against external evidence.
For OS, the assumption of proportional hazards appeared to hold. For docetaxel, the log-
logistic model was deemed to be the best with regards to both within-sample goodness of fit and
plausibility. The treatment effect for nivolumab was modelled as a hazard ratio. It is noted that
treatment effects within a log-logistic model do not have a proportional hazards interpretation.
An alternative approach to analysing the treatment effect is provided in Section 6.4.1. For PFS,
the proportional hazards assumption was judged to be violated. Hence the company modelled
both treatments using an RPM with two internal knots on the hazard scale.
The probabilistic base-case incremental cost-effectiveness ratio (ICER) arising from this ap-
proach was £86,000 (for this chapter, all ICERs discussed in text are given to the nearest £500
and are per QALY gained), with a survival gain of 1.31 years for nivolumab [213]. This value was
robust to alternative approaches to extrapolation for PFS, but not for OS. For example, when
varying the hazard ratio across its plausible range the ICER varied from £55,000 to £169,000.
6.1.2 Independent critique
The independent ERG were critical of the company’s OS extrapolations, in particular the fact
that the extrapolated hazard (mortality rate) eventually fell below that of the age-matched
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general population:
“The ERG considers this to be wholly implausible, and inconsistent with any clinical evidence
of treating metastatic disease” [215] p88.
The ERG contented that the extrapolated hazard for OS was likely to increase over time due
to ageing. Despite this, they extrapolated a constant hazard over time (using an exponential
model). This was fit from 40 weeks (9.2 months) of follow-up, with the ERG suggesting that
this cut-off was supported by the data. The ERG’s approach to OS extrapolation increased
the company’s base-case ICER from £86,000 to £132,000, whilst the estimated lifetime survival
gain more than halved, from 1.31 to 0.64 years. In response, the company amended their
extrapolation approach to cap the extrapolated hazard rate so that it never fell below that of
the corresponding general population mortality. The company’s revised base-case ICER was
£92,000, with a survival benefit of 1.16 years [216]. However, the ERG were critical of the
company’s revised approach:
“This change does not address the fundamental problem, that the log-logistic curve can never
accurately represent a human population which in the long-term always experiences steadily
increasing mortality hazards with advancing age” [217] p2.
To summarise, the approach to extrapolating OS was identified as both a key area of uncertainty
and a key driver of estimates of cost-effectiveness. The company fit survival models to all the
available data and extrapolated a decreasing trend in the hazard. In contrast, the ERG fit a
survival model to a subset of the available data and extrapolated a constant value (no trend),
whilst also criticising the company’s original extrapolations for eventually falling below that of
the age-sex matched general population. The company in turn criticised the ERG’s approach
as ignoring the trend in the hazard observed in the trial and lacking robustness by not using all
the available data.
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6.2 Re-analysis of the clinical effectiveness data
6.2.1 Analysis without external evidence
Data on OS were digitised from the pivotal trial publication [214] using Engauge digitiser [218].
These digitised data were used to replicate the original individual patient data using the algo-
rithm of Guyot and colleagues, as implemented in the R package survHE [219, 220].
For consistency with the original company submission, the treatment effect for nivolumab is
modelled as a hazard ratio compared with docetaxel, for which both current practice and RP
models are considered. For RPMs, up to five internal knots are considered. Within-sample
goodness of fit is measured using AIC (there were no substantial differences when using BIC
instead of AIC). As with the previous chapter, values of the IER (relative goodness of fit, which
is 100% for the best-fitting model) are also provided. Results are provided in Tables 6.1 and






















Table 6.1: Goodness of fit statistics for the current practice models.
Model Log-logistic Lognormal Generalized gamma Gamma Weibull Exponential Gompertz
AIC 721.3 723.0 723.6 724.9 726.9 730.8 732.0
IER 100% 42% 31% 17% 6% 1% 0%
Table 6.2: Goodness of fit statistics for the Royston Parmar models.
Interior knots AIC: Hazard AIC: Normal AIC: Odds IER: Hazard IER: Normal IER: Odds
None 726.9 723.0 721.3 6% 42% 100%
One 724.5 722.8 722.9 19% 45% 44%
Two 724.4 724.0 724.8 21% 25% 17%
Three 724.1 722.6 723.1 24% 50% 39%
Four 722.4 722.7 722.4 55% 48% 57%
Five 725.8 725.9 725.7 11% 10% 11%
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The results show that the log-logistic model is both the best-fitting (based on AIC) of the
standard survival models and of the more flexible RPMs (as an RPM on the odds scale with
no interior knots is equivalent to a log-logistic model). Estimates of the hazard function from
the second-best fitting RPM (four internal knots, odds scale) were visually very similar to the
log-logistic model for both the within-sample and extrapolated periods (estimates not shown).
Two DSMs are evaluated: a local trend and a damped trend model, both with a global level. The
focus of this case-study is on comparing dynamic models with the models used in the original
appraisal (current practice models and RPMs). An advantage of using a DSM is that it allows
for a direct estimate of the trend in the hazard function over time, along with the uncertainty
in this estimate. This is of particular use in this case-study, as there was disagreement on the
observed trend at the end of follow-up, with the company modelling a decreasing trend and the
ERG modelling no trend in the hazard (by assuming a constant hazard). Figure 6.1 displays the
time-varying estimate of the trend from the two DSMs. The trend estimate from both models is
initially positive followed by a decrease. For the local trend model this decrease starts at about
four months, whilst for the damped trend model this decrease starts immediately. For both
models the trend becomes negative at about half a year. For the local trend model the trend
estimates continue to decrease, albeit with a large degree of uncertainty. For the damped trend
model the trend is almost zero after half a year, suggesting that after this time the assumption
of a constant hazard may be appropriate. Neither of the dynamic models estimated a monotonic
trend, suggesting that models which assume monotonicity (such as the Weibull and Gompertz)
are inappropriate. In contrast, use of a log-logistic or lognormal model may be acceptable, as
the hazards from these can increase then decrease. Further, the confidence intervals from both
models include zero at all time points, indicating that a constant hazard model cannot be ruled
out.
A visual comparison of the fit from the two DSMs along with the original company approach
(log-logistic) and ERG approach (hybrid exponential) is provided in Figure 6.2. For the ex-
trapolations, estimates of the annual hazard of all-cause mortality for the age-matched general
population are also included. These estimates came from lifetables supplied by the Human Mor-
tality Database [200] and are 2016 data for the UK, assuming a starting age of 63 (the median
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Solid-blue line: point-estimates, with 95% confidence intervals in pale blue. Black line = no trend.
age of participants in the pivotal CheckMate 017 trial). For the first year of follow-up estimates
of the hazard function from the log-logistic and two dynamic models are visually similar, albeit
the peak in the hazard (which occurs between four and six months for these three models) is
more pronounced for the log-logistic. At one year of follow-up there are only 30 people still
at risk (22% of the starting sample); this small sample size may be driving the difference in
estimates from the three models observed after one-year. These differences continue into the
extrapolated phase; the current practice log-logistic model estimates the strongest decrease in
the hazard function. In contrast, the damped trend model estimates almost constant hazards;
in the short-term these estimates are very similar to those from the ERG approach, but they
become increasingly smaller than the ERG extrapolations as the time horizon increases. Two
advantages of using the dynamic model in preference to the ERG approach are that first extrap-
olations are based on all the data (using the ERG approach only a third of the original sample,
45 people, contribute to hazard estimates), and secondly the DSM avoids the arbitrary choice
of a cut-point.
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Extrapolations from the local trend model fall between the log-logistic and damped trend mod-
els, eventually falling below corresponding age-matched estimates from the general population
at approximately 15 years. Hence, long-term extrapolations from the local trend model are
implausible for the outcome of all-cause mortality. It is possible to provide a post-hoc correction
to the extrapolations to ensure that they never fall below general population hazards, but as
noted by the ERG this approach is not entirely satisfactory. A better approach would be to
formally incorporate this relevant external evidence within the statistical models to ensure that
extrapolations are plausible. These can be achieved using the framework of relative survival
models (Section 6.2.2).


























Red line: general population hazard
Model Log−logistic Hybrid exponential Local Trend Damped Trend
Black line: observed hazard. Red line: general population hazard.
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6.2.2 Analysis with external evidence
External evidence, in the form of general population lifetables, are included in the dynamic
models via DRSMs. The technical specification for these is provided in Section 3.3. An alterna-
tive approach would be to incorporate these within dynamic cure-fraction models as described
in the same section and implemented in Section 5. Cure models were not considered as clinical
input (in the original submission) did not mention cure as a possibility. In contrast, DRSMs
will ensure that extrapolated hazards never fall below that of the general population hazards.
This makes their use ideal in this case-study where this aspect of long-term plausibility had
previously been highlighted.
Three DRSMs were evaluated: local trend, damped trend, and local level implementations.
Estimates from these are provided in Figure 6.3. Within-sample estimates from the two trend
models are very similar to the corresponding dynamic models which do not include external
evidence. Visually, the local level DRSM provides within-sample estimates that are similar to
an exponential model and do not fit the data as well as the other DRSMs. This suggests that,
without a trend, the local level model would require large variation in the level to closely match
the observed data. If estimates from the local level DRSM were more variable then there is a
danger that they could over-fit the data, particularly as follow-up time increases and the sample
size decreases. Extrapolations from the local level and damped trend DRSMs are very similar
to each other, showing that (as with the damped trend DSM) there is a pronounced dampening
of the trend before the end of follow-up. After 20 years, hazards from all the DRSMs are greater
than the general population estimates, implying that there is a non-negligible extrapolated
excess hazard. After about ten years the local trend DRSM extrapolates an increasing hazard,
suggesting that after this point the influence of ageing on the hazard function outweighs the
extrapolated decrease in the excess hazard.
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6.3 Re-analysis of the cost-effectiveness data
6.3.1 Health economic model
The company submitted a three-state partitioned survival economic model, with the states
‘progression-free’, ‘progressed disease’, and ‘death’. State membership can be derived from
lifetime estimates of OS and PFS:
• The area under the PFS curve corresponds to progression-free state membership.
• The difference between the area under the OS curve and the area under the PFS curve
corresponds to progressed disease state membership.
• The area above the overall survival curve corresponds to membership of the death health
state.
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An example of the survival estimates is provided in Figure 6.4. The time-horizon for the economic
evaluation was 20 years, assumed to represent a lifetime (the median age of trial participants
was 63 years), with a 1-week time cycle. Utility data and resource use were primarily taken
from CheckMate-017 [213].













Estimate Overall survival Progressed disease Progression−free survival (stable disease)
The health economic model uses discrete time cycles. Let Dt, St and Pt be the proportion of
patients in the dead, stable, and progressed health states at time t, respectively. Hence, the
proportion of the cohort in each health state over time was calculated as follows:
• Hazard estimates (λ) for OS and PFS were converted to transition probabilities using the
formula: p = 1− exp(−λ× τ), where τ is the cycle length.
• Dt = Dt−1 + (St−1 + Pt−1)× pOSt
• St = min(St−1 × (1− pPFSt ), 1−Dt)
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• Pt = 1− (Dt + St)
For this re-analysis a partitioned survival analysis model was used for consistency with the
original company submission. An advantage of this economic modelling approach is that it can
be used with digitised patient level data. However, it should be noted that there are a number
of limitations associated with this approach [221]. This includes two simplifying assumptions
when implementing a partitioned survival analysis model. First that the probability of death is
independent of a patient’s health state, secondly that the OS and PFS curves are independent.
Neither assumption is likely to be realistic. These limitations are inherent to partitioned survival
analysis models and are independent of the statistical approach used for extrapolation. As such,
they are noted as limitations, but not addressed here as this is beyond the scope of this thesis.
An overview of the costs included are provided in Table 6.3. Implementation of the PSA was
based on the company approach of using a Gamma distribution, assuming that the standard error
was 10% of the mean. In this replication, drug acquisition costs are only applied for the stable
disease health state because evidence for progressed disease were submitted as confidential-in-
confidence and hence were not publicly available.
Table 6.3: Costs included in the health economic model.
Description Mean value (£)
Stable disease costs
Disease management (per 4 weeks) 313.55
Drug acquisition: nivolumab (per 2 weeks) 2,634
Drug acquisition: docetaxel (per 3 weeks) 900
Administration: nivolumab 269.92
Administration: docetaxel 167.34
Monitoring (per 4 weeks) 151.89
Progressed disease
Disease management (per 4 weeks) 766.62
Drug acquisition cost Not reported
Transition to death
End of life care 3,628.70
Data on the frequency of adverse events were also marked as commercial-in-confidence. A
breakdown of results from the company’s submission states that, of the average discounted
costs per patient, adverse events contributed £228 and £1,304 for nivolumab and docetaxel,
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respectively [213]. As such, the average discounted results from the replicated model were
adjusted by these amounts to reflect the impact of adverse events. As with costs, a post-hoc
adjustment was made to the model outputs from the replicated model to reflect the impact of
adverse events. These were to decrease the average QALYs by 0.01 and 0.05 for nivolumab and
docetaxel, respectively.
The utility values attributed to the two alive health states were 0.750 and 0.592 for the stable
and progressed states, with standard deviations of 0.236 and 0.315, respectively. Details on the
distribution used in company’s PSA were not provided. Hence, the available data (mean and
standard deviation) were used to derive parameters of the beta distribution using the method
of moments [222].
6.3.2 Replicating the original submission
The company’s model was replicated in R, a comparison of the cost-effectiveness results is
provided in Table 6.4. The comparison is against the original company submission (using their
approach to extrapolation) as this had the most detailed reporting of results. For OS this
approach used a log-logistic for docetaxel and applied a hazard ratio for nivolumab. For PFS
RPMs were used.
Given that the individual patient level data were not available and these data were recreated,
identical results are not expected. There is in general close agreement between the original
company submission and the replication for the deterministic results. There is a slight under-
estimation of the mean life-years with nivolumab (2.22 vs 2.26) and hence QALYs (1.28 vs 1.30).
The corresponding values for docetaxel were identical to two decimal places when comparing the
original and replicated submission. For both treatments there was also a slight under-estimation
of absolute costs (by about £500 and £1,000 for nivolumab and docetaxel, respectively) however,
it is known that the replication will slightly under-estimate absolute costs, as it was not possible
to include a drug acquisition cost for the progressed disease health state. Patients in the doc-
etaxel arm spend about twice as long in the progressed health state (after time is discounted),
which matches with the under-estimate being about twice as large for this health state than for
nivolumab. The probabilistic results values are also similar to the deterministic results. The
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number of probabilistic iterations (samples) used in the company submission was 1,000. For the






















Table 6.4: Comparison of cost-effectiveness results: original submission and replication.
Absolute Value Incremental values
ICER
Deterministic results Life Years QALYs Cost QALYs Cost
Original submission
Nivolumab 2.26 1.3 £86,599
0.76 £65,355 £85,950
Docetaxel 0.95 0.54 £21,243
De novo replication
Nivolumab 2.22 1.28 £86,073
0.74 £65,891 £89,309
Docetaxel 0.95 0.54 £20,182
Probabilistic results Life Years QALYs Cost QALYs Cost ICER
Original submission
Nivolumab NR 1.35 £91,677
0.77 £68,938 £89,343
Docetaxel NR 0.58 £22,739
De novo replication
Nivolumab - 1.29 £85,882
0.74 £65,470 £87,926
Docetaxel - 0.55 £20,413
ICER = incremental cost-effectiveness ratio = incremental costs / incremental QALYs. All values are discounted with the exception of
life-years. NR: Not reported.
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6.3.3 Results for dynamic survival models
Results are provided in Table 6.5 for two DSMs (which do not incorporate data on general
population mortality) and three DRSMs (which do). For comparison, three replicated analyses
are also shown. These are:
• The company’s original submission (extrapolation with a log-logistic model)
• The company’s original submission, with extrapolations capped so that hazard estimates
never fall below those of the general population.
• The ERG’s approach (use Kaplan-Meier estimates up to 40 weeks, fit an exponential to
the remaining data and use to extrapolate).
As shown in Table 6.5 and in Figures 6.2 and 6.3, extrapolations can differ between the five
dynamic models; this in turn leads to variation in the cost-effectiveness results. Of the dynamic
models, the largest predicted number of QALYs gained for the nivolumab cohort occurs for
the local trend DSM (1.06), but as previously noted the extrapolated hazards from this model
eventually fall below that of the age-matched general population, which is likely to be clinically
implausible. The smallest numbers of QALYs gained for the nivolumab cohort occurs for both
damped trend dynamic models and the local level DRSM (0.86 to 0.88). These three models
all extrapolate a near-constant hazard (or excess hazard). Of the dynamic models, the three
incorporating external evidence (general population mortality) are likely to provide the most
plausible extrapolations. Incremental QALYs arising from the three DRSMs range from 0.34
(damped trend) to 0.45 (local trend). This reflects the different extrapolations from these models
(see Figure 6.3) and is reflected in ICERs ranging from £142,825 to £122,328 respectively. Whilst
estimates of the incremental QALY gain varied notably between the DRSMs, there was a much
smaller variation in estimates of the incremental cost. This is because the majority of the costs
are incurred during the start of the economic model, for which hazard estimates are similar.
Variation in ICERs across the three DRSMs (£122,328 to £142,825) was slightly greater than
variation between the ERG approach (£124,807) and the company submission with a cap
(£139,958). Advantages of using dynamic models in preference to the ERG approach have
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already been noted: dynamic models use all the data and avoid the arbitrary choice of which
data to use for the extrapolating model. Two additional advantages of the DRSMs are first
that model choice may be guided by clinical input into the likely behaviour of the long-term
excess hazard, and secondly that external evidence is formally included as part of the model
fitting procedure, instead of via a post-hoc adjustment. Collectively, this allows for a stronger
emphasis on understanding the likely behaviour of the long-term excess hazard function and the
plausibility of different assumptions about the long-term behaviour.
As a side-note, whilst estimates of effectiveness were similar in the replicated company approach
(see Table 6.4), the replicated ERG approach provided markedly different estimates: QALYs
gained were 0.66 and 0.34 for nivolumab and docetaxel (respectively) in this replication, whilst
they were 0.89 and 0.44 (respectively) in the original ERG approach. A potential explanation is
that the ERG’s methodology may have been inappropriate; when critiquing it the NICE decision
support unit noted that it was unclear if the ERG accounted for differing sample sizes when






















Table 6.5: Cost-effectiveness estimates from different extrapolation approaches.
Absolute Value Incremental values ICER
QALYs Cost QALYs Cost (per QALY)
Replicated submission (no cap)
Nivolumab 1.29 £85,882
0.74 £65,470 £87,926Docetaxel 0.55 £20,413
Replicated submission (with cap)
Nivolumab 0.95 £72,943
0.39 £54,412 £139,958Docetaxel 0.56 £18,530
Replicated ERG approach
Nivolumab 0.66 £56,985




0.50 £56,699 £113,170Docetaxel 0.56 £18,361
Damped trend
Nivolumab 0.87 £67,328
0.35 £49,600 £141,236Docetaxel 0.52 £17,728
Dynamic relative survival models
Local level
Nivolumab 0.88 £67,880
0.36 £50,229 £139,657Docetaxel 0.52 £17,651
Local trend
Nivolumab 0.99 £72,990
0.45 £54,847 £122,328Docetaxel 0.54 £18,143
Damped trend
Nivolumab 0.86 £66,899
0.34 £49,196 £142,825Docetaxel 0.52 £17,702
DSM: dynamic survival model. ERG = Evidence review group. ICER = incremental cost-effectiveness ratio = incremental costs / incremental
QALYs. QALY = quality-adjusted life-years.
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6.4 Additional analyses
The analyses so far have demonstrated a number of potential benefits of dynamic models over
current practice models. This includes an explicit modelling of the long-term trend, incorporat-
ing external data to inform extrapolations, and encoding clinical views on long-term survival via
model specification. This section demonstrates further advantages of dynamic models: the abil-
ity to incorporate time-varying treatment effects and quantify extrapolation uncertainty. These
two further topics are very important; a thorough treatment is beyond the scope of this thesis,
but the fundamental points are introduced here with suggestions for further research.
6.4.1 Time-varying treatment effects
This case-study has focused on modelling the hazard function (or the excess hazard function)
for the docetaxel group. In the original company submission, estimates for the nivolumab group
were obtained by applying a single (time-invariant) hazard ratio to the docetaxel estimates.
This hazard ratio represents the treatment effect, which was assumed to be constant over-time.
A strength of DSMs is that it is straightforward to incorporate a time-varying treatment effect,
relaxing the potentially restrictive assumption of a constant treatment effect. This is achieved
in the same way that estimates of the level or trend of the hazard function are allowed to vary;
by specifying a time series model for the temporal evolution. To illustrate this approach, the
DRSM of Equation (3.3) in Chapter 3 is extended to include a time-varying excess hazard ratio,
which in its general form is:






[exp(β1,ti + δ1,ti × j) + λPti ]× τti
)
β1,ti = β1,ti−1 + φ1 × β2,ti−1 × ωti
β2,ti = φ1 × β2,ti−1 + ζ
β2
ti
δ1,ti = δ1,ti−1 + φ2 × δ2,ti−1 × ωti
δ2,ti = φ2 × δ2,ti−1 + ζ
δ2
ti
ζβ2ti ∼ N(0, Z)
ζδ2ti ∼ N(0, Z).
(6.1)
Where j is the group indicator (here = 0 for those receiving docetaxel and 1 for those receiving
nivolumab), Y (j) are the observed deaths for group j, δ1,ti and δ2,ti are the level and trend for
the treatment effect, and the trend has an innovation variances ζδ2ti (the innovation variance
for β2,ti has similarly been amended). As with the excess hazard function, the treatment effect
may be modelled as following either a local level, local trend, or damped trend time series
model. Extensions to allow both the level and trend components of the treatment effect to vary
over time are also possible, which would further increase the number of candidate models. As
with standard DSMs, it is noted that the primary focus is on identifying and extrapolating any
changes in the trend over time. Hence for this analysis all models with a trend have a global
level.
This model requires specification of the time series models to use for both the excess hazard
and the treatment effect. Six possible models are included here: three models for the treatment
effect (local level, local trend, and damped trend) are displayed, whilst both a local trend and
a damped trend are evaluated for the excess hazard in Figure 6.5 (a local level for the excess
hazard was not considered as this visually gave a poor fit to the data in Figure 6.3). Both figures
also include a black reference line for a hazard ratio of one (no treatment effect).
Visually, estimates of the nivolumab treatment effect were similar for the two approaches to
modelling the excess hazard, but varied depending on the model used for the treatment effect.
Use of a local level model for the treatment effect provided estimates that were virtually con-
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stant over time, whilst use of a local trend suggests a short-term decrease in the treatment
effect, followed by a long-term increase (moving away from a hazard ratio of one). Estimates
of uncertainty are also greater from the local trend model when compared with the local level
model. As expected, use of a damped trend model for the treatment effect leads to estimates
(both point estimates and estimates of uncertainty) that fall between the local level and lo-
cal trend models. It is further noted that in Equation (6.1) the treatment effect is applied to
the disease-specific (excess) hazard function. This is intuitively appealing, as it is likely to be
more realistic than assuming that the treatment effect applies to the overall all-cause hazard.
Modelling the treatment effect as applying to the overall hazard can lead to biased results as it
includes the unrealistic assumption that treatment will reduce mortality that is unrelated to the
disease [224]. Extending DRSMs to incorporate time-varying treatment effects allows for the
analysis of both treatment groups simultaneously whilst also incorporating external data and
employing very weak structural assumptions about both the baseline hazard and any treatment
effect. As such, these models are very appealing. A potential drawback is the large number
of possible model specifications. This could lead to cherry-picking of the specific models based
on the extrapolations that they provide. Future work could identify how robust extrapolations
are to model specification and how accurately these models can uncover the true treatment
effect. This would require datasets with long-term observed treatment effects, which may be
used as case-studies or used to inform the design of simulation studies. As no such datasets were
identified during this fellowship, this was not pursued here.
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Figure 6.5: Within-sample estimates of the treatment effect, with 95% confidence intervals.
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6.4.2 Extrapolation uncertainty
Estimates of the extrapolated hazard function will be associated with uncertainty. This uncer-
tainty is incorporated within probabilistic sensitivity analyses and will impact on both decision
uncertainty and value of information analyses (such as the expected value of collecting further
information) [45]. A full treatment of these important topics is beyond the scope of this thesis,
but would be worthy of future research. To illustrate this issue, the uncertainty in extrapo-
lations arising from the models of this chapter is presented in Figure 6.6. This expands on
work performed for this fellowship into extrapolation uncertainty [2]. This work considered the
use of current practice models for extrapolation, using simulated representative hazard patterns
and a hypothetical cost-effectiveness analysis. It found that estimates of uncertainty differed
with model choice, with confidence interval widths varying three-fold. Further, uncertainty es-
timates were too narrow: the impact of model choice on decision uncertainty was marked, but
extrapolation uncertainty had a near-negligible contribution to value of information estimates.
In addition, the intuitive understanding that uncertainty should increase as the time-horizon of
extrapolations increases was not reflected in estimates of uncertainty from many current practice
models.
For Figure 6.6 uncertainty is quantified via 95% confidence intervals (or 95% credible intervals
for the dynamic models, due to their Bayesian implementation) and includes GAMs and FPs
for completeness. The current practice model (log-logistic), RPM and GAM all provide very
similar point-estimates, but markedly different uncertainty estimates. Estimates of uncertainty
do not fan-out over time for either the log-logistic or the RPM, whilst those from the GAM do.
Uncertainty estimates arising from the DSMs also fan-out over time, with larger uncertainty
arising from the local trend model than for the damped trend model. In general estimates
of uncertainty from a damped trend model will be less than those from a corresponding non-
damped DSM, due to the process of dampening. Both DSMs provide estimates of extrapolation
uncertainty that are less wide than corresponding estimates from the GAM. For example, at
15 years the width of the 95% confidence interval from the GAM is approximately 10 units,
whilst the width from the damped trend DSM is approximately 2.5 units (four times smaller).
The two DRSMs demonstrate that by incorporating external evidence they can substantially
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reduce extrapolation uncertainty (as there is no modelled uncertainty for the general population
lifetables). Extrapolations (point-estimates) from the best-fitting FP were implausible as they
very quickly went to zero (so tended to −∞ on the log-scale), although uncertainty estimates
did fan-out over time. As demonstrated by Figure 6.6, estimates of uncertainty vary markedly
by survival model. Further research could explore which model(s) provide realistic estimates of
uncertainty. For example, whilst those from the log-logistic model appear to be too narrow in
this example, it is unclear if the true magnitude of uncertainty is best reflected by the GAM, the
damped trend DSM, or a different model. Ideally this future research would use real datasets,
as simulation studies would be strongly affected by the choice of data-generating mechanism.
Figure 6.6: Model estimates of the hazard, with 95% confidence intervals.
Royston−Parmar GAM FP2
Trend (DRSM) Damped (DRSM) Level (DRSM)
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Note that the ERG approach is not included in Figure 6.6, as there is no established method to
model uncertainty in the choice of cut-point. The sensitivity of cost-effectiveness estimates to
the choice of cut-point is illustrated in Figure 6.7; ICER values range from £82,000 to £134,000
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depending on how much evidence is used in the extrapolation model. It is further noted that
the use of non-parametric hazard estimates (as occurs for the ERG approach) can lead to a
substantial increase in uncertainty when compared with a parametric model [27].
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6.5 Conclusions
This case-study has demonstrated that dynamic models can provide flexible fits to the observed
data. A specific advantage of these models in contrast to other survival models is that they
explicitly model a trend in the hazard, allowing for insight into the evolution of the hazard
function over time. At the first NICE appraisal committee, there was disagreement between the
company and ERG about the properties of the extrapolated hazard. The company believed that
it was decreasing, whilst the ERG favoured a constant hazard (no trend). The results shown in
Figure 1 demonstrate that the best estimate is a decreasing trend at the end of follow-up, but
also that this estimate is associated with a lot of uncertainty and a constant trend cannot be
ruled-out.
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A further advantage of the DSMs is that, as local models, they can incorporate all the data
without letting early outcomes unduly influence estimates towards the end of follow-up, as these
will be more relevant when forming extrapolations. This is demonstrated in the trend analysis
of Figure 1 where it is shown that at early times the trend is positive, but over time this becomes
negative. This approach is more efficient than the approach of the ERG which was to discard
all data collected before nine months when generating extrapolations.
The clinical plausibility of extrapolations is very important. Implausible extrapolations resulted
from the use of both standard and spline-based survival models, as over time the hazard function
fell below that of the age-matched general population. Similar extrapolations were seen for the
local trend DSM. The extension to incorporate this external general population evidence and
instead extrapolate the excess hazard (or relative survival) leads to DRSMs, which ensure that
the extrapolated hazard function does not fall below that of the general population. Assessing
if extrapolated hazards fall below corresponding general population hazards is not the only
measure of extrapolation plausibility, but it is an important one that should be considered.
Different model specifications are possible for DRSMs, reflecting different assumptions about the
long-term behaviour of the excess hazard. The options included here were that the excess hazard
was constant, the observed trend continued until the excess hazard became zero, or the observed
trend continued in the short-term, with subsequent values of the excess hazard being constant.
This flexibility in model specification and the direct interpretation of the extrapolations is a
significant advantage of DRSMs when compared with other survival models and allows for the
natural inclusion of clinical opinion about both the natural history of the disease and the likely
mechanism of action of treatments. This case-study also demonstrated two additional important
advantages of dynamic models. The first is the ease with which time-varying treatment effects
may be incorporated, the second is that explicit modelling of innovation variances (the variation
of model parameters over time) provides plausible estimates of extrapolation uncertainty.
Recreated patient-level data was used in this case-study. The recreated company submission
demonstrated close agreement with the original submission, demonstrating the usefulness of
using recreated data. One limitation with not having patient-level data is that it was not
possible to explore the effects of covariates on survival. In particular, when estimating relative
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survival it has been demonstrated that including age can lead to increased accuracy [225]. It
is straightforward to extend DRSMs to include age; this was implemented for the case-study of
Section 4.1.
The results from the DRSMs suggest that the ICER arising from the company’s original approach
(£88,000) is likely to be too low; depending on the long-term prognosis of patients the ICER
is likely to be between £122,000 and £143,000. This range of ICERs is above the acceptable
threshold for end-of life-treatment, which is typically assumed to be £50,000. Following their
original submission, the company offered a discount to the cost of their treatment to lower the
ICER (and so improve the possibility of a positive recommendation). The magnitude of discount
required to make the treatment cost-effective will be strongly affected by the extrapolation
approach used. Of the approaches evaluated here, it is not possible to definitively state which
extrapolation approach would be the preferred base-case analysis, but the use of a dynamic
model which incorporates external evidence appears to be the most useful. Future research
could identify the situations when the different DRSM specifications (including the modelling
of the treatment effect) are appropriate.
Chapter 7
Discussion
Extrapolation of survival data plays a key role in HTA, influencing decisions about which tech-
nologies are funded and hence are made available to patients. The primary aim of this thesis
is to provide answers to the question “What is the value and role of time series methods for
generating predictions of future survival in HTAs?”. This chapter begins with an overview and
discussion of the main findings from this thesis, discussing their implications along with how
they add value to the current evidence on extrapolation in HTA. These results are consolidated
within a suggested good practice framework for extrapolation in HTA, given the current evi-
dence base. Limitations with the thesis are then discussed, which motivates areas for future
research. A summary conclusion ends this chapter and the thesis.
7.1 Overview of key findings
Dynamic models were the main focus of this thesis, but a number of alternative survival mod-
els were also considered. As such, an evaluation of the role and value of dynamic models is
contextualised by also considering the role and value of the alternative models.
In both simulation studies (Chapters 4 and 5) the dynamic models often provided some of the
best overall goodness of fit. This was despite these models never being correctly specified. Sim-
ilar results were observed for the GAM (Chapter 4) and RP cure model (Chapter 5). This
suggests that sufficiently flexible models may be able to adequately describe and extrapolate
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complex hazard patterns. These more flexible models have less strict model assumptions than
current practice models as they replace strong parametric assumptions with an assumption of
smoothness. These weaker parametric assumptions may explain their robustness to misspecifi-
cation. However, this did not always occur. For example, FPs and RPMs (non-cure) provided
poor extrapolations, whilst all the models considered (flexible and current practice) provided
poor extrapolations in scenarios with short follow-up where the turning point in the hazard
function was not captured by any model. In addition, in the cure simulation, use of models
without a cure fraction led to substantially worse extrapolations when compared to models with
a cure fraction. In a similar vein, use of models with a cure fraction provided relatively poor
extrapolations when the truth was a non-cure mixture model (and so not a special case of a cure
model with a cure fraction of 0%).
These findings suggest that flexible models (such as DSMs, GAMs, DRSMs, and DCFMs) may
be viable options for the analysis and extrapolation of survival data under certain circumstances.
Namely, if there is adequate follow-up and if the presence of a cured fraction is appropriately
identified and modelled. In practice it will be very difficult to determine if either of these cir-
cumstances are met. Having adequate follow-up will occur only if the observed data can be used
to predict the unobserved future. This is by definition an assumption that cannot be verified.
Similarly, for some disease areas, the presence of a cured fraction may only be known when
patients have been followed-up to death. Results from the abiraterone case-study (Section 4.1)
highlight the poor extrapolations that can occur in practice when there is insufficient follow-up.
These considerations have two implications. The first is the importance of clinical input into
both the disease natural history and the impact of treatment on this. This may provide some
insight into any expected changes in the hazard function in the future and into the plausibility
of assuming the presence of a cured fraction. The second implication is the need for additional
(external) evidence or longer follow-up, where possible, to help inform extrapolations. For both
of these implications there are advantages to using a dynamic model. First, clinical input into
future outcomes can be reflected by the choice of model as demonstrated in the HTA case-study
of Chapter 6, where the extrapolated excess (disease-specific) mortality could be constant or
decrease to either zero or a non-zero number. Secondly, the two novel extensions of DSMs in
Chapter 3 demonstrate that it is possible to incorporate external evidence within dynamic mod-
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els. Increasing the length of follow-up can also produce improved extrapolations for dynamic
models. For NICE appraisals of cancer drugs there is the possibility of interim funding via the
cancer drugs fund. This is considered for appraisals in which the cost-effectiveness model is
considered to be robust for decision making and the drug has the potential to be cost-effective
but further data collection is required to reduce the uncertainty in the funding decision. This
further data collection would result in longer follow-up times, hence increasing the relevance of
dynamic models.
By incorporating time series methods, DSM can use of all the data when generating extrapo-
lations whilst simultaneously giving more weight to more recent observations. The amount of
additional weight to give is estimated from the data. This avoids the subjective choice of how
much data to use in the extrapolating model, as estimates of cost-effectiveness can be sensitive
to this choice. This is illustrated in Figure 6.7 of Chapter 6. Giving more weight to more recent
observations increases the potential for DSMs to identify turning points in the hazard function
near the end of follow-up. In the simulation study of Chapter 4 only DSMs and GAMs were
able to correctly identify the long-term increases in the hazard (albeit, only in scenarios with
long follow-up). A further advantage of incorporating time series methods is that extrapolation
uncertainty from these models reflects the intuitive notion that the more distant the prediction
the more uncertain it is. In addition, the use of Bayesian methods for model estimation pro-
vides a natural representation of parameter uncertainty (via posterior distributions) for use in
cost-effectiveness analyses [226].
Both dynamic models and emerging practice models provide flexible within-sample estimates.
Dynamic models also provide parsimonious extrapolating models which have direct interpreta-
tions. For example, the local trend model used in this thesis assumes that the extrapolated
log-hazard will follow a linear model. As such, it allows for an explicit quantification of the dis-
tribution of the extrapolated trend. This allows for questions such as if the extrapolated trend
is positive or negative, and if the uncertainty in this trend includes zero. These are important
questions for an appraisal committee, which alternative models cannot easily answer, as dis-
cussed in Chapter 6. The damped trend DSM allows for an extrapolated trend that decreases as
extrapolations move further into the future so that eventually extrapolations become constant.
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This is a particularly attractive assumption as it combines the desire to incorporate observed
evidence about the trend at the end of follow-up with the desire for conservative extrapola-
tions (to avoid implausible estimates). In the mixture-Weibull simulation study of Chapter 4
damped trend models generally out-performed local trend models, whilst giving near-identical
performance (of the cure fraction extensions) in the cure fraction simulation study of Chapter
5. For both simulation studies all three versions of the damped trend model (DSM, DCFM,
DRSM) provided some of the best overall goodness of fit values. Dampening of the extrapolated
trend also helps to alleviate the impact of an unexpected turning-point in the hazard function
during the extrapolated period. This occurred in the abiraterone case-study in Section 4.1,
where damped trend models provided the best extrapolations. The use of damped trend models
to extrapolate survival data is a novel development for this thesis. This includes creating an
algorithm to accommodate unevenly spaced observations.
Dynamic models can also be extended to incorporate time-varying treatment effects. This
relaxes the restrictive assumption that treatment effects are constant over time. Again, the
use of explicit models for the extrapolated treatment effect enables both inferences (such as if
the uncertainty in the extrapolations include no treatment effect) and scenario analyses around
different assumptions. This includes a local level model for no trend in treatment effects and
a damped trend model for changes in treatment effects that persist in the short-term but not
the long-term. This extension can be combined with a DRSM to provide a single analytic
framework for combining short-term trial data with longer-term external data, whilst explicitly
modelling the evolution of the disease-specific hazard function and any time-varying effects of
treatment on this. It is noted that the 2013 NICE ‘Guide to the methods of technology appraisal’
recommends assessing three possibilities for extrapolations: a continued effect, a diminishing
effect, and no further effect beyond the end of follow-up [10]. These assumptions relate to local
trend, damped trend, and local level dynamic models for the treatment effect, respectively.
Finally, the use of dynamic models requires the very weak structural assumption that outcomes
which are close together in time will exhibit some degree of correlation, with the magnitude of
correlation estimated from the data. This structural assumption is much less restrictive than
the assumptions employed by current practice models (including their extension to include a
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cure fraction). The results of Chapter 5 demonstrate that dynamic models are more robust to
model misspecification than current practice models.
7.2 Contributions to the literature
The analyses of this thesis represent the first applications of DSMs in HTA. The extrapolation
of survival outcomes is an important and common task in HTA, but less frequent in other
disciplines. As such, there was little existing literature on the use of DSMs for extrapolation,
with studies typically focusing on obtaining flexible within-sample estimates. The results of
this thesis provide useful evidence on model specification when using DSMs for extrapolation,
including the choice of prior distribution for innovation variances and how to generate continuous
extrapolations for a damped trend model. Two novel extensions to the DSMs were also developed
to incorporate external evidence in the form of life tables. Both relative survival and cure fraction
methods were included. The resulting models are of particular importance for extrapolations
as the inclusion of long-term mortality data helps to simultaneously reduce the uncertainty in
extrapolations and improve their plausibility. These extensions to dynamic models also benefit
from the direct interpretation of the extrapolating model. The ability to base model choice on
the likely long-term hazard (or excess hazard) function is of particular benefit since the results
of this thesis demonstrate that measures of within-sample goodness of fit have very limited use
when choosing an extrapolating model. The analysis of current practice models in Section 4.3.1
provides a dramatic example of this as the Gompertz nearly always had the best within-sample
fit but the worst extrapolations.
Any assessment of the value of dynamic models will depend on the comparator models that
are included. The field of survival analysis is extensive, so comprehensive literature reviews
were performed in Chapter 2 to ensure that appropriate comparators were identified. These
reviews covered both the academic literature (peer-reviewed and grey literature) as well as
NICE appraisals. The multitude of evidence sources allowed for the categorisation of methods
into ‘current practice’ which served as a benchmark when evaluating model goodness of fit, and
‘emerging practice’ which included other models that may be used for extrapolation in HTA and
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so represent viable alternatives.
Simulation studies, covering a wide variety of scenarios and models, were conducted in Chapters 4
and 5 to evaluate the within-sample fit and extrapolation performance of DSMs and comparator
models. This included various model specifications, differing lengths of follow-up and sample
size, and two data-generating mechanisms. These mechanisms were a mixture-Weibull and a
Weibull cure model. Both represent clinically plausible scenarios of heterogeneous outcomes,
due to either patient frailty or a cured fraction. These simulation studies were complemented by
a case-study using patient-level data and a re-analysis of an existing NICE technology appraisal
using recreated (via digitisation) patient-level data. The appraisal re-analysis of Chapter 6
represents the first use of DSMs and DRSMs in HTA and demonstrated their use in this setting.
Together, these analyses illustrate the feasibility of estimating dynamic models using state of
the art (HMC) Bayesian methods.
The mixture (non-cure) simulation study of Chapter 4 was relatively simple, comprising two
monotonic (Weibull) hazard functions. Yet producing accurate extrapolations, with low bias
and low variance, remained challenging for the majority of methods, even with a follow-up of
three years. Across the nine scenarios considered the current practice models had some of the
best overall goodness of fit values, despite entirely failing to capture the long-term shape of the
hazard function. This dataset and the results of this thesis will provide useful test-cases and
benchmarks for future research to see if it is possible to improve on the current extrapolation
performance of both current practice models and the dynamic models. A further contribution
to the literature is the finding that when multiple model specifications are available, models
that include the logarithm of time as a covariate provide superior extrapolations to models that
include time without a transformation. This issue has not been discussed previously in the
literature to my knowledge. Both approaches provide similar within-sample estimates but use
of the logarithm of time contracts the time variable and so reduces the impact of extrapolating
an incorrect trend.
Collectively, the analyses of this thesis provide valuable insight into the performance of dynamic
models along with current and emerging practice in different situations. These findings are
expanded on and encapsulated within the good practice guidance contained in the next section.
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7.3 Good practice guidance on the role of dynamic models
A flowchart to assist in model choice is provided in Figure 7.1. Additional considerations are
also listed to support this flowchart.
Figure 7.1: Flowchart for model selection.
The analyses of this thesis suggest that when the truth includes a cure fraction then cure models
will provide good estimates for both the within sample and extrapolated period. As such, this
should be a key consideration in model choice. Of the cure models considered, the dynamic and
RPMs appear to be the most robust to misspecification of the hazard function for the uncured
fraction and so both should be considered. When there is uncertainty about the presence of a
cure fraction the sensitivity of results to the use of non-cure models should be considered. When
there was no cure fraction none of the models considered in this thesis (current and emerging
practice, including dynamic models) performed consistently well, highlighting the importance
of considering multiple candidate models. Flexible models (DSMs and emerging practice) can
fit better the observed data and so extrapolate trends observed towards the end of follow-up.
However, they are also at danger of overfitting and so extrapolating non-existent trends. This
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danger increased with shorter follow up and/or smaller sample size. Hence current practice mod-
els, which were less flexible and so in general less likely to generate implausible extrapolations,
should also be considered as candidate extrapolation models. FPs were particularly vulnerable
to overfitting as were models that didn’t use the logarithm of time (including the Gompertz),
so neither should be considered. A damped trend model partly mitigates the danger of extrapo-
lating an incorrect trend, so should be considered as a candidate model. Incorporating external
data helps to improve the plausibility of extrapolations whilst reducing their variability. In the
absence of a cured fraction a damped trend DRSM appears to outperform the other methods
for including external evidence considered here. As such, it is recommended that a damped
trend DRSM be included in the set of candidate extrapolation methods. The choice of base-case
model should be driven by considerations of clinical plausibility, noting also that within sample
fit can be a poor predictor of extrapolation performance. To aid this, it is very useful to plot
the empirical hazard function. Benefits of this include the direct clinical interpretation (as it is
non-cumulative, it is more informative than the cumulative hazard function), and hazard esti-
mates are very similar to the transition probabilities that are used in health economic models.
As part of this fellowship, code has been made available to generate hazard plots [2]. Sensitivity
to model choice should always be assessed.
7.4 Limitations and future research
The simulation studies of Chapters 4 and 5 considered a wide variety of models for data with
and without a cure fraction. Whilst the results for dynamic models were promising, no single
model was identified as providing the best estimates across the range of scenarios considered.
To compound this, the use of a model without (with) a cure fraction led to poor extrapolations
when the true data-generating mechanism included (did not include) a cure fraction, for the
data-generating mechanisms considered. In addition, the simulation studies only looked at two
data-generating mechanisms and only three case-studies were included. Hence more experience
is required of the performance of DSMs, their extensions, and comparator models. This would
ideally include simulation studies with different data-generating mechanisms and further case-
studies, including in non-cancer disease areas. The three case-studies were for different diseases
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(prostate cancer, non-small-cell lung cancer, and breast cancer) and all demonstrated an initial
increase from a low value, followed by a turning point and a long-term decrease back to a low
value. Many studies do not plot the hazard function, but similar hazard patterns have also been
observed for Merkel cell carcinoma and melanoma [209, 227]. This raises the interesting potential
that the shape of hazard function observed in clinical oncology trials follows a common pattern.
Further quantification of hazard patterns, including for non-cancer trials, and an assessment of
their impact on extrapolations when included as external evidence, is likely to be a key future
research area. I am currently supervising a PhD short-project into using external trial evidence
to inform extrapolations (using the case-study of Section 4.1).
The specification of dynamic models followed that used in the literature ([128, 143]) which was
Bayesian, whilst comparator models used available software ([100, 140]) and were frequentist
in implementation. Ideally these two approaches would not be compared due to their different
assumptions. The Bayesian approach assumes that parameters are random and the sample fixed.
For the frequentist approach this assumption is the other way around. Some of the observed
findings may be due to these differences in approach. For example, the performance of GAMs was
often similar to DSMs; of the frequentist models the GAMs are the only ones to penalise for model
complexity during model fitting, which makes them the most similar to a Bayesian approach
(as discussed in Chapter 4 of Wood [135]). The current comparisons are motivated by noting
that Bayesian versions of current practice are not routinely used (although implementations are
available [220]), whilst Bayesian implementations of emerging practice models were not available
at the time of this thesis.
A comparison of the extrapolation performance of DSMs and GAMs was conducted for both
the Weibull-mixture simulation study (Chapter 4) and the abiraterone case-study (Section 4.1).
The results suggest that both models may be useful for the extrapolation of survival data. This
finding for DSMs supports the hypothesis of this thesis that time series methods are useful for
the extrapolation of survival data, as they take advantage of the temporal structure of the data.
The finding for GAMs was not anticipated, further research into the reasons for this relatively
good performance would be beneficial. Also, it would be useful to replicate the extensions to
DSMs (such as to incorporate external evidence) for GAMs. The penalty term in GAMs ensures
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a certain degree of smoothness in estimates; this implicitly acknowledges the temporal structure
of data, as smoothness requires that estimates which are close in time are similar.
For the DSM specifications considered in this thesis up to five model types are possible (local
level, local trend with a global or local level, damped trend with a global or local level). In
addition, novel extensions to incorporate external evidence resulted in DCFMs and DRSMs.
A further extension to incorporate time-varying treatment effects was also demonstrated. It
would be possible to combine all these extensions, providing a DCFM in which the hazard for
the uncured fraction follows a DRSM with a treatment effect acting upon the excess hazard
for the uncured population and/or the cure fraction. A (potentially time-varying) standardised
mortality ratio could also be applied to the general population mortality data for the cured
fraction if it is believed that the ‘cured’ people still have an elevated risk compared to the
general population. Such a model is likely to more closely reflect reality than any of the models
currently considered (either in this thesis or in the literature), but it also presents an extensive
range of potential model specifications. This raises the risk of potentially cherry-picking the
model that provides the most convenient extrapolations for the user. Hence future research
should explore the robustness of extrapolations to model specification along with identifying
the situations when certain specifications will be more useful. An alternative approach would
be to consider averaging results from different model specifications. I am supervising an MSc
dissertation exploring this using the case-study of Chapter 6.
There are a variety of other options for expanding the research of this thesis. These include:
• Extrapolation uncertainty and time-varying effects were briefly considered in this thesis.
A thorough exploration of these topics was beyond the scope of this thesis and should be
covered in future research.
• DSMs have not previously been used in HTA. There is a learning-curve associated with
the use of a new statistical method and this opportunity cost has not been considered.
That is, do the incremental benefits of using DSMs outweigh the cost of learning to use the
models? Ideally, future developments would include user-friendly interfaces to fit DSMs
and their extensions.
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• The innovation variance controls the smoothness (or wiggliness) of the model-based hazard
estimate over time. For the applications considered here a constant variance was assumed
in order to decrease the potential for over-fitting that could occur if the model were too
flexible. Other applications of DSMs have used time-varying innovation variances [40, 128].
This could be explored in future research; for example the innovation variation could be
correlated with sample size; allowing for larger variation at the start of follow-up (where
there are more data) and less at the end. This could be achieved by linking the innovation
variance to the at-risk sample size.
• Comparing estimates from models fitted with HMC to those fitted using filtering methods,
which can be based on minimising one-step ahead predictions.
7.5 Conclusions
Survival data describe the occurrence of deaths over time and so form a natural time series.
This motivates the use of dynamic models, which can exploit the temporal evolution of the
hazard function when generating extrapolations. These models combine flexible within-sample
estimates with simple models for extrapolations which have meaningful clinical interpretations.
Compared with the parametric models representing current practice, dynamic models make
minimal structural assumptions. This makes them less prone to model misspecification, which
can impact on goodness of fit. A further strength of dynamic models is that it is relatively
straightforward to extend them to incorporate external evidence and time-varying treatment
effects which increases their applicability when used for extrapolation in HTA. Despite these
strengths of dynamic models, it should be noted that they also have limitations. The simulation
studies demonstrated that, as with all the flexible models, they can provide poor extrapolations
when there is short follow-up data or small sample sizes. Extrapolation performance can be
improved by incorporating external evidence, which is an important area for future research.
In addition, the abiraterone case-study demonstrated that if the available evidence can not be
used to predict the future, for example if there is a turning point in the hazard during the
extrapolated period, then predictions of the future will be poor. This limitation is applicable to
CHAPTER 7. DISCUSSION 179
all models that are used for extrapolation, again future research into the use of external evidence
to alleviate this problem would be fruitful.
To conclude, dynamic models for the analysis and extrapolation of survival data have value
in HTA. Currently, their role may be best thought of as complementary to both the current
practice and spline-based models identified in this thesis. More experience of these models and
their extensions when used with different datasets is required to provide more specific guidance
about their role in HTA, including when they should be used as the base-case model. Dynamic
models are another option in the toolkit of methods for the analysis and extrapolation of survival
data. They are theoretically attractive, and the initial results of this thesis are promising, with
dynamic models often providing some of the best within-sample estimates and extrapolations.
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Appendix 1
Technical appendix
1.1 Survival data and analyses
This section introduces some of the key concepts for survival analyses and describes how they
are related. Survival data measure the elapsed time until the event of interest, relative to a
defined time origin, such as the time of randomisation in a clinical trial. Typically, not all
individuals have experienced the event of interest at the end of follow-up. Such individuals are
said to have (right-)censored event times. In these situations the true event time is not known,
only that it will be greater than the observed censored time. Reasons for censoring include if the
individual is event-free at the end of data collection, or if they are lost to further follow-up before
experiencing the event of interest. Survival models are required for the analysis of censored data.
Standard survival models are described in Section 1.1.2, key introductory concepts are provided
below.
Standard approaches to analysing survival data assume that censoring is uninformative [17].
That is, conditional on any covariates that have been collected, patients with censored outcomes
are no different to patients without censored outcomes. Analyses of informative censoring are
beyond the scope of this thesis.
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1.1.1 Key concepts
The probability density function f(t): For an individual, let t denote their observed event
time. This can be viewed as an observation of a random variable T which can take any
non-negative number (T ∈ R≥0). The distribution of T is the probability density function.
The probability that an event occurs before time t (the cumulative density function) is
then:




The hazard function h(t): This is derived from the probability that an event occurs within
the interval (t to t + ∆t) conditional on the event not having occurred by (or before)
time t. Dividing this conditional probability by the interval width ∆t turns it into a rate
(probability per unit time). The hazard function h(t) is obtained as the limiting value of








The survival function S(t): This is a cumulative distribution, which represents the probabil-
ity that an individual survives beyond time t:




It is related to the hazard function:
h(t) = − d
dt
{logS(t)} (1.4)
The cumulative hazard function H(t): This is the integral of the hazard as defined in Equa-
tion (1.2). It may be interpreted as either the cumulative risk of an event occurring by
time t or the expected number of events by time t. It may also be derived from the survivor






= − logS(t) (1.6)
Equations (1.1), (1.3) and (1.2) are linked by the relationship:
f(t) = h(t)× S(t) (1.7)
Hazard estimation
Life-table (actuarial) estimates: These group the observed survival times into a series of m
time intervals. For example, if survival is measured in years, the time intervals may be
two years: 0 to 2 years, 2 to 4 years, 4 to 6 years, and so on. To remove ambiguity if
an observed survival time is equal to the end (or start) of an interval (say t∗ = 4), the
intervals are defined as tj−1 ≤ t∗ < tj , or equivalently [tj−1, tj) (so a survival time of t∗ = 4
would be assigned to the interval ‘4 to 6 years’). The width of the j-th interval (∆j) is the
time between the start and end times of the interval. For the example given, ∆j = 2 for all
intervals, in general ∆j can vary for each interval. Also, for the j-th interval, let nj be the
number of individuals alive at the start of the interval, dj be the number of events in the
interval and cj be the number of censored times within the interval. Under the actuarial
assumption that both the censoring and event times occur at a constant rate within the
interval (are uniformly distributed), the number at risk, hazard rate and its (asymptotic)
standard error (se) during the jth time interval may be estimated as:









Kaplan-Meier type estimate: This uses the observed survival times t∗. Unlike the life-table
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estimate, there is no grouping of event times. It should be noted that events are only
observed at discrete times and it is assumed that the underlying continuous hazard function
is constant during the interval between event times. If there are dj events and nj individuals









Let δi be an event indicator which = 1 if t
∗
i is an observed survival time and = 0 if it is a
















denotes multiplication. For individuals with an observed event their pdf contributes
to the likelihood. Individuals with censored times contribute their cumulative survivor function
(as their pdf is not fully observed but it is known that they survived up to time ti). The
log-likelihood contribution for the ith patient is:






= di log{f(t∗i )}+ (1− δi) log{S(t∗i )}
(1.9)
Substituting Equations (1.7) and (1.3) into the above gives:
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1.1.2 Standard distributions (models)
For the following distributions both the survivor distribution S(t) and the pdf f(t) are presented.
If a simple expression for the hazard function h(t) is available, this is also provided. Otherwise
it is noted that this may be derived from Equation (1.7). With regards to terminology, terms
‘distribution’ and ‘model’ are used interchangeably. The below specifications are primarily based













When γ = 1, the Weibull is the same as the exponential distribution. Otherwise, the hazard
function is either monotone increasing or monotone decreasing over time (that is, there are no
turning points in the hazard function). This property may be easier to identify when considering
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the logarithm (log) of the hazard (as the logarithm of a monotone function is itself monotone):
log[h(t)] = log(λγtγ−1)
= log((λ) + log(γ) + log(tγ−1)
= c+ (γ − 1) log(t)















h(t) = λeθt = exp(α+ θt)
The Gompertz distribution has similar properties to the Weibull distribution. For the Gompertz,
the log-hazard function is a linear function of time:
log[h(t)] = log(λeθt)
= log(λ) + log(eθt))
= c+ θt
When θ = 0 the Gompertz is the same as the exponential distribution. As with the Weibull,
the hazard function is otherwise monotone increasing or monotone decreasing.
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Log-logistic (θ, κ)







The log-logistic is more flexible than the Weibull and Gompertz distributions, as it can model a
unimodal hazard (that is, a hazard function with a turning-point), which occurs for κ > 1. For
κ ≤ 1 the log-logistic models a monotonic decreasing hazard. The log-logistic distribution does
not include the exponential distribution as a special case.
Lognormal (µ, θ)

















t−1 exp{−(log t− µ)2/2θ2}
It can be seen that the hazard function involves an integral, which makes interpretation difficult.
It has been noted however that, for any given dataset, the fitted log-logistic distribution is very
similar to the fitted lognormal distribution with the lognormal θ parameter multiplied by 1.82
[102, 17]. As with the log-logistic distribution, the lognormal distribution allows for unimodal
hazard functions but does not simplify to an exponential.
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Gamma (λβ)[102, 17]










As with the Weibull and Gompertz distributions, the gamma distribution is always monotonic
and has the exponential distribution as a special case when λ = 1.
Generalised Gamma (λ, θ, β) [102]
S(t) = 1− Γ[λ−2 exp(λ[log(t)− β]/θ);λ−2]
(if λ > 0) = 1− Γ[λ−2(e−βt)λ/θ;λ−2]





This three-parameter model includes the exponential, Weibull, gamma, and lognormal disribu-
tions as special cases (with λ = θ = 1, λ = 1, λ = θ, and λ → 0 respectively). The hazard
function may be a constant, monotone increasing or decreasing, ‘bath-tub’ shaped (initially
decreasing before a turning-point and then increasing), or arc-shaped.





where B(m1,m2) is the beta function evaluated at m1,m2.
The equation for the survival function is not straightforward but it may be obtained via equation
(1.3).
The generalised F includes both the log-logistic and the generalised gamma distributions as
special cases (m1 = m2 = 1 for the former and either m1 → ∞ or m2 → ∞ for the latter). As
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such, it can take any of the shapes covered by these two distributions.
1.2 Parameter estimation for dynamic models
Three main estimation methods are currently used for DSMs: Linear Bayes, posterior mode
estimation, and MCMC. The technical details of these three methods are provided here.
1.2.1 Markov chain Monte Carlo
MCMC algorithms estimate the posterior distribution of model parameters: p(θ|y) where θ rep-
resents the model parameters and y represents the available data. Inferences typically require
integrating the posterior distribution. For example, to estimate the mean of the model param-
eters requires evaluating E[θ|y] =
∫
θ θ p(θ|y) dθ [180]
MCMC algorithms may be thought of as a general method for estimating integrals. A particular
strength of MCMC algorithms is their flexibility as they may applied to almost any complex
problem [228]. As their name suggests, MCMC algorithms have two main components: the use
of Markov chains and Monte Carlo simulation.
Integration via Monte Carlo simulation relies on drawing a sample from the target distribution









A Markov chain has the property that the current distribution of X at time t only depends on
the value of X at the previous time-points and not on any of the preceding values (states). The
Markov chains used in MCMC algorithms have certain additional properties which ensure that
it will have a stationary probability distribution (See Chapter 6 of Robert and Casella for more
details [185]) . Hence, if X(t) ∼ f then X(t+1) ∼ f where the superscript denotes the iteration
number. Over time the values from such a Markov chain will produce samples from the target
density. These samples may then be used to perform Monte Carlo integration - the combination
of these two approaches is formalised in the framework of MCMC algorithms. These are iterative
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algorithms: as the number of iterations increases, the approximating distribution created by the
Markov chain converges towards the target (posterior) distribution. This convergence will occur
independently of the starting values chosen. As such MCMC algorithms represent a powerful
and flexible method for analysing statistical problems. However, a key limitation with these
algorithms is that they only provide information on the areas of f that they have explored,
with no indication of how much of f remains unexplored. In other words “you’ve only seen
where you’ve been” [185] (p238). As such, it is important that the Markov chain explores all
of the target density: the properties of Markov chains used in MCMC algorithms ensure this
asymptotically but do not provide any guarantee that this will happen for a finite sequence.
The Metropolis-Hastings algorithm
An initial MCMC algorithm was proposed by Metropolis et al in 1953 and generalised by
Hastings in 1970 [229, 230]. The resulting Metropolis-Hastings (M-H) MCMC algorithm is:
Given x(t),




Yt with probability p(x
(t), Yt),
x(t) with probability 1− p(x(t), Yt),
where








and q() is a candidate (proposal) distribution, that may be simulated from [185]. The value
p(x, y) is the acceptance probability. Averaging this across iterations provides the acceptance
rate.
The basic idea underlying the M-H algorithm is as follows. For a Markov chain in a given
state, a proposal state is simulated from q(). If this state is more likely to come from the target
distribution f , then the Markov chain moves to the proposed state. Otherwise it remains in
its current state. The M-H algorithm includes the original algorithm by Metropolis et al as a
special case, for which q() is a random walk centred on the current value of x(t) (and the ratio
APPENDIX 1. TECHNICAL APPENDIX 220
involving q() cancels) . As such, the M-H algorithm explores the local neighbourhood of the
current value of the Markov chain x(t). Another special-case of the M-H algorithm occurs if each
component of θ is updated once per iteration, which is known as Gibbs sampling [228].
An advantage of an MCMC algorithm with a random walk is that it can be used in virtually
any situation. However, use of a random walk is also inefficient: it does not take advantage
of the characteristics of the target function (such as local gradients), so will return to areas
of the target that have already been explored. Due to the symmetric nature of the random
walk, about half of all iterations will re-visit already explored parts of the target density. As
with all MCMC algorithms, the M-H algorithm also requires tuning, which can be difficult. In
particular, it is typically unclear what the ideal value of the acceptance rate would be. High
acceptance rates suggest both that the Markov chain is exploring different parts of the target
density (which is good) and also that the chain has not yet converged (which is not good).
Conversely, low acceptance rates suggest that the chain has converged but provide no guarantee
that it has explored enough of the target density (Wilkinson, Chapter 9 [231]). There are also
computational implications: lower acceptance rates will produce chains with higher correlation,
which leads to a loss of efficiency. Higher acceptance rates will reduce correlations but typically
require smaller transitions of the Markov chain. As such, it will take longer to explore the target
density [232].
1.2.2 Filtering methods
Filtering algorithms provide a method for sequentially updating posterior distributions. For
example, with a filtering algorithm, estimates of model coefficients at time ti use all the evidence
up to and including time ti. This is in contrast to MCMC methods, which are smoothing methods
as an estimate at ti uses all of the available data [173]. After obtaining filtered estimates, it is
possible to use all of the data to smooth these, as described here.
If a dynamic generalised linear model is used with the Normal distribution, the optimal filtering
algorithm is that described by Rudolf Kalman in 1960 [173], so this approach is typically referred
to as Kalman filtering. This algorithm is optimal as that it provides an exact description of the
posterior (which is Normally distributed, so may be fully described by its mean and covariance).
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It also provides minimum least-squares estimates of one-step ahead prediction [178]. DSMs
have non-Gaussian outcomes so require alternative filtering approaches such as posterior mode
estimation and linear Bayes. Both share similarities with the Kalman filter, so this approach is
described first.
Kalman Filter
The Kalman filter uses the following derived variables:
One-step ahead forecast errors: eti = yti − ŷti|ti−1 = yti − zx′ti β̂ti|ti−1




Further, it is assumed that the distribution of the states is normal, with mean β̂ and variance-
covariance matrix P .
It has four main steps:
1. Initialization:
β0 ∼ N(β̂0|0, P0|0)




3. Filter correction (for ti = 1, . . . , T ):
β̂ti|ti = β̂ti|ti−1 + kt−1et−1
Pti|ti = Pti|ti−1 − qti|ti−1kt−1k
′
t−1.
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4. Filter smoothing (for ti = T, T − 1, . . . , 1):
β̂ti−1|T = β̂ti−1|ti−1 +Bt(β̂ti|T − β̂ti|ti−1)








The Kalman gain is used during filter correction. It controls both the degree to which state
estimates are effected by the one-step ahead errors and also the amount of decrease in the state
variances. There are four stages in a filtering algorithm. The first is initial of the algorithm: in a
Bayesian context this involves specifying prior values. The second is to generate one-step ahead
predictions (extrapolations, or forecasts). The process of forecasting the (unobserved) future
creates additional uncertainty so the variance of the states increases. These forecasts are then
corrected in the third step, using data for the new time-period. This correction leads to filtered
estimates, for which the variance decreases due to using more data. The final step generates
smoothed estimates. It is implemented after all of the prediction and correction steps have been
estimated.
The Kalman gain may also be interpreted as proportion of the total variance attributed to the
states. For given values of σ2, the larger the uncertainty in the parameter estimates, the more
they are ‘corrected’ by the error value (eti). For given values of Pti|ti−1, larger (smaller) values
of σ2 implies smaller (larger) precision in the observations (were precision is defined as 1/σ2) so
a smaller (larger) correction occurs. As such, the Kalman gain may be interpreted as controlling
the relative trade-off between faith with previous model estimates (kti → 0) and faith with the
observed data (kti → 1).
Linear Bayes
This is implemented in a similar way to the Kalman filter but it does not make any distributional
assumptions [128]. As such, it is applicable in non-Gaussian settings. However, to make infer-
ences about either the states (β values) or the model estimates of the outcome, it is necessary
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to assume that these follow a distribution.
1. Initialization. Note that the distribution of the βs is no longer specified.:
β0 ∼ (β̂0|0, P0|0)
2. Prediction is the same as for the Kalman filter.
3. Correction is based on conjugate analysis and differs from the Kalman filter. It is defined
at the patient-level (denoted by the subscript j). For a Poisson model, where the outcome
is the hazard λti for times ti = 1, . . . , T :








1 + qtij(ωti) exp(−zj β̂tij|ti−1)
)









where qtij = zjPtij|ti−1z
′
j , δti is an indicator of if the individual died in the interval (=1,
else = 0). Values are updated across patients with β̂ti,j+1|ti−1 = β̂tij|ti , Pti,j+1|ti−1 = Ptij|ti
4. Smoothing is the same as for the Kalman filter.
As with the Kalman filter, the correction step leads to a decrease in the variance of the states;
this decrease only occurs for patients who experienced an event during the interval. A difference
to the Kalman filter is that with linear Bayes, parameter estimates are updated one patient at a
time (as opposed to one-time-period at a time). Resulting estimates can depend on the order of
updating (if patients with δtij = 1 are updated first or second), which is an undesirable feature
of linear Bayes [156]. It also assumes that Zti is known (in contrast, most of the other estimation
methods allow for unknown Zti .
The linear Bayes approach also shares many similarities with posterior mode estimation, which
is described next.
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Posterior mode estimation
This approach obtains a linear approximation to the response function used in the DSM. This
approximation is based on local linearisation, using a Taylor series expansion [173, 233]. This
approach is also known as a Laplace approximation [234]. The description here is implemented
using the extended Kalman filter, so may be viewed as a filtering method. In general, let
X ′ = g(X) be the transformation of the random variable X by the response function g(·). Denote
the probability density function of X by fX(·) and denote the probability density function of
X ′ by f ′X(·). The two are related by the equation:
f ′X(X
′) = fX [g
−1(X ′)]






∣∣ is known as the ‘Jacobian’ (Chapter 2 of [235]).
As an example, let X ′ = exp(X), hence g(·) = exp(·), g−1(·) = log(·) and ddX′ log(·) = 1/(·).
Summary measures for the transformed variable X ′ (such as the mean and variance) are obtained
from f ′X(X
′). This demonstrates that a Jacobian adjustment may be used to calculate outcomes
of interest when non-linear transformations (in this context, response functions) are used. One
of their uses is in posterior mode estimation
In general, posterior mode estimation may be thought of as approximating the (non-linear) DSM
by a dynamic linear model, for which the Kalman filter may be applied. The approximation is
based around the posterior mode of the DSM. The algorithm for posterior mode estimation is
as follows:
1. Initialization:
β0 ∼ N(β̂0|0, P0|0)
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3. Filter correction (for ti = 1, . . . , T ):
β̂ti|ti = β̂ti|ti−1 + Pti|tiut















where dtj is the Jacobian of the response function evaluated for individual j at time t
(using any relevant covariates xt), and summation is across at-risk individuals.
Note that when the response function is the logistic function, the Jacobian will evaluate
to λ̂tj|t−1(1− λ̂tj|t−1), so the fraction in both ut and Ut will cancel.
4. Filter smoothing (for ti = T, T − 1, . . . , 1):
β̂t−1|T = β̂ti−1|ti−1 +Bti(β̂ti|T − β̂ti|ti−1)





The initialisation, prediction and smoothing steps are the same as for the Kalman filter (so
the prediction and smoothing steps of posterior mode estimation are also the same as those for
linear Bayes).
The filter correction step differs from that used in the Kalman filter but it has the same inter-
pretation, with Pti|ti the equivalent of the kalman gain kti and the error being quantified by uti
(which incorporates an adjustment for non-linearity).
The main differences between the three approaches (Kalman filter, linear Bayes and posterior
mode estimation) are the implementation of the filter correction step. For the Kalman gain the
correction step adjusts the filtered state estimate by the product of the kalman gain kti and
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the one-step ahead forecast error. The Kalman gain varies between zero (when the variance
of the states is zero) and one (as the variance of the states → ∞) and may be thought of as
measuring the degree of faith that is placed in the previous state estimate (kti = 0 implies perfect
faith with the state estimates, kti = 1 implies no faith). Both the linear Bayes and posterior
mode estimation approaches share this interpretation albeit with different implementation due
to the non-linearity of the DSM. A key difference between the linear Bayes and posterior mode
estimation is (when the same response function and distribution for the outcomes are used) how
residuals are defined. For posterior mode estimation residuals are based on the difference between
observed and modelled estimates of the hazard λtij − λ̂tij|ti−1 . For linear Bayes the residuals are
based on the approximate difference between prior and posterior estimates of zj β̂tij|ti−1 .
A final difference of note is that with posterior mode estimation (implemented with the extended
Kalman filter), the filter-correction for the β̂ti uses the filtered value of the variance Pti|ti . In
contrast, both the Kalman filter and linear Bayes approaches use the predicted value Pti|ti−1
1.3 Model specification for dynamic survival models
To improve clarity, the descriptions in this section omit the subscript i from time; that is t, t−1
here correspond to ti, ti−1.
1.3.1 Local level model with a random walk
Model specification for the linear predictor is:
g(yt) = ηt = βt
βt = βt−1 + ζt
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with ζt ∼ Normal(0, Zt). It is often assumed that Zt = Z ∀ t.
Extrapolations: The extrapolated value h time steps into the future, given observed data up
to time T is η̂T+h|T = βT .
Variance: The variance at time t is
∑t
i=1 Zi (or t× Z if the ζt are constant).
Limitations: As t→∞ then the variance of the βt →∞, which is unlikely to be realistic. The
assumption of a constant extrapolated hazard is also unlikely to be realistic.
1.3.2 Local trend model with a random walk
These may be defined as:
ηt = β1t
β1t = β1,t−1 + β2,t−1 + ζ1,t
β2t = β2,t−1 + ζ2,t
Hence:
β1t = β1,t−1 + β2,t−1 + ζ1,t
= β1,t−2 + 2β2,t−2 + ζ1,t + ζ1,t−1 + ζ2,t−1
= β1,t−3 + 3β2,t−3 + ζ1,t + ζ1,t−1 + ζ1,t−2 + ζ2,t−1 + 2ζ2,t−2
= . . .







where the first two terms are a linear function and the last two terms are random error.






If we assume that the Zt are constant over time we get t× Z1 + (
∑
j = 1t−1)2 × Z2.
Limitations: As with the local-level random walk model, the variance of the local-trend random
walk model will→∞ as t→∞ (this holds even if we were to remove the local-level component).
In addition, there is empircal evidence (albeit not from the field of survival analysis), that
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assuming a persistent trend during the extrapolated period generally leads to worse forecasts
than if that trend is ‘dampened’ (reduced) over-time [236, 237]. However, a response function is
applied to the extrapolations, which will have a similar effect to dampening (current empirical
evidence is for when there is no transformation of the trends), so it is unclear if this empirical
evidence generalises to both the field of survival analysis and situations where the trend is
transformed via a response function.
A final limtation is the potential lack of identifiability due to the flexibility of this model. In
particular, a local-level can visually look like a local-trend, so it may not be possible to accurately
estimate both.
1.3.3 Local trend model with an autoregressive process
A model which allows seperate AR processes for the level and trend is given by:
E(yt) = β1t
β1t = φ1β1,t−1 + φ2β2,t−1 + ζ1,t






2β2,t−2 + φ2φ1β2,t−2 + ζ1,t + φ1ζ1,t−1 + φ2ζ2,t−1







+ ζ1,t + φ1ζ1,t−1 + φ
2
1ζ1,t−2 + φ2ζ2,t−1 + φ
2
2ζ2,t−2 + φ2φ1ζ2,t−2
















+ φ2ζ2,t−1 + φ
2
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A special case is if only the trend has an AR process with Zt constant. The model simplifies to:



















Below equations for extrapolations and variance relate to this special model.





The last term is a geometric progression, so as t→∞ its sum shall become φ2β2,T /(1−φ). For
a large enough time-horizon, extrapolations shall converge to a constant value (that is, the trend




















. Again appealing to the properties of a geometric progression,










which has a finite sum as t → ∞ if |φ| ≤ 1. There are a finite sum of these in the second term
of the variance calculation so the variance remains finite.
Limitations: This model has potential issues of identifiability (see discussion for local-trend
model with a random walk).
1.4 Estimating the Monte Carlo standard error when the esti-
mand varies with observations
As motivation, consider a simulation study where the generated data are survival data. For this
each simulated dataset is T observations of hazard values over time (λ1, . . . , λT ). The aim of the
study is to compare how well different models estimate the true hazard values θi, i ∈ {1, . . . , T}.
Hence the true value of the estimand is the same for all simulated datasets, but it varies with
time (observations) within a simulated dataset.
Let θ̂i be the model estimate of θi. Then mean-squared error (MSE) and its variance may be
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estimated as:















√√√√∑nsimj=1 [(θ̂i,j − θi)− µi]2
nsim(nsim − 1)
Note that the subscripts i, j denote time-points and simulated datasets, respectively (the esti-
mate is also weighted by sample size as this varies over time, but this detail is omitted for clarity
here).








Calculating E[f(x)] is straightforward, calculating Var[f(x)] is not. In some instances the delta
method may be employed to estimate Var[f(x)] using Taylor-series expansions [238]. This
approach is used by White to calculate Var[f(x)] for some performance measures [239], but it
is unclear if this approach may be used for MSE.
A simulation-based approach has been suggested as an alternative to the delta method, and
has been shown to provide similar results without the need to calculate derivatives [240]. One
approach to simulating Var[f(x)] would be to sample µ̃i ∼ N(µi, σ2i ), use this to get a distribtion
for f(x) and derive the variance from this (assuming that the µi, and hence µ̃i are independent).
This approach is used for the bias as this is an unbounded performance measure. For MSE,
which is constrained to be positive, an alternative distribution needs to be used instead of the
Normal. An advantage of using the gamma distribution is that the mean and variance (on
the scale of the data) may be used to specify the parameters: gamma(shape = µ2i /σ
2
i , scale =
σ2i /µi). Hence the gamma is used for the MSE in this thesis.
Appendix 2
Further results appendix
2.1 Methodological mapping review search details
2.1.1 Bibliographic databases
Of the database reviews, the first review was designed to identify examples when methods have
been used to extrapolate survival data. The search was performed in two databases; PubMed
and Web of Science (WoS). For PubMed, the following search terms were used:
1. survival analyses[MeSH Terms]
2. actuarial analysis[MeSH Terms]
3. 1 or 2
4. extrapolat*[Title/Abstract]
5. forecast*[Title/Abstract]
6. 4 or 5
7. 3 and 6
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2. time-to-event[TOPIC]
3. failure time[TOPIC]
4. 1 or 2 or 3
5. extrapolat*[Title/Abstract]
6. forecast*[Title/Abstract]
7. 5 or 6
8. 4 and 7
During the initial searches, an alternative search term of “expectation of life” was identified [71],
so a further search for this key-word was performed in PubMed.
The second review was designed to identify review articles on the analysis of survival data.
Based on the results of the first review, it was decided to focus on just PubMed, as the use
of WoS provided little additional benefit. The second review had two components. The first
component included any review papers. A broad statistical search term was used to keep the
number of identified studies manageable. The following search terms were used:
1. survival analyses[MeSH Major Topic]
2. review[Title/Abstract]
3. review[Publication Type])
4. 2 or 3
5. 1 and 4
The second component searched for reviews specifically in the context of HTA, as it was believed
that these would be of the most relevance to this work. As it was more focused, it used more
detailed search terms. Note that due to the use of more statistical search terms, this search
would not be a subset of the previously described search.
1. analysis, cost benefit[MeSH Terms]
2. models, economic[MeSH Terms]
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3. decision support techniques[MeSH Terms]
4. “health services research/methods” [MeSH Terms]
5. “Technology Assessment, Biomedical/methods”[MeSH Terms]
6. 1 or 2 or 3 or 4 or 5
7. Survival Analysis[MeSH Terms]
8. longitudinal studies[MeSH Terms]
9. models, proportional hazards[MeSH Terms]
10. forecasting[MeSH Terms]
11. 7 or 8 or 9 or 10
12. Review[Title/Abstract]
13. Review[Publication Type]
14. 12 or 13
15. 6 and 11 and 14.
Hand searching key journals
Hand-searching was performed for two key journals. The first was the JRSS B. This journal is
restricted to papers that describe methodological developments in statistics, making it suitable
for hand-searching. To keep the searching to an achievable level, searching went back to the
start of 2010 inclusive. The second journal was Statistics in Medicine. Searching was restricted
to “tutorials in biostatistics”. These are designed to provide an overview of key issues in the
statistical design and analysis of data. As there was a relatively small number of tutorials,
searching went back to the start of 2000 inclusive.
In addition, a Medical Decision Making special issue on “Methods for Extrapolating Survival in
Cost-Effectiveness Analyses” was published in May 2017 [241]; the articles from this issue were
also included in the review.
Grey literature
Two types of grey literature were considered. These were academic textbooks, and methods
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available within computer software. The search of textbooks was restricted to those available
from the University of Sheffield. A list of textbooks was obtained using ‘StarPlus’; the Univer-
sity’s online library catalogue. Textbooks were identified by searching for the keyword “survival
analysis”, with a pragmatic restriction to textbooks published within the last 10 years. If mul-
tiple editions of a book were available, the most recent edition was used to define the date of
publication. Two different software packages were reviewed: STATA [242] and R [243]. These
were chosen due to familiarity with the packages. In addition to the methods available in the
base package, the methods available via user-contributed packages were also considered. For
STATA this involved a search for “survival analysis, net” using the inbuilt search dialogue box.
For R the CRAN task-view was used. Task views provide a list of the different statistical meth-
ods available for a given subject, and their associated packages. The survival analysis task view
is available at https://cran.r-project.org/web/views/Survival.html.
Citation searching
This used the results from the search of HTA review articles as pearls. Articles citing these
pearls were identified via WoS. There was no restriction on the number of citations considered.
2.2 Literature review: incorporating external data
This section describes methods for incorporating external data within extrapolations, as iden-
tified via the literature searches of Chapter 2. Relative survival models and cure models are
discussed in Chapter 3, so are not replicated here. Two of the studies described here assumed
that after a certain point, the hazard may be modelled as a function of age (instead of as a
function of time since diagnosis) [23, 76]. Whilst this approach does not require external data,
long-term external evidence on how the hazard varies with age may be used, so this approach is
included here. The same terminology as Chapter 3 is used, where λPti and λ
E
ti denote the general
population hazard and the disease-specific (excess) hazard respectively (both at time ti), with





APPENDIX 2. FURTHER RESULTS APPENDIX 235
2.2.1 Methods used in technology appraisals
The earliest identified description of incorporating external data is that by Hwang and Wang
[70]. This method was originally developed for the extrapolation of quality-adjusted (weighted)
survivor functions but a later publication demonstrates that this method may also be applied
to survival functions [65]. This method has the following steps:
1. Creating (or obtaining) the external data. This external population should have long-term
data on survival (so that no extrapolation is necessary). The external population should
also be as similar to the internal population as possible.
2. Using the length of follow-up of the observed data, calculate the survival ratio: observed survivalexternal survival .
3. Fit a linear regression model to the logit-transformation of this survival ratio, with time
as the only covariate.
4. For the extrapolated period, estimates of survival are obtained by multiplying the external
survivor function by the inverse logit of the model estimate of the survival ratio.
The authors suggested that for step three the analysis could exclude data from early time-
points if the survival ratio is not stable for these, although the choice of what data to exclude
is essentially arbitrary. Bootstrapping may be used to provide an estimate of uncertainty, but
it would not incorporate uncertainty in the choice of what data to exclude. The authors justify
the use of a logit transformation as it is assumed that the survival ratio will never exceed 1
(in other words, the observed survival shall never be greater than the corresponding external
survival). To relax this assumption, the logarithm of the survival ratio could be used instead.
Messori and Trippoli implicitly suggest using an implicit cure model [75], recommending that
extrapolation be achieved by assuming that ‘long-term survivors‘ have the same life expectancy
as the general population. That is, over time the hazard function for the population of interest
will converge to that of the general population. Identifying the time at which cure can be as-
sumed may not be straightforward. The practical guide to extrapolating survival data in HTA
presented by Latimer [20] stressed the importance of considering external data when assessing
clinical plausibility. Four examples of incorporating external data within NICE appraisals were
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presented, with a recommendation that further research into this area was required. The ex-
amples applied mortality rates from external life tables for the extrapolated period, and so can
be viewed as equivalent to an implicit cure model. Similarly, Meacock and colleagues note that
policy evaluations typically use published data on life expectancy, and so assume that long-term
survival is the same as for the general population [82].
Other methods for incorporating external data for extrapolation in a HTA context are reviewed
by Jackson and colleagues [79]. In addition to the above-described methods, other approaches
include assuming a systematic relationship between the observed and external hazards, such as
proportional hazards, additive hazards, or proportional cause-specific hazards.
2.2.2 Bayesian methods
Demiris and Sharples describe how Bayesian methods may be used to incorporate external data,
which acts as prior data [68]. This is then combined with the observed data, and the resulting
posterior distributions are used to generate extrapolations. A case-study compared the use of a
proportional hazards Weibull model with a variety of semi-parametric models: both proportional
and additive hazards were considered, along with different weights for the prior data. For the
parametric Weibull model, the external data influenced the scale parameter. For the semi-
parametric models, a gamma process was used to model the baseline hazard; the parameters
for this were estimated based on the external data. Model-fitting was performed in WinBugs
[180]. The authors noted that more flexible parametric models could have been employed. For
the semi-parametric models the extended gamma process and the Beta-Stacey process were
mentioned as potential alternatives for the baseline hazard. Finally, the authors noted that for
certain model specifications (such as the additive semi-parametric model), the methods struggled
to adequately fit both the external and observed datasets, “Hence for long term prediction, it
appears that the modeler should be particularly careful in the implementation of these methods”
[68]. Consequences of not having enough data were noted to be poorer predictive ability and
sensitivity to the choice of prior (even when uninformative priors are used).
The methods of Demiris and Sharples were extended by Benaglia, Jackson and Sharples to model
cause-specific hazards [64]. The authors consider two separate causes: deaths due to the disease
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of interest, and deaths from all other diseases. It was assumed that the hazard for the disease
of interest is proportional between the observed and external populations, whilst the hazard for
other diseases was the same in the two populations. The hazard function was modelled using a
poly-Weibull model, which is a special case of the polyhazard model, as described by Demiris,
Lunn and Sharples [67].
Guyot and colleagues used a Bayesian framework to incorporate three different types of external
evidence: (1) general population survival, (2) registry data on one-year conditional survival,
and (3) clinical input into the likely long-term treatment effect. These three types of external
evidence were incorporated by defining their impact on the likelihood function and hence includ-
ing them in parameter estimation [22]. The authors noted that incorporating external evidence
led to an increased reliability and plausibility of extrapolations but could also lead to numeri-
cal problems during parameter estimation. This method was evaluated in a subsequent paper,
which identified both difficulties with convergence and sensitivity of the method to treatment
effects, as it only produced plausible extrapolations when the hazard ratio was less than 1 plus
minus 0.3 [244].
2.2.3 Approaches used in demography
Day, Reynolds and Kush describe methods for estimating the life expectancy of individuals
with cerebral palsy via extrapolation [66]. They recommend the use of the ‘proportional life
expectancy’ method. This is not described in detail, but a reference is provided to Strauss,
Vachon and Shavelle [245]. These authors describe five methods for extrapolation, all of which
are modelled on the hazard scale, and described here. For the following, the value C is used for
the relative effect, the definition of which depends on the approach used.
Constant excess death rate: This method assumes that λti−λPti = C, where C is a constant.
Hence the excess hazard is λEti is assumed to be constant for both the duration of the
observed data and for the extrapolations.
Constant relative risk: Whereas the previous method assumed a constant additive effect,
this method assumes a constant relative effect: C = λti/λPti
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‘Rating Up’: This method assumes that the hazard observed for the observed population at a
given age (x), is equal to the hazard observed for the external population at a higher age
(x+ C). Hence λti=x = λPti=x+C .
This method has been suggested in the context of HTA by Bagust and Beale [19]. In this
situation the hazard was a function of time since diagnosis (instead of a function of age),
and the observed and external data were replaced by the control and intervention study
arms.
Proportional life expectancy: This applies the relative survival methodology to life expectan-
cies. Let C = eti/ePti , where C is assumed to be a constant at all times, eti is the life ex-
pectancy for an individual aged ti in the observed population, and e
P
ti is the corresponding
measure for the external population. The authors note that assuming proportional life
expectancy is the same as assuming that the excess death rate for a given age is inversely
proportional to the remaining life expectancy at that age, hence the excess death rate
increases with increasing age.
Log-linear declining relative risk: This method is motivated by the observation that age-
specific mortality often follows the Gompertz Law: λti = exp(γ + kti), where γ and k
are constants. Under the assumption that the hazard function for both the observed and
external populations follows this law (with separate constants for each), then the following
equation is derived: log(λti/λ
P
ti ) = β(α − ti), where β and α are constants. The value of
α is referred to as the parity age as it is the age at which the hazards of the observed and
external populations become the same. The name of this method reflects the linear model
for the logarithm of the relative risks. It may be viewed as relaxing the assumption of a
constant relative risk to allow it to vary with time.
The authors note that these methods are designed for chronic, non-progressive conditions. This
appears to be mainly because the relative effects (the C) are assumed to be constant at all times.
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2.2.4 Modelling on both the age and timescales
Information on how the hazard of mortality varies with age may be used to complement extrap-
olations. There were two main approaches to this: modelling extrapolations as a function of age
only, or as a function of both age and time. These two approaches are discussed in turn.
Nelson and colleagues [76] describe a method which assumes that after a certain time ti the
hazard function is stable with respect to time, and so the only variation is due to ageing.
Provided that the available data cover a sufficient range of ages, this method removes the need
for extrapolation: the survival experience for an individual during the unobserved follow-up
period is described by their ageing. The effect of ageing on the hazard is estimated directly from
the sub-set of individuals who survived up-to time ti (hence their data will be left-truncated
at time ti). The key assumption of the method described by Nelson and colleagues is that
after a certain time-point any further changes in the hazard are solely due to ageing [76]. The
same assumption was applied by Jackson and colleagues, who took the time ti to be equal
to five years, based on a plot of the hazard function over time [23]. In addition, Nelson and
colleagues also suggest that the value for ti could be based on clinical opinion, or it could be set
equal to the maximum follow-up time. They further note that there may be insufficient data
to estimate the hazard as a function of age at upper ages, and so suggest fitting a Gompertz
model, whose parameters may be informed by observing the mortality at equivalent ages in the
general population. These two studies were both in a HTA context [23, 76].
Extrapolations that used age and time employed a Lee-Carter model [72, 73]. This model takes
the form:
logµx,ti = αx + βxκti + εx,ti (2.1)
where µx,ti is the hazard for an individual aged x at time ti. The εx,ti independent and identically
distributed random variables following a Normal(0, σ2) distribution. The remaining three terms
are parameters to be estimated: αx and βx are age-related parameters and assumed to be fixed
over time. The parameter κti is assumed to vary with time and is modelled as a time series.
In theory any timeseries model may be used to estimate the κti , but in practice a random walk
model with drift is typically used [73].
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The Lee-Carter model is notable for not including any observable quantities in the right-hand
side. It is also not identifiable from the data. To make the model identifiable, constraints are
typically applied to the two terms κti and βx: that the latter sums to unity and the former
to zero. Under this constraint, the αx may be interpreted as the age-specific average of the
observed hazard (over time). The κti correspond to a latent process of the trend in the hazard
over time and βx represents the effect of age on this latent process. The method described by
Nelson and colleagues [76] may be thought of as an application of the Lee-Carter model, with
the product βxκti set to zero.
Haberman and Renshaw also describe alternative specifications for the above model [72]. These
include using a negative-Binomial distribution instead of a Poisson distribution, or using the
probability of death as the outcome and modelling using a Binomial distribution. Majer and
colleagues demonstrated that the Lee-Carter model may be applied within a multistate model
with the health-states of ‘nondisabled’, ‘disabled’ and ‘dead’ [73]. There were three possible
transitions: from nondisabled to disabled, and from either alive state to dead. The resulting
estimates were used to derive a measure of health expectancy. There were no examples of the
Lee-Carter model being used within a HTA context.
Within HTA, when extrapolating hazards, interest is usually on the change in hazard as a func-
tion of time; either since randomisation or diagnosis. However, for the outcome of mortality, it
is known that the hazard varies with age. This information may be used to enhance extrapola-
tions; a formal statistical model for this (the Lee-Carter model) is used within the demography
literature. This model uses time series methods to extrapolate the hazard as a function of time,
whilst also including an interaction with the effect of age and a main effect of age. There were
no examples of using this model within HTA, but a simpler assumption that the hazard may be
modelled as a function of age alone has been used.
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2.3 Prior distributions for the innovation variance: case-studies
2.3.1 Methods
This used the two case-studies introduced elsewhere in the thesis, which were the trials of
‘nivolumab vs docetaxel for previously treated squamous non-small-cell lung cancer’ and ‘abi-
raterone acetate for metastatic castration-resistant prostate cancer’ [198, 214]. For this analysis
the control arms are used. Three models of increasing complexity were considered: a local level
model, a local trend model with a global level, and a local trend model with a local level. The
available data are patient survival times, these were converted to time intervals based on unique
observed death times.
Specification of initial values was not required for the local level model. For the two local trend
models (with global or local level), initial values were specified for the innovation variance alone
(Nivolumab case-study) or the innovation variance and the level and trend (Abiraterone case-
study). Initial values were sampled from the following distributions: U(0, 0.2) for Z, U(-10,
0) for β1,t and N(0, 0.1) for β2,t. The use of multiple starting values increases confidence that
when the model-fitting algorithm converges, it does so to the global maximum of the likelihood
function. Without specifying these initial values, models did not converge for some prior distri-
butions. As the true value of the innovation variance was not known, performance was assessed
based on three criteria: if the models converged, the effective sample size (based on the number
of iterations, scaled to adjust for correlations. Larger values are better), and visual goodness of
fit to the observed data.
Results
All priors converged for the local level model (R̂ ≤ 1.01), with the exception of the Uniform(−∞,∞)
for log(standard deviation) prior for the Nivolumab case-study and the Gamma(0.02, 0.1) prior
for the Abiraterone case-study. For the local trend global level model a lack of convergence was
noted for the Uniform(−∞,∞) for log(standard deviation) prior for both case-studies and for
prior IDs (8, 10) for the Abiraterone case-study. All models converged for the local trend local
level model with the exception of the Gamma(0.01, 0.01) prior for the Abiraterone case-study.
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Trace plots were in visual agreement with the R̂ statistic for assessing convergence.
Table 2.1 compares the effective sample size from each prior distribution (averaged over the three
models considered) for both case studies. To aid comparison, these are scaled to be relative to
the largest sample size, and results from the simulation study are also included. Due to its
consistently poor performance, the Uniform(−∞,∞) for log(standard deviation) prior (ID 2) is
excluded. Visual comparisons of the model-based mean hazard estimates with 95% posterior
intervals, and the observed hazards are provided for the local trend local level model (visual
results were very similar for all three models) in Figure 2.1.
Table 2.1: Effective sample size relative to the largest value for each model (R̂) for the prior
distributions.
ID Uninformative priors Nivolumab Abiraterone Simulation study
1 Uniform(0,∞) std. dev. 37% 37% 62%
3 Uniform(0,∞) 46% 50% 69%
4 Inv.Gamma(0.01, 0.01) 30% 55% 88%
5 Inv.Gamma(1, 0.005) 60% 46% 100%
6 Half-Cauchy(0, 0.3) 50% 59% 82%
ID Weakly-informative priors
7 Half-normal(0, 0.3) 100% 81% 67%
8 Half-normal(0, 5) 46% 53% 74%
9 Gamma(0.01, 0.01) 26% 36% 79%
10 Gamma(0.02, 0.1) 24% 12% 73%
11 Gamma(2, 1) 81% 89% 71%
12 Log-normal(0, 1) 79% 84% 71%
For both case-studies the largest effective sample sizes were observed for three weakly informative
priors (IDs 7, 11, 12). However, the last two of these priors were associated with very large bias
and mean squared error values in the simulation studies. In contrast, for the simulation study the
largest effective sample size was observed for two uninformative priors (the two inverse gamma
[IG] priors). The IG(1, 0.005) prior has the largest effective sample size for the simulation
study, fourth largest for the Nivolumab case study and 8th largest for the Abiraterone case-
study. This poor performance for the Abiraterone case-study is partly due a lack of convergence
for one model; excluding this model, the IG(1, 0.005) prior has the 4th largest effective sample
size.
For the Nivolumab case study, for all three models, prior IDs (3, 9 and 10) led to visual estimates
that were too flat. All other priors led to very similar visual results. For Abiraterone, prior IDs
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(9 and 10) led to visual estimates that were too flat, as did prior ID 7 for the local level model.
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2.4 Mixture Weibull simulation study
The following graphs are displayed:
• Visual goodness of fit (comparing model estimates with the truth) are provided in Figures
2.2 and 2.3 for sample sizes of 100 and 600, respectively. This uses the same specification
for the models as for the main analysis.
• Estimates of mean-squared error and bias over time are provied in Figures 2.4 and 2.5 for
sample sizes of 100 and 600, respectively. This uses the same specification for the models
as for the main analysis.
• The impact of using time as a covariate (instead of log-time) on visual goodness of fit is
demonstrated in Figure 2.6 for a sample size of 300 and all three follow-up times (results
for the other two sample sizes were very similar and are not presented). Royston-Parmar
models are not included as by definition they use the logarithm of time. Both dynamic
models have a global level.
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Figure 2.2: Model estimates of the log-hazard (blue lines) and true values (black lines), sample
size = 100.
(a) Dynamic survival models.
(b) Current and emerging practice (excluding Gompertz).
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Figure 2.3: Model estimates of the log-hazard (blue lines) and true values (black lines), sample
size = 600.
(a) Dynamic survival models.
(b) Current and emerging practice (excluding Gompertz).
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Figure 2.4: Mean squared error and bias values over time (within-sample and extrapolations),
sample size = 100.
(a) Mean squared error (MSE).



























Black reference line is for current practice model
(b) Bias.





























Black reference line is for current practice model
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Figure 2.5: Mean squared error and bias values over time (within-sample and extrapolations),
sample size = 600.
(a) Mean squared error (MSE).



























Black reference line is for current practice model
(b) Bias.





























































Figure 2.6: Model estimates of the log-hazard (blue lines) and true values (black lines) for models using time as a covariate, sample size
= 300.
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2.5 Cure fraction simulation study
The following graphs are displayed:
• Visual goodness of fit (comparing model estimates with the truth) are provided in Figures
2.7 and 2.8 for sample sizes of 100 and 600, respectively. This uses the same specification
for the models as for the main analysis.
• Estimates of mean-squared error and bias over time are provied in Figures 2.9 and 2.10 for
sample sizes of 100 and 600, respectively. This uses the same specification for the models
as for the main analysis.
Figure 2.7: Estimates of the log-hazard compared to the truth: cure models, sample size = 100
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Figure 2.8: Estimates of the log-hazard compared to the truth: cure models, sample size = 100
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Figure 2.9: Mean squared error and bias values over time (within-sample and extrapolations),
sample size = 100.
(a) Mean squared error (MSE).


























Black reference line is for current practice model
(b) Bias.






























Black reference line is for current practice model
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Figure 2.10: Mean squared error and bias values over time (within-sample and extrapolations),
sample size = 600.
(a) Mean squared error (MSE).





























Black reference line is for current practice model
(b) Bias.




























Black reference line is for current practice model
Appendix 3
Generalised linear models for flexible
parametric modelling of the hazard
function
In many medical studies the outcome of interest is the time until an event occurs. Examples
include mortality, disease progression, or hospital admission. To aid with decision-making the
hazard function is estimated from parametric models. A prominent example is health technology
assessment (HTA), which aims to quantify both the benefits to patients and the costs a healthcare
system would occur if a treatment were funded [3]. To allow for fair comparisons across different
treatments it is important that all relevant benefits and costs are quantified, which often requires
use of a lifetime horizon [10]. However, time-to-event (TTE) data with complete follow-up are
rarely available. As such, parametric models may be used to extrapolate model-outcomes to a
lifetime, and hence obtain estimates of mean TTE (such as mean survival) [18, 241].
Standard one and two parameter models are available, including the exponential, Weibull, Gom-
pertz, log-logistic and lognormal [17]. However, these models may not be sufficiently flexible to
capture complex, time-varying hazards [98, 134]. In Section 3.1 we introduce generalised linear
models (GLMs) and show that standard survival models may be expressed as GLMs. This
provides insight into the limitations of the standard models: they all impose an assumption of
255
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linearity. More flexible parametric models that relax this assumption are required. A number of
these have been proposed within the framework of GLMs and its extensions, but to-date they
are seldom used to analyse TTE. These are described in Sections 3.2 and 3.3, with an overview
in Section 3.4. An application of these is described in in Section 3.5, which demonstrates that
the GLM-based models can provide superior within-sample estimates and more plausible ex-
trapolations than standard survival models. Concluding remarks are provided in Section 3.6.
This manuscript has two aims. The first is to propose the use of GLMs for the analysis of TTE
data. This includes flexible GLMs such as fractional polynomials (FPs) and restricted cubic
splines (RCS), which are closely related to Royston-Parmar (R-P) models. The second aim is to
present generalisations to GLMs: generalised linear mixed models (GLMMs) [246], generalised
additive models (GAMs) [135] and dynamic generalised linear models (DGLMs) [174, 128].
3.1 Analysing time-to-event data within a generalised linear
modelling framework
3.1.1 Standard survival models as linear models
The framework of GLMs extends (generalises) the standard linear model to response variables
with distributions in the exponential family, including Normal, Poisson, Binomial, Gamma and
Inverse Gaussian distributions [247]. An advantage of GLMs is that they provide a unified
framework - both theoretical and conceptual - for the analysis of many problems, including
linear, logistic and Poisson regression [146]. A random variable Y belongs to the exponential
family of distributions if its probability density (or mass) function can be written as:
f(yt; θ) = exp[a(y)b(θ) + c(θ) + d(y)] (3.1)
where a(y) and d(y) are functions of the data, whilst b(θ) and c(θ) are functions of the distribu-
tion parameter θ and assumed to be twice differentiable. Equation (3.1) may also include other
parameters, which are treated as nuisance parameters [146]. Examples for the Normal, Poisson
and Binomial distributions are provided in Table 3.1. For these, a(y) = y.
APPENDIX 3. GLM MANUSCRIPT 257
Table 3.1: Normal, Poisson and Binomial distributions as members of the exponential family
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µ and σ2 are a mean and variance, π is a probability, n the






y!(n−y)! is the binomial coefficient.
For a TTE GLM, the observed outcome is the number of deaths during an interval: yt. This
is linked to the at-risk population at time t (denoted by τt) using a distribution from the
exponential family. Use of the Poisson distribution assumes that yt = τt × λt where λt is the
hazard at time t. Alternatively, use of the Binomial distribution assumes that yt = τ1×pt where
pt is the cumulative probability of death. Model specification is [247]:
Observation model: E[yt] = µt × τt, yt ∼ exponential family distribution (3.2a)
Response function: µt = h(x
T
t β) (3.2b)
where E[·] denotes the expected value, bold font denotes a vector, and:
β is a vector of parameter coefficients to be estimated from the data,
xt is a covariate, assumed known (with transpose x
T
t ), and
h() is a one-to-one response function which maps the linear predictor (xTt βt) to µt. Its
inverse is known as the link function, and is denoted as g().
Model parameters may be obtained via maximum likelihood estimation. The general expression
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In summary, a GLM may be specified by three components:
1. The distribution from the exponential family, as defined in equation (3.1),
2. the response (or link) function, and
3. the covariate vector.
For survival analyses, options for µt include the (cumulative) survival function, its complement
the (cumulative) failure function, the hazard function, and the cumulative hazard function -
see [17, 124] for more details. Depending on the specification, we can express standard survival
models as a linear model: µt = β0 + β1xt. Table 3.2 provides these specifications. The log-
logistic and lognormal distributions have a cumulative function as their outcome. It would
not be sensible to model such an outcome as a constant value which demonstrates why there
is no single-parameter special case of these models. In contrast, the Weibull and Gompertz
distributions model a non-cumulative outcome, so it is possible to model this as a single value,
resulting in the exponential model.
Table 3.2: Specification of standard survival models as generalised linear models
µt Distribution Response function Covariate Model
Hazard Poisson Exponential None Exponential
Hazard Poisson Exponential Time Gompertz
Hazard Poisson Exponential Log(time) Weibull
Cumulative Failure Binomial Logistic Log(time) Log-logistic
Cumulative Failure Binomial Inverse probit Log(time) Lognormal
An important aspect of survival data is that there is typically censoring of observations. Cen-
soring occurs because for standard models the outcome is the time of the event occurring, and
for some individuals the event is not observed (so it is censored). Within the GLM formulation,
time changes from being the outcome to a covariate, so there are no censored observations.
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Information on censoring is included by calculating the ‘at-risk’ sample, and including this in-
formation in the model. For models with a binomial distribution there is an explicit parameter
for the sample size. For models with a Poisson distribution, information on the sample size may
be incorporated as an ‘offset’ term.
3.1.2 Limitations with linearity
The assumption of linearity may not always be realistic. For example, for overall survival the
hazard of all-cause mortality will increase over time due to patient ageing. In contrast, frailty
effects may result in disease-specific mortality decreasing over time (as those with an increased
hazard will die sooner, leaving those with a lower hazard). The impact of treatment on survival
may also vary over time: there may be an initial elevated risk of death due to adverse events;
treatment-related toxicities may increase other-cause mortality over time, treatment stopping
rules and trial inclusion criteria may have an effect [19]. These considerations motivate the need
for more flexible survival models, which are considered within the GLM framework in the next
two Sections.
3.2 Relaxing the assumption of linearity
We briefly describe flexible models that may be applied to survival data within a GLM frame-
work, more details are provided in the Appendix. Without loss of generality, y is used to denote
either a random variable or the observed data.
3.2.1 Fractional polynomials
FPs represent the outcome as a sum of polynomial terms; increasing the number of terms (the
order of the FP) increases the flexibility of the model. A closed-test procedure may be used to
identify the order. For a single variable, an ith order FP is defined as:
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where the set of powers pj is pre-specified, and may include fractional powers (hence the name
fractional polynomials). FPs include linear models as special cases, so depending on specification
may include one of the standard models from Table 3.2. Some limitations with FPs are that
they may not have sufficient power to detect non-linearity, and they can be sensitive to extreme
values in the data. This sensitivity occurs because FPs are global models: β values are assumed
to be constant over time.
3.2.2 Restricted cubic splines and Royston-Parmar models
A cubic spline represents a continuous function as a series of piecewise cubic polynomials [124],
hence relaxing the assumption of global time effects. Model flexibility is based on the number of
piecewise intervals (equivalently, the number of ‘knots’). For extrapolation, the cubic polynomial
from the last interval may be used, or it may be restricted to a linear function: this latter
assumption results in an RCS. An example specification is provided in the Appendix.
R-P models use RCSs, but not in the GLM framework. Typically the outcome is the log
cumulative hazard, which is monotonic. However, model estimates are not guaranteed to be
monotonic, so implausible values may result.
As they are not global models, splines may over-fit local ‘noise’ in the data [205], and there is
in general no closed test procedure for choosing between different models.
3.3 Extensions to the generalised linear model
This section provides a brief overview of extensions to GLMs, with more details in the Appendix.
3.3.1 Generalised linear mixed models
A GLMM extends the GLM by incorporating random effect terms, which can help to quantify
the impact of unmeasured covariates and provide more realistic estimates of uncertainty. An
example of an FP(2) with a random-effect (denoted by bt) is:
E(yt) = FP(2) = β0 + bt + β1x
p1 + β2x
p2 , bt ∼ N(0, ψ2)
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GLMMs are also referred to as frailty models [107]. In theory, any GLM may be extended
by adding a random term as shown above. The main limitation with GLMMs is that as the
random effects are not observed, there may be difficulties in model specification and parameter
estimation.
3.3.2 Generalised additive models
A GAM is a GLM in which one or more of the covariates are modelled as a set of basis functions





Where bj(t) is the jth basis function, and q is the dimension of the basis function. Higher values
of q result in more flexible models. Both FPs and RCSs may be viewed as GAMs. The main
extension provided by a GAM is that model complexity is penalised during parameter estimation
(via shrinkage of the β). GAMs with a cubic spline basis have theoretical justification as being
approximate ‘smoothest interpolators’ [135] - see the Appendix for more details. Limitations of
GAMs will depend on the basis function used. For example, if a spline is used, the limitations
of these will still apply.
3.3.3 Dynamic generalised linear models and dynamic survival models
In a DGLM model coefficients (β) are allowed to vary over time. When applied to TTE data,
DGLMs are known as dynamic survival models (DSMs) [144]. Specification is (compare with
Equation 3.2a):
Observation model: E[yt] = µt × τt yt ∼ exponential family distribution (3.5a)
Response function: µt = h(x
T
t βt) (3.5b)
Transition model: βt = Fβt−1 + ζt (3.5c)
Initial conditions: β0 ∼MVN(b0,Z0) (3.5d)
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where MVN denotes a multivariate Normal distribution, F is a function describing how the
coefficients evolve over time, and ζt is an error term - see the Appendix for further details.
DGLMs may be viewed as combining GLMs with time-series methods. In particular, parameter
estimates may be based on minimising the error of within-sample extrapolations. This makes
these models particularly appealing when the primary objective of the analysis is extrapolation.
The main limitations with DGLMs are identifying suitable initial values, and convergence of
algorithms to estimate model coefficients [143, 144].
3.4 Theoretical comparison of approaches
Five different modelling approaches were considered: FPs, splines, GAMs, GLMMs, and DGLMs.
The frailty terms from a GLMM may be combined with either of the other four models. The
following prompts are provided to aid with choosing between the different approaches.
What is the primary objective of the analysis? If the main objective is in generating ex-
trapolations, this implies the use of a DGLM, as this is the only one of the models for
which parameter estimation is based on minimising forecasting error. If instead the main
objective is to provide estimates of the observed data, then any of the approaches may be
used.
Fractional polynomials or spline-based models? Spline-based models may be preferred
on theoretical grounds, as being approximate smoothest interpolators, whilst there are
a number of limitations with the use of FPs (see the Appendix). This suggests the use of
a spline-based model in preference to an FP within a GLM framework, with the latter as
a form of sensitivity analysis.
To penalize during or after estimation? Parameter estimation with a GAM automatically
penalises for model complexity, which helps to avoid over-fitting. Alternatively, informa-
tion criteria may be used. There are a number of different information criteria that could
be used, whereas GAMs have a specific objective function. The choice between these is
likely to be study specific: sometimes there may be good reasons to use a specific informa-
tion criteria, whilst in others the more automated approach of a GAM may be preferred.
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For both approaches it is not possible to use significance tests to choose between model
specifications.
Are there any subject matter considerations? For example, there may be reason to be-
lieve that there are important unmeasured confounders, which suggests incorporating ran-
dom effects. Or it may be thought that there will be important local fluctuations in this
hazard, which suggests the use of either a spline or dynamic model in preference to the
global FPs.
3.5 Empirical comparison of approaches
3.5.1 Dataset
We use a freely available dataset to demonstrate both the limitations of assuming linearity and
the use of more flexible models. Analyses were performed in R; the code used is available as
supplemental material. Hence the case-study is fully reproducible.
The data are on the survival of individuals following a diagnosis of breast cancer, and from a
study conducted by the German Breast Cancer Study Group [136, 100]. Individuals with pri-
mary node positive breast cancer were recruited between July 1984 and December 1989. Events
are defined as either cancer recurrence or death (from any cause). Data are available for 686
individuals, of which 299 experienced an event during follow-up. The maximum follow-up was
7.28 years, with mean follow-up of 3.08 years. Use of GLMs requires that individual-level data
are restructured in the form of life tables. Samples of the individual-level data and the corre-
sponding (monthly) life table are provided in Tables 3.3 and 3.4, respectively. For Table 3.3, an
event indicator of one denotes that an event occurred (otherwise the indicator is zero, and the
outcome is time to censoring).
As described in Section 3.1.2, the assumptions of linearity imposed by standard two-parameter
survival models may be unrealistic. To highlight this, we show model estimates against the
observed data in Figure 3.1 for each model (the one-parameter exponential model is not shown
as it would only be appropriate if both the Weibull and Gompertz estimates had no slope). The
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Table 3.3: A sample of the breast cancer data



















Table 3.4: Data from Table 3.3 restructured for Poisson regression
Month Sample size Events (µ) Censorings At risk (τ) Hazard (λ)
(0, 1) 686 0 7 682.5 0
(1, 2) 679 0 3 677.5 0







(22, 23) 477 5 3 475.5 0.011
(23, 24) 469 7 4 467 0.015







(87, 88) 1 0 1 0.5 0
specification of the x and y axis is such that the model estimates form a straight-line. Figure
3.1 shows that the linear estimates generally provide a poor visual description of the data, with
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3.5.2 Methods
We considered five broad classes of model:
FP models. We considered FP(2) models, with the complexity of the chosen model based on
the closed-test procedure, and the chosen powers based on minimising AIC.
Generalised linear mixed models. We fit FP models as described above, but we also in-
cluded frailty terms.
Spline-based models. Both RCS models and GAMs were considered. For the RCS model
between 1 and 5 internal knots were considered, with the choice based on minimising
AIC. For the GAM we considered two approaches to selecting the dimension of the basis
function: one used a fixed (arbitrary) value of 11 (v1), the other was based on minimising
AIC (v2). These two approaches were considered as some penalisation for over-fitting is
included during model-fitting, so it is unclear if model choice based on AIC is required. For
all models, the knots were placed at equally-spaced percentiles of the observed uncensored
death times [136].
Dynamic models. We examined three specifications: local-level, local-trend, and local-level
with global trend. There was no need to base model choice on minimising AIC (as the
data used to estimate the model parameters are separate to the objective function, which
is based on minimising one-step ahead forecasts).
Standard survival models. Eight survival models were considered: exponential, Weibull,
Gompertz, gamma, log-logistic, lognormal, generalised gamma, and generalised F. Results
are displayed for the three best fitting models (based on AIC). Note that the generalised
gamma and generalised F models have three and four parameters respectively, so are more
flexible than the standard survival models of Table 3.2.
The above choice of models was designed to be representative of the variety of different ap-
proaches possible, but not exhaustive. All of the models used the natural logarithm of time as
the only covariate of interest (with the exception of the Gompertz, which uses time). All of the
GLM-models assumed a Poisson distribution with an exponential response function.
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3.5.3 Goodness of fit
Goodness of fit (GoF) measures how well the statistical model describes the observed data.
It should be distinguished from predictive ability, which measures how well the model predicts
external data (such as future observations). One measure of GoF is Akaike’s information criterion
(AIC), which is defined as:
−2 logL+ 2k (3.6)
where L is the model likelihood and k is the number of parameters in the model [201]. Because
the likelihood is multiplied by a negative number, lower AIC values are to be preferred.
A number of variants on AIC have been proposed [201, 42]. An empirical study by Hyndman
and colleagues [42] compared five GoF measures, and noted that they all performed similarly.
Further, Burnham and Anderson note that the AIC has strong theoretical motivation [201],
whilst Jackson and colleagues note that the AIC is preferable when models are used to represent
complex phenomena (such as survival processes) [249]. Due to having both empirical and theo-
retical support, the AIC shall be used in this manuscript. Any GoF measure should be used in
combination with subject-matter considerations. In addition, estimates of the hazard function
were visually compared to the observed hazard function.
The AIC measures GoF to the observed data. It is unknown if models with a good within-sample
fit provide good extrapolations [124]. To measure the extrapolation performance of the models
we split the dataset into two parts. The first part considered events occurring within the first
three years, censoring all events after three years (half of the sample were at-risk of an event at
three years). Extrapolation performance was defined as the sum of squared errors (SSE) between
the model-estimate of the hazard and the observed hazard (calculated for monthly intervals) for
the remaining follow-up: (
λ̂t − λt
)2
, t ∈ {37 to 88 months} (3.7)
3.5.4 Results
Table 3.5 provides GoF values for each model and estimates of lifetime mean life expectancy.
Two AIC values are provided: one using the entire dataset, the other using the first three years.
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The number of parameters is provided as a measure of model complexity: the two GAMs do not
have an integer number of parameters, as parameter effects are shrunk during model estimation.
Plots of the estimated hazard function for each model are displayed in Figure 3.2 for the observed
data. Corresponding extrapolations are given in Figure 3.3. As the best-fitting two-parameter
standard survival model (based on all the available data), the lognormal is provided as a black
reference line on all panes.
Within-sample goodness of fit
All of the more flexible models provide lower AIC values than the lognormal, although in general
differences between values are small, and cannot be tested for statistical significance. Visually,
all of the models provide a good fit to the observed data in Figure 3.2, although there is variation
in the degree to which local fluctuations are captured.
Of the 11 models, the lowest AIC values arose from two DSMs. However, the third DSM had the
highest AIC of all the flexible models. This suggests that the extension to dynamic models can
lead to an improved GoF, but there is no guarantee that this will always occur. The next best
AIC values arose from the three spline-based models, which all had very similar GoF. However,
the two approaches to GAM estimation did result in markedly different models: the one with
automated fitting was more complex (with almost three times as many parameters) than the one
based on minimising AIC, whilst also providing a better absolute fit (based on log-likelihood).
Of the three standard survival models, the two generalised models (gamma and F) both provided
similar GoF, and both improved on the two-parameter models. Fit for the two FPs was similar
to that for the generalised gamma and generalised F survival models, and lower than that for
the spline-models. The inclusion of random effects had a negligible impact on the AIC.
Flexible parametric modelling of the hazard provides insight into how it varies over time. The
GAM (v1) and DSMs were slightly better at capturing local fluctuations in the hazard rate.
This is most notable at approximately 1 and 1.5 years. However, as the most flexible models
considered, there is a danger that these local fluctuations represent noise. If this is the case
then the best-fitting models may be over-fitting the data, with no guarantee that this will lead
to improved extrapolations.
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Extrapolation goodness of fit
When fitting the 11 models to the first three years, the ranking of the models was generally
the same as for the full dataset, with the local level model providing the lowest AIC, and
the lognormal one of the highest. An exception is the DSM with drift, which changes from
having the second lowest AIC to the second highest. GoF to the observed data did not predict
extrapolation performance. For example, the lognormal and local trend models both had the
highest AIC values but the lowest SSEs. As with the AIC values, in general there was little
difference between SSE values. An exception is the DSM with a drift, which provided poor
extrapolations as it predicted an increasing trend.
In general the results in Table 3.5 demonstrate that there is little difference between the com-
peting models, both for within-sample and extrapolated GoF. However, Figure 3.3 shows that
resulting extrapolations (beyond the full data follow-up) can vary markedly by model. Differ-
ences begin at about four years, and are likely to be due to the small patient numbers. For
example, at five years the sample size at risk is 113, at six years it is 34 and at seven years it
is three. When choosing between the models, it is very important to assess the plausibility of
the extrapolations with clinical experts, noting the outcome definition used. For this case-study
the mean age of the sample is 53 years and the outcome is either cancer recurrence or death
from any cause. The mean survival for German women of this age was 32.6 years in 2000 (the
oldest year for which there is data). This acts as an upper-bound on the likely survival of this
sample, as women with breast cancer are likely to have worse survival than the age-matched
general population, and cancer recurrences would further reduce the estimated survival. Of the
11 models considered, only the four which predicted an increasing extrapolated hazard (DSM























Table 3.5: Breast cancer case-study: log-likelihood and information criteria for the models
Model Log-likelihood Parameters AIC: full Data AIC: years 1-3 SSE: years 4-7 Life Expectancy
Local level -142.72 3 291.45 168.48 3.84 37.62
Local level with drift -142.09 4 292.19 180.25 18.58 23.41
GAM v2 -150.63 3.84 308.94 172.08 4.01 37.12
RCS -150.55 4 309.10 172.12 4.05 35.46
GAM v1 -144.05 10.66 309.42 173.89 3.81 14.13
Generalised Gamma -153.03 3 312.06 175.31 3.78 43.40
FP with random effects -152.13 4 312.27 173.54 4.25 15.70
FP -153.42 3 312.84 172.51 4.29 15.40
Generalised F -152.97 4 313.94 174.40 4.01 43.87
Local level local trend -152.36 5 314.71 180.68 3.76 41.61
Lognormal -157.55 2 319.11 179.42 3.73 40.64
AIC: Akaike’s information critera. FP(2): Second-order fractional polynomial. SSE: Sum of squared errors (× 10,000)
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0 2 4 6
Model Generalised F Generalised Gamma
FP: fractional polynomial. RE: random effects. RCS: restricted cubic spline. GAM: generalised additive model. Gen: generalised. Hollow circles
represent observed data; sizes are proportional to the denominator. For all panes the lognormal is included in black. Three observations are removed:
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Model Generalised F Generalised Gamma
FP: fractional polynomial. RE: random effects. AR: autoregression. RCS: restricted cubic spline. GAM: generalised additive model.
Gen: generalised. For all graphs the lognormal is included in black.
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3.6 Discussion
A wide variety of flexible parametric models may be used to analyse and extrapolate TTE data
within a GLM framework, along with its extensions to GAMs, GLMMs and DGLMs. These
include FPs, spline based models and DSMs. An advantage of the GLM-based models over
standard survival models is that they can be made arbitrarily flexible as required to match the
complexity of the observed hazard function (for example, increasing the order of an FP or the
number of knots in a RCS). In contrast, to obtain more complex standard survival models,
different specifications are required (such as moving from a Weibull to a generalised gamma
model). Further, two of the GLM-extensions (GAMs and DGLMs) penalise for over-fitting as
part of parameter estimation [143, 135], thus removing much of the subjectivity over model
choice. To our knowledge, this is the first time that all of these approaches have been compared
at both a theoretical and an applied level, with recommendations to aid in choosing between
the models.
The case-study demonstrated that it is straight-forward to perform a TTE analysis within a
GLM framework and that results are at least as good as, and often superior to, those from
standard survival models. However, differences in GoF were typically small, and in this exam-
ple there was no relationship between within-sample GoF and extrapolation performance. A
strength of the case-study is that we considered a variety of different statistical models, some
of which are currently infrequently used in survival analyses [18, 144]. The fully reproducible
nature of the case-studies shall help to increase the uptake of these more advanced methods.
There were marked differences in the extrapolations from each model, and hence estimates of
lifetime mean survival. Using external evidence, only the extrapolations from one each of the
DSMs and GAMs along with both FPs were plausible, whilst the best three standard survival
models all provided implausible extrapolations. This highlights a further benefit of the GLM-
approach, as it increases the potential to identify models which simultaneously provide good
within-sample fit and plausible extrapolations. Formally incorporating such evidence is an im-
portant area of on-going research [79, 22]. However, this task is often non-trivial. For example,
external datasets may exist but they may not be fully generalizable to the decision problem.
This could be due to differences in the patient population, the healthcare system, or the time-
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period. Hence this external dataset may need to be adjusted, and assumptions shall be required
about how the observed data relate to the external dataset.
Parametric analysis of TTE data typically has up to two objectives: to obtain a parsimonious
description of the observed data, and/or to predict outcomes for the unobserved future (extrap-
olation). More work is required into the relative strengths and weaknesses of the alternative
models in both settings. For example, for the best-fitting FP model, inclusion of random effects
had a negligible impact on the AIC. Further research is required to see if this is a general phe-
nomenon, or if more nuanced modelling would lead to a more substantive improvement in fit, or
that these enhancements would be beneficial for other observed hazard patterns. The case-study
also highlights that a within-sample measure of GoF cannot be used to choose between models
for extrapolation, as has been observed previously [23, 7, 22]. The case-study expands on these
findings as it compares global models (FPs and survival models), piecewise models (spline-based
models), and local models (DSMs). Further work on model choice when used for extrapolation
could build upon the work of forecasting competitions [250].
The case-study had limitations. First, we compared models based on AIC (within-sample) and
SSE (extrapolations). We were not able to test the differences for statistical significance. For
AIC, there is some guidance on what differences may be important, but this only holds for
nested models [201]. Whilst the more flexible models generally improved within-sample fit, they
did not improve extrapolation performance. In addition, for many analysts, use of the more
flexible models will come at an additional ‘cost’ as there will be a need to understand both the
theoretical details (strengths and limitations) of the method, as well as how to implement the
model. The guidance of Section 3.4 and the reproducible case-study should help to reduce these
costs, although they will still be a factor when choosing between the difference models.
The use of a single case-study may also be viewed as a limitation. It is unclear if the (generally)
superior GoF provided by DSMs and GAMs generalises to other settings. The results for the
three DSMs illustrate an important caution against generalisation: if only the two DSMs without
a local trend were considered then DSMs would provide the best-fitting models. In contrast, if
only the DSM with a local trend were considered than we would conclude that their fit is not
as good as spline-based models. The GoF of the DSM with drift also varied markedly between
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using the full dataset and using the first three years of data. More experience with these different
models and their performance for different sample sizes and follow-up times is required before
firm conclusions can be made about which (if any) will provide more accurate estimates.
In conclusion, parametric modelling of the hazard function allows for predictions of future out-
comes. Standard survival models may be insufficiently flexible to reflect the complexities of
observed hazard patterns. The GLM framework and its extension to GAMs, GLMMs and
DGLMs can provide insight into the structure of standard one- and two-parameter models, and
their assumptions of linearity. In addition to providing more flexible models (as we have demon-
strated here), it also allows for a rich class of model specifications via different combinations of
the outcome, distribution and response function - although this comes at the cost of needing to
understand how and when to implement these models. We have provided guidance to aid with
choosing between these models. Further, spline-based GLMs provide a useful alternative to R-P
models: with appropriate response function these models cannot estimate implausible negative
hazards, unlike R-P models. A motivating and fully reproducible case-study has demonstrated
that these currently under-used approaches can sometimes provide better GoF and more plau-
sible extrapolations than standard survival models.
Appendix 4
Appendices: Generalised linear
models for flexible parametric
modelling of the hazard function
4.1 Flexible generalised linear models
This section describes flexible models that may be applied within a GLM framework, and hence
may be used for the analysis of survival data. To aid interpretation, the focus is on situations
where the only covariate of interest is time (a common occurrence in HTA), although extensions
to additional covariates are straight-forward. Subsequent sections describe extensions to GLMs.
4.1.1 Fractional polynomials
FPs have been developed to provide a systematic framework for identifying and modelling non-
linear effects of a continuous variable [133]. The degree of flexibility of an FP is defined by its
order (how many terms it includes). For a single variable, an ith order FP is defined as:
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where typically the powers pj are chosen from the set {-2, -1, -0.5, 0, 0.5, 1, 2, 3}, with x0 denoting
log x. If the power of a term is duplicated then the duplicated term is multiplied by log x. Hence,
for example, a second order FP of a single variable may be written as FP(2) = β0 +β1x
p1 +β2x
p2
if p1 6= p2 and FP(2) = β0 + β1xp1 + β2xp2 log x if p1 = p2. It is possible to consider FPs with
order > 2, and values of pj other than those described. However, in practice these extensions
are unlikely to lead to improvements in goodness of fit [251]. Similarly, other possible values
for pj may be considered, but may not. For any given order, the powers to use may be based
on minimising the AIC. To choose the order of FP, the following (approximate) closed test
procedure may be used [133]:
• Overall association of the outcome with time, comparing FP(2) model with model omitting
time (Non-significant result = stop testing, do not include time in model).
• Evidence for non-linearity, comparing FP(2) model with a model that is linear in time
(Non-significant result = stop testing, use a linear model: power = 1).
• Simpler or more complex non-linear model, comparing FP(2) model with FP(1) model
(Significant result = use FP(2) model, non-significant = use FP(1) model).
Comparisons are performed using likelihood ratio tests, with a pre-specified significance level. A
limitation of FPs is that, when using the eight powers described above, the continuous variable
has to be > 0. This is not a restriction for TTE data, but it can be a problem if transformations
of time are used. For example, the generalised F (and hence its special cases, which include the
generalised Gamma, Weibull, lognormal and log-logistic amongst others[130]) use the logarithm
of time, which can be negative. Of the eight powers described above, only five may be used with
negative values: {-2, -1, 1, 2, 3}. Further, it is not possible to handle repeated powers, which
would result in taking the lograithm of the covariate. Hence, for log time there are five FP(1)
models and 10 FP(2) models. For time as a covariate (no log transformation) there are eight
FP(1) models and 36 FP(2) models. If the closed test procedure rejects a non-linear model, and
a Poisson GLM is used, then the chosen model will be the same as a standard TTE model. A
linear model in time is analogous to a Gompertz model, a linear model in log-time is analogous to
a Weibull model, and a model without time as a covariate (and so just an intercept) is analogous
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to an exponential.
Limitations
Whilst FPs are flexible and relatively parsimonious, they have some limitations:
• Insufficient power to detect non-linearity [133]
• Inability to model a variety of functional forms including logarithmic functions and ‘thresh-
old effects’ [252]
• Lack of invariance with respect to the coding used for covariates: any transformations such
as centering or scaling can lead to different FPs being chosen [253]
• Reduced options for modelling covariates that can be positive.
• Sensitivity to extreme values in the data [207]
The last limitation can be a particular issue if extreme values occur near the end of follow-up
time, with subsequent implications for extrapolation.
4.1.2 Restricted cubic splines and Royston-Parmar models
A cubic spline represents a continuous function as a series of piecewise cubic polynomials [124].
These cubic polynomials are restricted to join (have the same value) at a set of ‘knots’. The
complexity of the cubic polynomial representation depends on how many knots are used. There
will always be at least two knots, known as ‘boundary’ knots. Any additional knots are known
as ‘interior’ knots and occur between the boundary knots. Hence for k interior knots the knot
locations are ξmin < ξ1 < · · · < ξk < ξmax, with the boundary knots being {ξmin, ξmax}. Cubic
splines also have continuous first and second derivatives.
A RCS is further restricted to be linear beyond the boundary knots (that is, before ξmin and
after ξmax) [136]. A spline has several alternative formulations. One common description for an
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RCS is as a truncated power series [136, 252]:
E(yt) = β0 + β1x+ β2V1(x) + · · ·+ βk+1Vk(x)
with Vj(x) = (x− kj)3+ − ψj(x− kmin)3+ − (1− ψj)(x− kmax)3+, j ∈ {1, . . . , k}
and ψj = (kmax − kj)/(kmax − kmin)
where (x− a)+ = max(0, x− a)
(4.2)
where the Vj(x) are referred to as basis functions. Alternative bases are formed by b-splines
or p-splines (which are a function of b-splines). B-splines are numerically more stable than
the truncated power series basis. However, in practice this advantage is usually negligible, and
b-splines cannot be used to generate extrapolations, whereas the truncated power series basis
can [252].
In the absence of any interior knots, an RCS is a linear function. Hence, as previously noted,
standard survival models may be obtained as special cases of RCSs. For extrapolations beyond
kmax the RCS is a linear function of x.
For a Poisson GLM, the outcome is the hazard rate. An alternative application of RCSs,
outside the GLM framework, is with an R-P model, for which the log cumulative hazard is the
outcome [136]. This is motivated by noting that the hazard function may be more noisy than
the cumulative hazard function. This increased noise is most likely near the end of follow-up
time, due to small numbers. These ‘end effects’ may induce spurious artefacts in the spline
function. A drawback of directly modelling the cumulative hazard is that this is monotonic (it
cannot decrease), but this property cannot be expressed by a simple set of constraints on the
parameters of the spline. Hence it is possible that implausible functions may be fitted, as a
modelled decreasing cumulative hazard would imply that there is a period for which the hazard
rate is negative. An example of implausible fit to real-data is provided in Figure 4b of [134].
Further developments of the R-P model are described by Lambert and Royston [254, 124].
The model specification for a RCS includes both the number of internal knots, and also their
placement. It has been suggested that the former decision is more important than the latter and
that a maximum of three internal knots is usually sufficient, as larger values may lead to over-
fitting the data [136, 252]. When introducing the R-P model, the authors also suggested that
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knots be placed at equally-spaced intervals of the uncensored event times (with the boundary
knots placed at the first and last of the observed uncensored event times)[136]. The choice of
how many interior knots to use is typically based on minimising an information criteria.
Limitations
The main limitation with RCS is that, due to their flexibility, they may over-fit local ‘noise’
in the data [205]. The can also be ‘data hungry’, as they can produce biased results in small
samples [255]. In addition, unlike FPs, there is in general no closed test procedure for choosing
between different models. One exception is that linear models are always nested within more
complex models, so a test for non-linearity is possible.
4.2 Generalised linear mixed models
The presence of unmeasured variables can lead to heterogeneity (overdispersion) in the outcome
that is in excess of what is implied by a model. This will lead to underestimating uncertainty in
covariate effects [107]. To remedy this, GLMs may be extended by incorporating random effect
terms, resulting in GLMMs. These terms have a mean of zero and a variance parameter, usually
unknown. Frailty refers to the feature that individuals have unequal conditional probabilities of
experiencing the outcome of interest, given these random (frailty) terms. [17]. Frailty models are
appropriate when data are collected on multiple levels; for example individuals may be clustered
within families, or they may be clustered by centre within a multicentre clinical trial. Because
of this, frailty models may also be referred to as multi-level models [91].
Frailty models may be used to analyse TTE data outside a GLMM framework [107]. However,
with the GMLM framework, frailty models may be modelled as mixed models, which have
been extensively researched [256, 246]. Mixed models are so-called as they contain both fixed
effects and random effects. Fixed effects occur in a standard GLM; for these effects (parameter
coefficients) are assumed to apply (are fixed) for all individuals. In contrast, random effects are
allowed to vary across individuals. To avoid identifiability issues, it may be assumed that the
random effects are drawn from a zero-mean Normal distribution (other zero-mean distributions
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such as t-distribution may also be used).
As an example, consider a fixed-effects 2nd-order FP which, if powers are not duplicated, may
be written as:
E(yt) = FP(2) = β0 + β1x
p1 + β2x
p2
When analysing TTE data with a GLM, individual observations relate to individual time in-
tervals. As there is only one observation per time-interval, a GLMM with a random intercept
may be used. That is, the linear predictor in any time-interval t is increased or decreased by an
additive amount bt. For example:
E(yt) = FP(2) = β0 + bt + β1x
p1 + β2x
p2 , bt ∼ N(0, ψ2) (4.3)
The above extension is not specific to FP models. That is, any fixed-effects GLM may be
extended by adding a random intercept as shown above.
4.2.1 Limitations
As the frailty terms are not observed, it may not be possible to identify them from the data,
which can lead to problems with model specification and estimation. [107, 139]. A further
limitation with the use of frailty models is that it is unclear how random effect terms should
be extrapolated. One option is to fit a model to the estimated random effects and use this to
predict future values. Alternatively the last estimated random effect may be carried-forwards.
4.3 Generalised additive models
A generalised additive model (GAM) may be viewed as a GLM in which a covariate x is replaced
by a linear combination of a finite set of smooth functions b1, . . . , bq [248]. For example, a




bj(t)βj = f(t) (4.4)
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Where bj(t) is the jth basis function, and q is the dimension of the basis function. Modelling
the effect of a covariate as a sum of basis functions results in extremely flexible models, with
more flexible models arising as more functions are added to the basis. The basis functions may
be non-parametric, which results in semi-parametric GAMs [248]. However, the focus here is on
parametric basis functions, and hence parametric GAMs [135].
Of the parametric basis functions, use of RCSs is of particular interest. Model estimation for a
GAM is different to that for a GLM. For the latter, model complexity may be penalised after
model fitting via the use of information criteria, such as the AIC. For a GAM, model complexity
is included in the objective function to be minimised. For example, for Normally distributed











The integral for the second term is taken over the range of the data and penalises the wiggliness
of function, to avoid over-fitting the data. The first term in equation (4.5) quantifies model
goodness of fit. In this example it is the sum of squared errors, but a more general representation
















As with AIC, the objective function measures the trade-off between model goodness of fit and
model complexity. The key difference is that for GAMs the complexity of the model is estimated
during the model-fitting process, and is not a post-hoc choice. For a GAM, Λ quantifies this
trade-off. As Λ → ∞ the estimated function tends towards a straight line. For Λ = 0 there is
no penalty on the regression spline (so the resulting model will be equivalent to a RCS model if
a RCS basis is used).
There are two components to model estimation, as the smoothing parameter Λ and the model
coefficients β are estimated separately [135]. One approach to estimating the degree of smooth-
ing is based on a generalisation of leave-one-out cross-validation, known as generalised cross-
validation. For given values of Λ, model coefficients are estimated based on penalised likelihood
estimation [257].
As with standard GLM models, GAMs may also be extended to incorporate random effects. The
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resulting models are known as generalised additive mixed models [258]. This extension does not
result in any concepts additional to those outlined in section 4.2.
4.3.1 Choice of basis function
A full RCS (with a knot at each unique value of t) has the desirable property of being a
‘smoothest interpolator’ [135]. That is, for all functions that are continuous over the range
of the data and also have an absolutely continuous first derivative, a full RCS will minimise
equation (4.6) [247]. In addition, a RCS is usually flexible enough to adequately describe most
functions. An alternative choice of basis function is to use polynomials. Here the jth basis
function is defined as [135]:
bj(t) = t
j−1 (4.7)
In comparison with equation (4.2), the basis for polynomials is much simpler. The first two
terms are also the same as for a RCS, and so the use of polynomial basis functions also includes
standard models such as the Weibull and Gompertz as special cases. However, the use of
polynomial basis functions is not recommended [135, 252]. Unlike RCSs, there is no guarantee
that polynomials will provide an adequate fit across the entire range of the data. Further, the fit
in a local region of the data can be strongly affected by the characteristics of the data in other
regions. Also, polynomials are unable to provide adequate descriptions of a number of functions,
such as those including ‘threshold effects’ or logarithmic functions. It should be noted that FPs
(section 4.1.1) do not follow the hierarchical rule that is used when constructing polynomial basis
functions. Indeed, FPs include fractional powers, which are not in the definition of a polynomial
basis function in equation (4.7). Hence, unlike R-P models, FPs cannot be viewed as a special
case of a GAM. As such the limitations that apply to the use of polynomial basis functions do
not necessarily apply to the use of FPs.
4.3.2 Regression splines
A full smoothing spline has as many parameters as there are data points. These full splines
may be approximated by regression splines, which are no longer ‘smoothest interpolators’, but
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are computationally easier to fit [135]. A simulation study comparing full splines with their
regression approximation found that the approximation led to a superior fit (to the known ‘true’
function) [259]. The author attributed this counter-intuitive finding to the fact that regression
splines are also less likely to overfit the data (or equivalently, the full splines was modelling
random variation).
When using regression splines, the basis dimension has to be specified (it is not part of model
estimation). In practice the smoothing parameter Λ in equation (4.6) has a larger impact on
model complexity than the choice of basis dimension. Hence the basis dimension acts as an
upper-bound for model complexity. Provided it is sufficiently large, model results are typi-
cally insensitive to the choice of basis dimension [135]. A slight exception is that larger basis
dimensions lead to a larger set of candidate models, which can sometimes affect model choice.
4.3.3 Limitations
When using RCSs as basis functions, GAMs share the same limitation in that they require
sufficiently large datasets, and they may over-fit local noise in the data [259]. However, the use
of a penalized objective function slightly mitigates this latter limitation.
4.4 Dynamic generalised linear models and dynamic survival
models
A DGLM extends a GLM by allowing the model coefficients to vary as a smooth function of
time. These may be used to analyse TTE data, resulting models are known as dynamic survival
models (DSMs). As an illustrative example, consider the exponential model: log(µt) = β0. This
may be interpreted as a global level model as the outcome is set to a fixed level for all times.
This assumption can be relaxed by allowing β0 to vary over time. Hence log(µt) = β0,t, giving
a local-level model.
Without further restrictions, this may lead to an over-fitting model. For example, setting β0,t =
yt would give a perfect fit to the observed data. However, this will over-fit the data, so to avoid
this the following restriction is used:
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• When estimating the local level at time t, only evidence available prior to time t is used.
This can include previous estimates of the local level, previous covariate values, and pre-
vious observations.
More formally, at time t, let the prior available evidence be denoted by the history of prior out-
comes: H(y)t = {y1, y2, . . . , yt−1}, the history of prior coefficient estimatesH(β)t = {β1, β2, . . . , βt−1},
and the history of prior covariates H(x)t = {x1, x2, . . . , xt−1}. Then the estimate of the local
level at time t is obtained as a function of all these histories H(y, β, x)t,= Ht for simplicity.
This estimate is a forecast (extrapolation) from the evidence at time t − 1 to time t. As such,
it is referred to as a one-step-ahead forecast.
The approach of DSMs represents a small, but significant change in estimation from previously
described approaches. For these, a model estimate of yt (denoted by ŷt) used all the observed
data. Such an estimate is known as a smoothed estimate, and models minimised the error of
smoothed estimates. In contrast, DSMs minimise the error of (within-sample) forecasts. Hence
the choice between a DSM and a GLM (or GAM) is likely to be based on if the analyst wants
to minimise the error of smoothed estimates or the error of forecasts.
Some further comments on the use of the forecasts are required.
• It shall be assumed that the Markov property is valid [178]; so ŷt|1:t−1 = ŷt|t−1. In addition,
sometimes an estimate at time t uses yt. This is no longer a one-step ahead forecast, but
is referred to as a filtered estimate, denoted as ŷt|1:t = ŷt|t.
• When estimating the one-step ahead forecast ŷt+1|t, evidence is available for all the prior
one-step ahead forecasts (which are a function of the βt). However, evidence is also avail-
able on the previous outcomes. This may be used to estimate the accuracy of the previous
forecasts, and this knowledge used to improve estimates of ŷt+1|t. Hence the one-step
ahead forecast ŷt+1|t is based on prior filtered values, and so the histories H(β)t include
filtered values, not one-step ahead forecasts.
• Specification of a DSM requires initial (starting) estimates. There will be no histories to
inform these, so they may be based on external data, expert opinion, or via a heuristic
[42].
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A limitation with DSMs is that model estimation can be difficult: either due to computational
issues, or if the use of approximate methods is inappropriate [168, 144]. Extrapolations from
a DSM are determined by the chosen model specification, which is described in the following
subsections.
4.4.1 Model specification
The general model specification for a DGLM (or DSM) is [247]:
Observation model: E[yt] = µt yt ∼ exponential family distribution (4.8a)
Response function: µt = h(x
T
t βt) (4.8b)
Transition model: βt = Fβt−1 + ζt (4.8c)
Initial conditions: β0 ∼MVN(b0, Z0) (4.8d)
where MVN denotes a multivariate Normal distribution, F is a transition matrix for the coef-
ficients over time, and the error term (ζt), also referred to as an innovation, is assumed to be
an independent and identically distributed series with ζt ∼ N(0, Zt), where Zt is a variance-
covariance matrix of the model coefficients. As before, for a Poisson GLM, the outcome is the
number of number of events in an interval (which, combined with knowledge of the at-risk popu-
lation, can be used to derive the hazard rate). Of note, the covariate time does not appear within
the model specification. That is, no assumptions are made about the relationship between time
and the hazard rate. Instead it is assumed that there exist latent states (the βs), such as an
average value (level) and trend - either of which may vary over time.
Three types of DLM are of particular interest. Two are the local level and local trend models,
which may be interpreted as zero-order and first-order Taylor series approximations, respectively
[42]. The third is the local level global trend model, also referred to as a local level with drift
model. These are defined below.
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Local level models
E(yt) = βt
βt = βt−1 + ζt
this type of model is referred to as a random-walk model. Extrapolations of the yt are a constant
value, equal to the last-estimated local level. That is, the extrapolated value h time steps into
the future, given observed data up to time T is ŷT+h|T = βT ,
Local trend (linear) models
These may be defined as:
E(yt) = x

















β1t = β1,t−1 + β2,t−1 + ζ1,t
β2t = β2,t−1 + ζ2,t
where βt = [β1t, β2t]
T , ζt = [ζ1t, ζ2t]
T . The formula for β1t may be written down recursively as:
β1t = β1,t−1 + β2,t−1 + ζ1,t
= β1,t−2 + 2β2,t−2 + ζ1,t + ζ1,t−1 + ζ2,t−1
= β1,t−3 + 3β2,t−3 + ζ1,t + ζ1,t−1 + ζ1,t−2 + ζ2,t−1 + 2ζ2,t−2
= . . .
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where the first two terms are a linear function, and the last 2 terms are random error. As
such, β1t represents the local level, which is a linear function of t. The parameter β2t may be
interpreted as the growth rate (local trend). Extrapolations are a linear function of the last-
estimated local level and local trend values: ŷT+h|T = β1T + hβ2T .
Local level global trend (drift) models
This may be viewed as a special case of the local trend model, with ζ2,t = 0. A single trend β2
is then estimated based on all the data. This estimate of the trend will be more stable than the
one estimated locally as towards the end of follow-up the number of observations is smallest.
However, this increased stability is at the loss of flexibility, as the estimate of trend is fixed and
so does not vary with time.
4.4.2 Likelihood specification
The likelihood for a DSM may be written as the product of likelihoods for individual time-
periods j (denoted by Lj), with tj denoting the jth time-period. Following Hemming and Shaw
















hence for an individual who experienced an event, δij = 1 for all time periods up-to and including
the time period which included the event. In all other situations it is zero. The indicator tij is
the observed survival time up-to and including the time period which included the observation.
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where N is the number of time-intervals, and τj is the set of individuals who have a survival
time ≥ tj . When equal interval widths are used, this is the same likelihood as for a Poisson
GLM with an offset (see Section 4.5).
4.4.3 Limitations
The flexibility of allowing model coefficients to vary as a function of time can lead to problems
with both convergence, and specification of initial estimates [128, 143, 40, 144].
4.5 Likelihood estimation
4.5.1 Parametric survival models
Let di be an event indicator which = 1 if ti is an observed survival time and = 0 if ti is a










For individuals with an observed event their probability density function contributes to the
likelihood. Individuals with censored times contribute their cumulative survivor function (as
their probability density function is not fully observed but it is known that they survived up to








= di log{f(ti)}+ (1− di) log{S(ti)}
(4.12)
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The following identities may be used to derive an expression of the likelihood purely in terms of
the hazard function [98]: S(t) = 1−
∫ t











4.5.2 Equivalence between a Poisson GLM with an offset and a Poisson DSM
Poisson GLM with an offset.

























[yi log(τiθ)− τiθ − log(yi!)]
=
∑
[yi log(τi) + yi log(θ)− τiθ − log(yi!)]
The first and last terms do not include the parameter θ. Thus, for a given dataset, the first
and last terms will always be the same, and so may be eliminated from the likelihood when
comparing different models. This gives the likelihood:
logL =
∑
[yi log(θ)− τiθ] (4.14)
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Poisson DSM.




exp(−[tij − tj−1]ezβj )ezβjδij

















= djzβj − τjezβj
where dj is the observed number of events in the jth time-interval, hence = yj . Let θj = e
zβj .
Then:
logLj = yj log(θj)− τjθj (4.15)
which is the same as applying equation (4.14) to a single time-period.
